{"text_format":"1","workbook":"xlsx","n_sheets":31,"sheets":["CoverSheet","Data","Impact Outcome Indicators_1A","Coverage Indicators_1B","ImpactOutcomeDisaggData","Impactoutcome","Coverage Indicators","CoverageDisaggregationData","WPTM_1C","Intervention By Modules old","Intervention By Modules","PR Cash Reconciliation_2A,B,C","SR_Cash Reconciliation_2D","Budget Variance_2E","Procurement_3","Grant Management_4","PR-LFA Evaluation_5","LFA_Findings&Recommendations_6","PR EFR_7A","LFA EFR_7B","Annual Cash Forecast_8A"," Request and Recommendation_8B","PR Authorization_9A","LFA Authorization_9B","PR_Disbursement Request_7","Modules","EFR Data","Checklist","Memo HIV","Memo TB","Memo Malaria"],"not_rendered":{"charts":0,"images":2,"macros":1,"external_links":8,"defined_names":553,"comments":2,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"CoverSheet","index":0,"n_rows":13,"n_cols":12,"rows_kept":13,"cut":false,"hidden":false,"merged":[[12,3,12,5],[9,0,9,2],[10,0,10,2],[0,0,0,11],[4,0,4,2],[5,0,5,2],[6,0,6,2],[7,0,7,2],[8,0,8,2],[1,0,2,14],[0,12,0,14]]}
["Ongoing Progress Update and Disbursement Request"]
["Cover Sheet: Instructions\n\n• This template is compatible with MS Excel 2000 and later versions. Some drop-downs and formulae may not work with earlier versions. Therefore, Principal Recipients with earlier versions of MS Excel are requested to upgrade to MS 2000 or more recent versions.\n\n• Principal Recipients are first required to complete the Cover Sheet with the General Grant Information listed in the boxes below. They can refer to their Grant Face Sheet/Grant Confirmation to fill part of this information.\n\n• Principal Recipients are required to fill in the information related to the periods covered by the progress update and disbursement request.\n\n• Principal Recipients are required to select the type of submission, i.e. whether they are submitting a Mid-Year (or Quarterly) Progress Update or a Year-End Progress Update/Disbursement Request. This is important as the forms will change depending on the type of submission selected."]
[]
["GENERAL GRANT INFORMATION"]
["Country:",null,null,"Georgia",null,"PROGRESS UPDATE "]
["(Disease) Component",null,null,"Tuberculosis",null,"Progress Update - Reporting Period:",null,null,"Cycle:","Semester","Number:",4]
["Grant Name/Number:",null,null,"GEO-T-NCDC",null,"Progress Update - Period Covered:",null,null,"Beginning Date:","2015-07-01","End Date:","2015-12-31"]
["Principal Recipient:",null,null,"NCDC"]
["LFA Name:",null,null,"UNOPS",null,"DISBURSEMENT REQUEST "]
["Program Start Date:",null,null,"2014-04-01",null,"Disbursement Request  - Disbursement Period:",null,null,"Cycle:","Semester","Number:",3]
["Currency:",null,null,"EUR",null,"Disbursement Request  - Period Covered:",null,null,"Beginning Date:","2016-01-01","End Date:","2016-06-30"]
[]
[null,null,null,"Are you submitting:\n•    A Progress Update (PU); or \n•    A Progress Update/Disbursement Request (PU/DR)."]

{"sheet":"Data","index":1,"n_rows":307,"n_cols":19,"rows_kept":307,"cut":false,"hidden":true,"merged":[]}
["Component","Catalog Module Name","Intervention Name","Old Component","Module - Intervention",null,null,null,"Component",null,null,"Component","Catalog Module Name",null,"Component","Impact/Outcome",null,null,"Data Sources "]
["Malaria","Specific prevention interventions (SPI)","Intermittent preventive treatment (IPT) - In pregnancy","Malaria",{"$f":"CONCATENATE(B2,\"  -  \",C2)","v":"Specific prevention interventions (SPI)  -  Intermittent preventive treatment (IPT) - In pregnancy"},null,null,null,"Malaria",null,null,"Malaria","Specific prevention interventions (SPI)","Module1","Malaria","Impact",{"$f":"CONCATENATE(O2,P2)","v":"MalariaImpact"},"Type1","HMIS"]
["Malaria","Specific prevention interventions (SPI)","Intermittent preventive treatment (IPT) - In infancy","Malaria",{"$f":"CONCATENATE(B3,\"  -  \",C3)","v":"Specific prevention interventions (SPI)  -  Intermittent preventive treatment (IPT) - In infancy"},null,null,null,"Tuberculosis",null,null,"Malaria","Vector control","Module2","Tuberculosis","Impact",{"$f":"CONCATENATE(O3,P3)","v":"TuberculosisImpact"},"Type2","Patient records"]
["Malaria","Specific prevention interventions (SPI)","Seasonal malaria chemoprevention","Malaria","Specific prevention interventions (SPI)  -  Seasonal malaria chemoprevention",null,null,null,"HIV/TB",null,null,"Malaria","Case management","Module3","HIV/TB","Impact","HIV/TBImpact","Type3","Training records"]
["Malaria","Specific prevention interventions (SPI)","IEC/BCC","Malaria","Specific prevention interventions (SPI)  -  IEC/BCC",null,null,null,"HIV/AIDS",null,null,"Tuberculosis","TB care and prevention","Module4","HIV/AIDS","Impact","HIV/AIDSImpact","Type4","MICS (Multiple Indicator Cluster Survey)"]
["Malaria","Vector control","Long-lasting insecticidal nets (LLIN) - Mass campaign","Malaria","Vector control  -  Long-lasting insecticidal nets (LLIN) - Mass campaign",null,null,null,"Health Systems Strengthening",null,null,"Tuberculosis","MDR-TB","Module5","Health Systems Strengthening","Impact","Health Systems StrengtheningImpact","Type5","DHS/DHS+ (Demographic and Health\nSurvey)"]
["Malaria","Vector control","Long-lasting insecticidal nets (LLIN) - Continuous distribution","Malaria","Vector control  -  Long-lasting insecticidal nets (LLIN) - Continuous distribution",null,null,null,null,null,null,"HIV/TB","TB care and prevention","Module6","Malaria","Outcome","MalariaOutcome","Type6","AIS (AIDS Indicator Survey)"]
["Malaria","Vector control","Indoor residual spraying (IRS)","Malaria","Vector control  -  Indoor residual spraying (IRS)",null,null,null,null,null,null,"HIV/TB","MDR-TB","Module7","Tuberculosis","Outcome","TuberculosisOutcome","Type7","BSS (Behavioral Surveillance Survey)"]
["Malaria","Vector control","Other vector vontrol measures","Malaria","Vector control  -  Other vector vontrol measures",null,null,null,null,null,null,"HIV/TB","Prevention programs for general population","Module8","HIV/TB","Outcome","HIV/TBOutcome","Type8","Health Facility survey"]
["Malaria","Vector control","Entomological monitoring","Malaria","Vector control  -  Entomological monitoring",null,null,null,null,null,null,"HIV/TB","Prevention programs for MSM and TGs","Module9","HIV/AIDS","Outcome","HIV/AIDSOutcome","Type9","SAMS (Service Availability Mapping\nSurvey)"]
["Malaria","Case management","Facility-based treatment","Malaria","Case management  -  Facility-based treatment",null,null,null,null,null,null,"HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Module10","Health Systems Strengthening","Outcome","Health Systems StrengtheningOutcome","Type10","Households survey"]
["Malaria","Case management","Epidemic preparedness and response","Malaria","Case management  -  Epidemic preparedness and response",null,null,null,null,null,null,"HIV/TB","Prevention programs for other vulnerable populations (please specify)","Module11",null,null,null,null,"Specific surveys and research (specify)"]
["Malaria","Case management","Integrated community case management (ICCM)","Malaria","Case management  -  Integrated community case management (ICCM)",null,null,null,null,null,null,"HIV/TB","Prevention programs for adolescents and youth, in and out of school","Module12",null,null,null,null,"Reports (specify)"]
["Malaria","Case management","Active case detection and investigation (elimination phase)","Malaria","Case management  -  Active case detection and investigation (elimination phase)",null,null,null,null,null,null,"HIV/TB","Prevention programs for sex workers and their clients","Module13",null,null,null,null,"Vital and disease-specific registry"]
["Malaria","Case management","Therapeutic efficacy surveillance","Malaria","Case management  -  Therapeutic efficacy surveillance",null,null,null,null,null,null,"HIV/TB","PMTCT","Module14",null,null,null,null,"Operational Research"]
["Malaria","Case management","Severe malaria","Malaria","Case management  -  Severe malaria",null,null,null,null,null,null,"HIV/TB","Treatment, care and support","Module15",null,null,null,null,"Health Provider survey"]
["Malaria","Case management","Private sector co-payment mechanism","Malaria","Case management  -  Private sector co-payment mechanism",null,null,null,null,null,null,"HIV/AIDS","Prevention programs for general population","Module16",null,null,null,null,"National Health Account"]
["Malaria","Case management","Private sector case management (other)","Malaria","Case management  -  Private sector case management (other)",null,null,null,null,null,null,"HIV/AIDS","Prevention programs for MSM and TGs","Module17",null,null,null,null,"Administrative records"]
["Malaria","Case management","Ensuring drug quality","Malaria","Case management  -  Ensuring drug quality",null,null,null,null,null,null,"HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Module18",null,null,null,null,"R&R TB system, quarterly reports"]
["Tuberculosis","TB care and prevention","Case detection and diagnosis","Tuberculosis; HIV/TB","TB care and prevention  -  Case detection and diagnosis",null,null,null,null,null,null,"HIV/AIDS","Prevention programs for other vulnerable populations (please specify)","Module19",null,null,null,null,"R&R TB system, yearly management report "]
["Tuberculosis","TB care and prevention","Treatment","Tuberculosis; HIV/TB","TB care and prevention  -  Treatment",null,null,null,null,null,null,"HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","Module20",null,null,null,null,"TB prevalence survey"]
["Tuberculosis","TB care and prevention","Prevention","Tuberculosis; HIV/TB","TB care and prevention  -  Prevention",null,null,null,null,null,null,"HIV/AIDS","Prevention programs for sex workers and their clients","Module21",null,null,null,null,"TB patient register"]
["Tuberculosis","MDR-TB","Case detection and diagnosis: MDR-TB","Tuberculosis; HIV/TB","MDR-TB  -  Case detection and diagnosis: MDR-TB",null,null,null,null,null,null,"HIV/AIDS","PMTCT","Module22",null,null,null,null,"TB laboratory register"]
["Tuberculosis","MDR-TB","Treatment: MDR-TB","Tuberculosis; HIV/TB","MDR-TB  -  Treatment: MDR-TB",null,null,null,null,null,null,"HIV/AIDS","Treatment, care and support","Module23",null,null,null,null,"TB treatment card"]
["Tuberculosis","MDR-TB","Prevention for MDR-TB","Tuberculosis; HIV/TB","MDR-TB  -  Prevention for MDR-TB",null,null,null,null,null,null,"HIV/AIDS","TB/HIV","Module24",null,null,null,null,"Specify- Reports, Surveys, Questionnaires etc."]
["HIV/TB","TB care and prevention","Case detection and diagnosis","Tuberculosis; HIV/TB","TB care and prevention  -  Case detection and diagnosis",null,null,null,null,null,null,"Tuberculosis","TB/HIV","Module25",null,null,null,null,"MIS (Malaria Indicator Survey)"]
["HIV/TB","TB care and prevention","Treatment","Tuberculosis; HIV/TB","TB care and prevention  -  Treatment",null,null,null,null,null,null,"HIV/TB","TB/HIV","Module26",null,null,null,null,"Situation Analysis"]
["HIV/TB","TB care and prevention","Prevention","Tuberculosis; HIV/TB","TB care and prevention  -  Prevention",null,null,null,null,null,null,"HIV/AIDS","Removing legal barriers to access","Module27",null,null,null,null,"Key informant survey"]
["HIV/TB","MDR-TB","Case detection and diagnosis: MDR-TB","Tuberculosis; HIV/TB","MDR-TB  -  Case detection and diagnosis: MDR-TB",null,null,null,null,null,null,"HIV/AIDS","HSS - Service delivery","Module28",null,null,null,null,"Surveillance systems"]
["HIV/TB","MDR-TB","Treatment: MDR-TB","Tuberculosis; HIV/TB","MDR-TB  -  Treatment: MDR-TB",null,null,null,null,null,null,"HIV/AIDS","HSS - Health and community workforce","Module29",null,null,null,null,"Modelled"]
["HIV/TB","MDR-TB","Prevention for MDR-TB","Tuberculosis; HIV/TB","MDR-TB  -  Prevention for MDR-TB",null,null,null,null,null,null,"HIV/AIDS","HSS - Health information systems and M&E","Module30",null,null,null,null,"Other survey, specify"]
["HIV/TB","Prevention programs for general population","RMNCH linkages and gender-based violence (GBV)","HIV/AIDS; HIV/TB","Prevention programs for general population  -  RMNCH linkages and gender-based violence (GBV)",null,null,null,null,null,null,"HIV/AIDS","Program management","Module31",null,null,null,null,"IBBS"]
["HIV/TB","Prevention programs for general population","Other interventions for general population - Please specify","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Other interventions for general population - Please specify",null,null,null,null,null,null,"HIV/AIDS","HSS - Procurement supply chain management (PSCM)","Module32"]
["HIV/TB","Prevention programs for MSM and TGs","Behavioral change as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Behavioral change as part of programs for MSM and TGs",null,null,null,null,null,null,"HIV/AIDS","HSS - Policy and governance","Module33"]
["HIV/TB","Prevention programs for MSM and TGs","Condoms as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Condoms as part of programs for MSM and TGs",null,null,null,null,null,null,"HIV/AIDS","HSS - Healthcare financing","Module34"]
["HIV/TB","Prevention programs for MSM and TGs","HIV testing and counseling as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  HIV testing and counseling as part of programs for MSM and TGs",null,null,null,null,null,null,"HIV/AIDS","HSS - Financial management","Module35"]
["HIV/TB","Prevention programs for MSM and TGs","Diagnosis and treatment of STIs as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Diagnosis and treatment of STIs as part of programs for MSM and TGs",null,null,null,null,null,null,"Tuberculosis","Removing legal barriers to access","Module36"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Needle and Syringe programs as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Needle and Syringe programs as part of programs for PWID and their partners",null,null,null,null,null,null,"Tuberculosis","HSS - Service delivery","Module37"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","OST and other drug dependence treatment (PWIDs and their partners)","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  OST and other drug dependence treatment (PWIDs and their partners)",null,null,null,null,null,null,"Tuberculosis","HSS - Health and community workforce","Module38"]
["HIV/TB","Prevention programs for other vulnerable populations (please specify)","Condoms as part of programs for other vulnerable populations","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Condoms as part of programs for other vulnerable populations",null,null,null,null,null,null,"Tuberculosis","HSS - Health information systems and M&E","Module39"]
["HIV/TB","Prevention programs for other vulnerable populations (please specify)","Behavioral change as part of programs for other vulnerable populations","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Behavioral change as part of programs for other vulnerable populations",null,null,null,null,null,null,"Tuberculosis","Program management","Module40"]
["HIV/TB","Prevention programs for other vulnerable populations (please specify)","Diagnosis and treatment of STIs (other vulnerable populations)","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Diagnosis and treatment of STIs (other vulnerable populations)",null,null,null,null,null,null,"Tuberculosis","HSS - Procurement supply chain management (PSCM)","Module41"]
["HIV/TB","Prevention programs for other vulnerable populations (please specify)","Other interventions for other vulnerable populations - Please specify","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Other interventions for other vulnerable populations - Please specify",null,null,null,null,null,null,"Tuberculosis","HSS - Policy and governance","Module42"]
["HIV/TB","Prevention programs for adolescents and youth, in and out of school","Behavioral change as part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Behavioral change as part of programs for adolescent and youth",null,null,null,null,null,null,"Tuberculosis","HSS - Healthcare financing","Module43"]
["HIV/TB","Prevention programs for adolescents and youth, in and out of school","Condoms part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Condoms part of programs for adolescent and youth",null,null,null,null,null,null,"Tuberculosis","HSS - Financial management","Module44"]
["HIV/TB","Prevention programs for general population","Behavioral change as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Behavioral change as part of programs for general population",null,null,null,null,null,null,"Malaria","Removing legal barriers to access","Module45"]
["HIV/TB","Prevention programs for general population","Condoms as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Condoms as part of programs for general population",null,null,null,null,null,null,"Malaria","HSS - Service delivery","Module46"]
["HIV/TB","Prevention programs for general population","Male circumcision","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Male circumcision",null,null,null,null,null,null,"Malaria","HSS - Health and community workforce","Module47"]
["HIV/TB","Prevention programs for MSM and TGs","Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs",null,null,null,null,null,null,"Malaria","HSS - Health information systems and M&E","Module48"]
["HIV/TB","Prevention programs for MSM and TGs","Other interventions for MSM and TGs - Please specify","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Other interventions for MSM and TGs - Please specify",null,null,null,null,null,null,"Malaria","Program management","Module49"]
["HIV/TB","Prevention programs for sex workers and their clients","Behavioral change as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Behavioral change as part of programs for sex workers and their clients",null,null,null,null,null,null,"Malaria","HSS - Procurement supply chain management (PSCM)","Module50"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Diagnosis and treatment of viral hepatitis (PWIDs and their partners)",null,null,null,null,null,null,"Malaria","HSS - Policy and governance","Module51"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Other interventions for IDUs and their partners - Please specify","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Other interventions for IDUs and their partners - Please specify",null,null,null,null,null,null,"Malaria","HSS - Healthcare financing","Module52"]
["HIV/TB","Prevention programs for other vulnerable populations (please specify)","HIV testing and counseling as part of programs for other vulnerable populations","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  HIV testing and counseling as part of programs for other vulnerable populations",null,null,null,null,null,null,"Malaria","HSS - Financial management","Module53"]
["HIV/TB","Prevention programs for adolescents and youth, in and out of school","HIV testing and counseling as part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  HIV testing and counseling as part of programs for adolescent and youth",null,null,null,null,null,null,"Health Systems Strengthening","Removing legal barriers to access","Module54"]
["HIV/TB","Prevention programs for adolescents and youth, in and out of school","RMNCH linkages and GBV as part of programs for adolescent youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  RMNCH linkages and GBV as part of programs for adolescent youth",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Service delivery","Module55"]
["HIV/TB","Prevention programs for adolescents and youth, in and out of school","Young Key Population interventions as part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Young Key Population interventions as part of programs for adolescent and youth",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Health and community workforce","Module56"]
["HIV/TB","Prevention programs for adolescents and youth, in and out of school","Other interventions for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Other interventions for adolescent and youth",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Health information systems and M&E","Module57"]
["HIV/TB","Prevention programs for general population","HIV testing and counseling as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  HIV testing and counseling as part of programs for general population",null,null,null,null,null,null,"Health Systems Strengthening","Program management","Module58"]
["HIV/TB","Prevention programs for sex workers and their clients","Condoms as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Condoms as part of programs for sex workers and their clients",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Procurement supply chain management (PSCM)","Module59"]
["HIV/TB","Prevention programs for sex workers and their clients","HIV testing and counseling as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  HIV testing and counseling as part of programs for sex workers and their clients",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Policy and governance","Module60"]
["HIV/TB","Prevention programs for sex workers and their clients","Diagnosis and treatment of STIs (sex workers and their clients)","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Diagnosis and treatment of STIs (sex workers and their clients)",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Healthcare financing","Module61"]
["HIV/TB","Prevention programs for sex workers and their clients","Harm reduction as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Harm reduction as part of programs for sex workers and their clients",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Financial management","Module62"]
["HIV/TB","PMTCT","Prong 1: Primary prevention of HIV infection among women of childbearing age","HIV/AIDS; HIV/TB","PMTCT  -  Prong 1: Primary prevention of HIV infection among women of childbearing age",null,null,null,null,null,null,"HIV/TB","Removing legal barriers to access","Module63"]
["HIV/TB","PMTCT","Prong 2: Preventing unintended pregnancies among women living with HIV","HIV/AIDS; HIV/TB","PMTCT  -  Prong 2: Preventing unintended pregnancies among women living with HIV",null,null,null,null,null,null,"HIV/TB","HSS - Service delivery","Module64"]
["HIV/TB","PMTCT","Prong 3: Preventing vertical HIV transmission","HIV/AIDS; HIV/TB","PMTCT  -  Prong 3: Preventing vertical HIV transmission",null,null,null,null,null,null,"HIV/TB","HSS - Health and community workforce","Module65"]
["HIV/TB","PMTCT","Prong 4: Treatment, care & support to mothers living with HIV, their children &","HIV/AIDS; HIV/TB",{"$f":"CONCATENATE(B67,\"  -  \",C67)","v":"PMTCT  -  Prong 4: Treatment, care & support to mothers living with HIV, their children &"},null,null,null,null,null,null,"HIV/TB","HSS - Health information systems and M&E","Module66"]
["HIV/TB","PMTCT","Other interventions for PMTCT- Please specify","HIV/AIDS; HIV/TB","PMTCT  -  Other interventions for PMTCT- Please specify",null,null,null,null,null,null,"HIV/TB","Program management","Module67"]
["HIV/TB","Prevention programs for sex workers and their clients","Other interventions for sex workers and their clients - Please specify","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Other interventions for sex workers and their clients - Please specify",null,null,null,null,null,null,"HIV/TB","HSS - Procurement supply chain management (PSCM)","Module68"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Behavioural change as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Behavioural change as part of programs for PWID and their partners",null,null,null,null,null,null,"HIV/TB","HSS - Policy and governance","Module69"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Condoms as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Condoms as part of programs for PWID and their partners",null,null,null,null,null,null,"HIV/TB","HSS - Healthcare financing","Module70"]
["HIV/TB","Treatment, care and support","Pre-ART care","HIV/AIDS; HIV/TB","Treatment, care and support  -  Pre-ART care",null,null,null,null,null,null,"HIV/TB","HSS - Financial management","Module71"]
["HIV/TB","Treatment, care and support","Antiretroviral Therapy (ART)","HIV/AIDS; HIV/TB","Treatment, care and support  -  Antiretroviral Therapy (ART)",null,null,null,null,null,null,"HIV/AIDS","Community systems strengthening","Module72"]
["HIV/TB","Treatment, care and support","Treatment monitoring","HIV/AIDS; HIV/TB","Treatment, care and support  -  Treatment monitoring",null,null,null,null,null,null,"HIV/AIDS","Results based Financing","Module73"]
["HIV/TB","Treatment, care and support","Treatment adherence","HIV/AIDS; HIV/TB","Treatment, care and support  -  Treatment adherence",null,null,null,null,null,null,"Tuberculosis","Community systems strengthening","Module74"]
["HIV/TB","Treatment, care and support","Prevention, diagnosis and treatment of opportunistic infections","HIV/AIDS; HIV/TB","Treatment, care and support  -  Prevention, diagnosis and treatment of opportunistic infections",null,null,null,null,null,null,"Tuberculosis","Results based Financing","Module75"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Diagnosis and treatment of STIs as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Diagnosis and treatment of STIs as part of programs for PWID and their partners",null,null,null,null,null,null,"Malaria","Community systems strengthening","Module76"]
["HIV/TB","Treatment, care and support","Counseling and psycho-social support","HIV/AIDS; HIV/TB","Treatment, care and support  -  Counseling and psycho-social support",null,null,null,null,null,null,"Malaria","Results based Financing","Module77"]
["HIV/TB","Treatment, care and support","Out-patient care","HIV/AIDS; HIV/TB","Treatment, care and support  -  Out-patient care",null,null,null,null,null,null,"HIV/TB","Community systems strengthening","Module78"]
["HIV/TB","Treatment, care and support","In-patient care","HIV/AIDS; HIV/TB","Treatment, care and support  -  In-patient care",null,null,null,null,null,null,"HIV/TB","Results based Financing","Module79"]
["HIV/TB","Treatment, care and support","Other interventions for treatment - Please specify","HIV/AIDS; HIV/TB","Treatment, care and support  -  Other interventions for treatment - Please specify"]
["HIV/TB","Prevention programs for general population","Diagnosis and treatment of STIs as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Diagnosis and treatment of STIs as part of programs for general population"]
["HIV/TB","Prevention programs for general population","Blood safety","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Blood safety"]
["HIV/AIDS","Prevention programs for general population","Orphan and vulnerable children (OVC) package","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Orphan and vulnerable children (OVC) package"]
["HIV/AIDS","Prevention programs for general population","RMNCH linkages and gender-based violence (GBV)","HIV/AIDS; HIV/TB","Prevention programs for general population  -  RMNCH linkages and gender-based violence (GBV)"]
["HIV/AIDS","Prevention programs for general population","Other interventions for general population - Please specify","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Other interventions for general population - Please specify"]
["HIV/AIDS","Prevention programs for MSM and TGs","Behavioral change as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Behavioral change as part of programs for MSM and TGs"]
["HIV/AIDS","Prevention programs for MSM and TGs","Condoms as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Condoms as part of programs for MSM and TGs"]
["HIV/AIDS","Prevention programs for MSM and TGs","HIV testing and counseling as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  HIV testing and counseling as part of programs for MSM and TGs"]
["HIV/AIDS","Prevention programs for MSM and TGs","Diagnosis and treatment of STIs as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Diagnosis and treatment of STIs as part of programs for MSM and TGs"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Needle and Syringe programs as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Needle and Syringe programs as part of programs for PWID and their partners"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","OST and other drug dependence treatment (PWIDs and their partners)","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  OST and other drug dependence treatment (PWIDs and their partners)"]
["HIV/AIDS","Prevention programs for other vulnerable populations (please specify)","Condoms as part of programs for other vulnerable populations","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Condoms as part of programs for other vulnerable populations"]
["HIV/AIDS","Prevention programs for other vulnerable populations (please specify)","Behavioral change as part of programs for other vulnerable populations","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Behavioral change as part of programs for other vulnerable populations"]
["HIV/AIDS","Prevention programs for other vulnerable populations (please specify)","Diagnosis and treatment of STIs (other vulnerable populations)","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Diagnosis and treatment of STIs (other vulnerable populations)"]
["HIV/AIDS","Prevention programs for other vulnerable populations (please specify)","Other interventions for other vulnerable populations - Please specify","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Other interventions for other vulnerable populations - Please specify"]
["HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","Behavioral change as part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Behavioral change as part of programs for adolescent and youth"]
["HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","Condoms part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Condoms part of programs for adolescent and youth"]
["HIV/AIDS","Prevention programs for general population","Behavioral change as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Behavioral change as part of programs for general population"]
["HIV/AIDS","Prevention programs for general population","Condoms as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Condoms as part of programs for general population"]
["HIV/AIDS","Prevention programs for general population","Male circumcision","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Male circumcision"]
["HIV/AIDS","Prevention programs for MSM and TGs","Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs"]
["HIV/AIDS","Prevention programs for MSM and TGs","Other interventions for MSM and TGs - Please specify","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Other interventions for MSM and TGs - Please specify"]
["HIV/AIDS","Prevention programs for sex workers and their clients","Behavioral change as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Behavioral change as part of programs for sex workers and their clients"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Diagnosis and treatment of viral hepatitis (PWIDs and their partners)"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Other interventions for IDUs and their partners - Please specify","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Other interventions for IDUs and their partners - Please specify"]
["HIV/AIDS","Prevention programs for other vulnerable populations (please specify)","HIV testing and counseling as part of programs for other vulnerable populations","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  HIV testing and counseling as part of programs for other vulnerable populations"]
["HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","HIV testing and counseling as part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  HIV testing and counseling as part of programs for adolescent and youth"]
["HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","RMNCH linkages and GBV as part of programs for adolescent youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  RMNCH linkages and GBV as part of programs for adolescent youth"]
["HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","Young Key Population interventions as part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Young Key Population interventions as part of programs for adolescent and youth"]
["HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","Other interventions for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Other interventions for adolescent and youth"]
["HIV/AIDS","Prevention programs for general population","HIV testing and counseling as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  HIV testing and counseling as part of programs for general population"]
["HIV/AIDS","Prevention programs for sex workers and their clients","Condoms as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Condoms as part of programs for sex workers and their clients"]
["HIV/AIDS","Prevention programs for sex workers and their clients","HIV testing and counseling as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  HIV testing and counseling as part of programs for sex workers and their clients"]
["HIV/AIDS","Prevention programs for sex workers and their clients","Diagnosis and treatment of STIs (sex workers and their clients)","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Diagnosis and treatment of STIs (sex workers and their clients)"]
["HIV/AIDS","Prevention programs for sex workers and their clients","Harm reduction as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Harm reduction as part of programs for sex workers and their clients"]
["HIV/AIDS","PMTCT","Prong 1: Primary prevention of HIV infection among women of childbearing age","HIV/AIDS; HIV/TB","PMTCT  -  Prong 1: Primary prevention of HIV infection among women of childbearing age"]
["HIV/AIDS","PMTCT","Prong 2: Preventing unintended pregnancies among women living with HIV","HIV/AIDS; HIV/TB","PMTCT  -  Prong 2: Preventing unintended pregnancies among women living with HIV"]
["HIV/AIDS","PMTCT","Prong 3: Preventing vertical HIV transmission","HIV/AIDS; HIV/TB","PMTCT  -  Prong 3: Preventing vertical HIV transmission"]
["HIV/AIDS","PMTCT","Prong 4: Treatment, care & support to mothers living with HIV, their children &","HIV/AIDS; HIV/TB","PMTCT  -  Prong 4: Treatment, care & support to mothers living with HIV, their children &"]
["HIV/AIDS","PMTCT","Other interventions for PMTCT- Please specify","HIV/AIDS; HIV/TB","PMTCT  -  Other interventions for PMTCT- Please specify"]
["HIV/AIDS","Prevention programs for sex workers and their clients","Other interventions for sex workers and their clients - Please specify","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Other interventions for sex workers and their clients - Please specify"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Behavioural change as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Behavioural change as part of programs for PWID and their partners"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Condoms as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Condoms as part of programs for PWID and their partners"]
["HIV/AIDS","Treatment, care and support","Pre-ART care","HIV/AIDS; HIV/TB","Treatment, care and support  -  Pre-ART care"]
["HIV/AIDS","Treatment, care and support","Antiretroviral Therapy (ART)","HIV/AIDS; HIV/TB","Treatment, care and support  -  Antiretroviral Therapy (ART)"]
["HIV/AIDS","Treatment, care and support","Treatment monitoring","HIV/AIDS; HIV/TB","Treatment, care and support  -  Treatment monitoring"]
["HIV/AIDS","Treatment, care and support","Treatment adherence","HIV/AIDS; HIV/TB","Treatment, care and support  -  Treatment adherence"]
["HIV/AIDS","Treatment, care and support","Prevention, diagnosis and treatment of opportunistic infections","HIV/AIDS; HIV/TB","Treatment, care and support  -  Prevention, diagnosis and treatment of opportunistic infections"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Diagnosis and treatment of STIs as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Diagnosis and treatment of STIs as part of programs for PWID and their partners"]
["HIV/AIDS","Treatment, care and support","Counseling and psycho-social support","HIV/AIDS; HIV/TB",{"$f":"CONCATENATE(B131,\"  -  \",C131)","v":"Treatment, care and support  -  Counseling and psycho-social support"}]
["HIV/AIDS","Treatment, care and support","Out-patient care","HIV/AIDS; HIV/TB","Treatment, care and support  -  Out-patient care"]
["HIV/AIDS","Treatment, care and support","In-patient care","HIV/AIDS; HIV/TB","Treatment, care and support  -  In-patient care"]
["HIV/AIDS","Treatment, care and support","Other interventions for treatment - Please specify","HIV/AIDS; HIV/TB","Treatment, care and support  -  Other interventions for treatment - Please specify"]
["HIV/AIDS","Prevention programs for general population","Diagnosis and treatment of STIs as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Diagnosis and treatment of STIs as part of programs for general population"]
["HIV/AIDS","Prevention programs for general population","Blood safety","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Blood safety"]
["HIV/AIDS","Prevention programs for general population","Orphan and vulnerable children (OVC) package","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Orphan and vulnerable children (OVC) package"]
["HIV/AIDS","TB/HIV","TB/HIV collaborative interventions","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  TB/HIV collaborative interventions"]
["HIV/AIDS","TB/HIV","Engaging all care providers","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Engaging all care providers"]
["HIV/AIDS","TB/HIV","Community TB care delivery","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Community TB care delivery"]
["HIV/AIDS","TB/HIV","Key Affected Populations","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Key Affected Populations"]
["HIV/AIDS","TB/HIV","Collaborative activities with other programs and sectors","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Collaborative activities with other programs and sectors"]
["Tuberculosis","TB/HIV","TB/HIV collaborative interventions","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  TB/HIV collaborative interventions"]
["Tuberculosis","TB/HIV","Engaging all care providers","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Engaging all care providers"]
["Tuberculosis","TB/HIV","Community TB care delivery","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Community TB care delivery"]
["Tuberculosis","TB/HIV","Key Affected Populations","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Key Affected Populations"]
["Tuberculosis","TB/HIV","Collaborative activities with other programs and sectors","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Collaborative activities with other programs and sectors"]
["HIV/TB","TB/HIV","TB/HIV collaborative interventions","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  TB/HIV collaborative interventions"]
["HIV/TB","TB/HIV","Engaging all care providers","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Engaging all care providers"]
["HIV/TB","TB/HIV","Community TB care delivery","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Community TB care delivery"]
["HIV/TB","TB/HIV","Key Affected Populations","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Key Affected Populations"]
["HIV/TB","TB/HIV","Collaborative activities with other programs and sectors","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Collaborative activities with other programs and sectors"]
["HIV/AIDS","Removing legal barriers to access","Training on rights for officials, health workers and police","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Training on rights for officials, health workers and police"]
["HIV/AIDS","HSS - Service delivery","Service organization and facility management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Service organization and facility management"]
["HIV/AIDS","HSS - Service delivery","Improving laboratory systems","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving laboratory systems"]
["HIV/AIDS","HSS - Service delivery","Improving service delivery infrastructure","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving service delivery infrastructure"]
["HIV/AIDS","HSS - Service delivery","Other","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Other"]
["HIV/AIDS","HSS - Health and community workforce","Health and community workers capacity building","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Health and community workers capacity building"]
["HIV/AIDS","HSS - Health information systems and M&E","Administrative and finance data sources","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Administrative and finance data sources"]
["HIV/AIDS","HSS - Health information systems and M&E","Vital registration system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Vital registration system"]
["HIV/AIDS","HSS - Health information systems and M&E","Routine reporting","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Routine reporting"]
["HIV/AIDS","HSS - Health information systems and M&E","Analysis, review and transparency","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Analysis, review and transparency"]
["HIV/AIDS","HSS - Health information systems and M&E","Surveys","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Surveys"]
["HIV/AIDS","Program management","Policy, planning, coordination and management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Policy, planning, coordination and management"]
["HIV/AIDS","Program management","Grant management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Grant management"]
["HIV/AIDS","HSS - Health and community workforce","Scaling up health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Scaling up health and community workers"]
["HIV/AIDS","HSS - Health and community workforce","Retention and distribution of health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Retention and distribution of health and community workers"]
["HIV/AIDS","HSS - Procurement supply chain management (PSCM)","Operationalization of procurement and supply chain management system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  Operationalization of procurement and supply chain management system"]
["HIV/AIDS","HSS - Procurement supply chain management (PSCM)","PSM infrastructure and development of tools","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  PSM infrastructure and development of tools"]
["HIV/AIDS","HSS - Policy and governance","Development and implementation of health legislation, strategies and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Development and implementation of health legislation, strategies and policies"]
["HIV/AIDS","Program management","Supporting procurement and supply management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Supporting procurement and supply management"]
["HIV/AIDS","HSS - Policy and governance","Monitoring and reporting implementation of laws and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Monitoring and reporting implementation of laws and policies"]
["HIV/AIDS","HSS - Healthcare financing","Financial sustainability","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Financial sustainability"]
["HIV/AIDS","HSS - Healthcare financing","Equity of healthcare financing","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Equity of healthcare financing"]
["HIV/AIDS","HSS - Financial management","Performance,transparency&accountability of financial management system in health","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Financial management  -  Performance,transparency&accountability of financial management system in health"]
["HIV/AIDS","Removing legal barriers to access","Legal and policy environment assessment and law reform","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal and policy environment assessment and law reform"]
["HIV/AIDS","Removing legal barriers to access","Legal aid services and legal literacy","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal aid services and legal literacy"]
["HIV/AIDS","Removing legal barriers to access","Community-based monitoring of legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Community-based monitoring of legal rights"]
["HIV/AIDS","Removing legal barriers to access","Policy advocacy on legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Policy advocacy on legal rights"]
["Tuberculosis","Removing legal barriers to access","Training on rights for officials, health workers and police","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Training on rights for officials, health workers and police"]
["Tuberculosis","HSS - Service delivery","Service organization and facility management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Service organization and facility management"]
["Tuberculosis","HSS - Service delivery","Improving laboratory systems","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving laboratory systems"]
["Tuberculosis","HSS - Service delivery","Improving service delivery infrastructure","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving service delivery infrastructure"]
["Tuberculosis","HSS - Service delivery","Other","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Other"]
["Tuberculosis","HSS - Health and community workforce","Health and community workers capacity building","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Health and community workers capacity building"]
["Tuberculosis","HSS - Health information systems and M&E","Administrative and finance data sources","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Administrative and finance data sources"]
["Tuberculosis","HSS - Health information systems and M&E","Vital registration system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Vital registration system"]
["Tuberculosis","HSS - Health information systems and M&E","Routine reporting","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Routine reporting"]
["Tuberculosis","HSS - Health information systems and M&E","Analysis, review and transparency","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Analysis, review and transparency"]
["Tuberculosis","HSS - Health information systems and M&E","Surveys","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Surveys"]
["Tuberculosis","Program management","Policy, planning, coordination and management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Policy, planning, coordination and management"]
["Tuberculosis","Program management","Grant management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Grant management"]
["Tuberculosis","HSS - Health and community workforce","Scaling up health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Scaling up health and community workers"]
["Tuberculosis","HSS - Health and community workforce","Retention and distribution of health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Retention and distribution of health and community workers"]
["Tuberculosis","HSS - Procurement supply chain management (PSCM)","Operationalization of procurement and supply chain management system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB",{"$f":"CONCATENATE(B195,\"  -  \",C195)","v":"HSS - Procurement supply chain management (PSCM)  -  Operationalization of procurement and supply chain management system"}]
["Tuberculosis","HSS - Procurement supply chain management (PSCM)","PSM infrastructure and development of tools","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  PSM infrastructure and development of tools"]
["Tuberculosis","HSS - Policy and governance","Development and implementation of health legislation, strategies and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Development and implementation of health legislation, strategies and policies"]
["Tuberculosis","Program management","Supporting procurement and supply management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Supporting procurement and supply management"]
["Tuberculosis","HSS - Policy and governance","Monitoring and reporting implementation of laws and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Monitoring and reporting implementation of laws and policies"]
["Tuberculosis","HSS - Healthcare financing","Financial sustainability","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Financial sustainability"]
["Tuberculosis","HSS - Healthcare financing","Equity of healthcare financing","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Equity of healthcare financing"]
["Tuberculosis","HSS - Financial management","Performance,transparency&accountability of financial management system in health","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Financial management  -  Performance,transparency&accountability of financial management system in health"]
["Tuberculosis","Removing legal barriers to access","Legal and policy environment assessment and law reform","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal and policy environment assessment and law reform"]
["Tuberculosis","Removing legal barriers to access","Legal aid services and legal literacy","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal aid services and legal literacy"]
["Tuberculosis","Removing legal barriers to access","Community-based monitoring of legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Community-based monitoring of legal rights"]
["Tuberculosis","Removing legal barriers to access","Policy advocacy on legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Policy advocacy on legal rights"]
["Malaria","Removing legal barriers to access","Training on rights for officials, health workers and police","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Training on rights for officials, health workers and police"]
["Malaria","HSS - Service delivery","Service organization and facility management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Service organization and facility management"]
["Malaria","HSS - Service delivery","Improving laboratory systems","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving laboratory systems"]
["Malaria","HSS - Service delivery","Improving service delivery infrastructure","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving service delivery infrastructure"]
["Malaria","HSS - Service delivery","Other","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Other"]
["Malaria","HSS - Health and community workforce","Health and community workers capacity building","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Health and community workers capacity building"]
["Malaria","HSS - Health information systems and M&E","Administrative and finance data sources","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Administrative and finance data sources"]
["Malaria","HSS - Health information systems and M&E","Vital registration system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Vital registration system"]
["Malaria","HSS - Health information systems and M&E","Routine reporting","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Routine reporting"]
["Malaria","HSS - Health information systems and M&E","Analysis, review and transparency","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Analysis, review and transparency"]
["Malaria","HSS - Health information systems and M&E","Surveys","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Surveys"]
["Malaria","Program management","Policy, planning, coordination and management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Policy, planning, coordination and management"]
["Malaria","Program management","Grant management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Grant management"]
["Malaria","HSS - Health and community workforce","Scaling up health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Scaling up health and community workers"]
["Malaria","HSS - Health and community workforce","Retention and distribution of health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Retention and distribution of health and community workers"]
["Malaria","HSS - Procurement supply chain management (PSCM)","Operationalization of procurement and supply chain management system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  Operationalization of procurement and supply chain management system"]
["Malaria","HSS - Procurement supply chain management (PSCM)","PSM infrastructure and development of tools","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  PSM infrastructure and development of tools"]
["Malaria","HSS - Policy and governance","Development and implementation of health legislation, strategies and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Development and implementation of health legislation, strategies and policies"]
["Malaria","Program management","Supporting procurement and supply management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Supporting procurement and supply management"]
["Malaria","HSS - Policy and governance","Monitoring and reporting implementation of laws and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Monitoring and reporting implementation of laws and policies"]
["Malaria","HSS - Healthcare financing","Financial sustainability","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Financial sustainability"]
["Malaria","HSS - Healthcare financing","Equity of healthcare financing","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Equity of healthcare financing"]
["Malaria","HSS - Financial management","Performance,transparency&accountability of financial management system in health","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Financial management  -  Performance,transparency&accountability of financial management system in health"]
["Malaria","Removing legal barriers to access","Legal and policy environment assessment and law reform","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal and policy environment assessment and law reform"]
["Malaria","Removing legal barriers to access","Legal aid services and legal literacy","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal aid services and legal literacy"]
["Malaria","Removing legal barriers to access","Community-based monitoring of legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Community-based monitoring of legal rights"]
["Malaria","Removing legal barriers to access","Policy advocacy on legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Policy advocacy on legal rights"]
["Health Systems Strengthening","Removing legal barriers to access","Training on rights for officials, health workers and police","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Training on rights for officials, health workers and police"]
["Health Systems Strengthening","HSS - Service delivery","Service organization and facility management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Service organization and facility management"]
["Health Systems Strengthening","HSS - Service delivery","Improving laboratory systems","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving laboratory systems"]
["Health Systems Strengthening","HSS - Service delivery","Improving service delivery infrastructure","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving service delivery infrastructure"]
["Health Systems Strengthening","HSS - Service delivery","Other","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Other"]
["Health Systems Strengthening","HSS - Health and community workforce","Health and community workers capacity building","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Health and community workers capacity building"]
["Health Systems Strengthening","HSS - Health information systems and M&E","Administrative and finance data sources","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Administrative and finance data sources"]
["Health Systems Strengthening","HSS - Health information systems and M&E","Vital registration system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Vital registration system"]
["Health Systems Strengthening","HSS - Health information systems and M&E","Routine reporting","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Routine reporting"]
["Health Systems Strengthening","HSS - Health information systems and M&E","Analysis, review and transparency","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Analysis, review and transparency"]
["Health Systems Strengthening","HSS - Health information systems and M&E","Surveys","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Surveys"]
["Health Systems Strengthening","Program management","Policy, planning, coordination and management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Policy, planning, coordination and management"]
["Health Systems Strengthening","Program management","Grant management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Grant management"]
["Health Systems Strengthening","HSS - Health and community workforce","Scaling up health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Scaling up health and community workers"]
["Health Systems Strengthening","HSS - Health and community workforce","Retention and distribution of health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Retention and distribution of health and community workers"]
["Health Systems Strengthening","HSS - Procurement supply chain management (PSCM)","Operationalization of procurement and supply chain management system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  Operationalization of procurement and supply chain management system"]
["Health Systems Strengthening","HSS - Procurement supply chain management (PSCM)","PSM infrastructure and development of tools","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  PSM infrastructure and development of tools"]
["Health Systems Strengthening","HSS - Policy and governance","Development and implementation of health legislation, strategies and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Development and implementation of health legislation, strategies and policies"]
["Health Systems Strengthening","Program management","Supporting procurement and supply management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Supporting procurement and supply management"]
["Health Systems Strengthening","HSS - Policy and governance","Monitoring and reporting implementation of laws and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Monitoring and reporting implementation of laws and policies"]
["Health Systems Strengthening","HSS - Healthcare financing","Financial sustainability","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Financial sustainability"]
["Health Systems Strengthening","HSS - Healthcare financing","Equity of healthcare financing","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Equity of healthcare financing"]
["Health Systems Strengthening","HSS - Financial management","Performance,transparency&accountability of financial management system in health","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Financial management  -  Performance,transparency&accountability of financial management system in health"]
["Health Systems Strengthening","Removing legal barriers to access","Legal and policy environment assessment and law reform","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal and policy environment assessment and law reform"]
["Health Systems Strengthening","Removing legal barriers to access","Legal aid services and legal literacy","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal aid services and legal literacy"]
["Health Systems Strengthening","Removing legal barriers to access","Community-based monitoring of legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB",{"$f":"CONCATENATE(B259,\"  -  \",C259)","v":"Removing legal barriers to access  -  Community-based monitoring of legal rights"}]
["Health Systems Strengthening","Removing legal barriers to access","Policy advocacy on legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Policy advocacy on legal rights"]
["HIV/TB","Removing legal barriers to access","Training on rights for officials, health workers and police","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Training on rights for officials, health workers and police"]
["HIV/TB","HSS - Service delivery","Service organization and facility management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Service organization and facility management"]
["HIV/TB","HSS - Service delivery","Improving laboratory systems","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving laboratory systems"]
["HIV/TB","HSS - Service delivery","Improving service delivery infrastructure","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving service delivery infrastructure"]
["HIV/TB","HSS - Service delivery","Other","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Other"]
["HIV/TB","HSS - Health and community workforce","Health and community workers capacity building","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Health and community workers capacity building"]
["HIV/TB","HSS - Health information systems and M&E","Administrative and finance data sources","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Administrative and finance data sources"]
["HIV/TB","HSS - Health information systems and M&E","Vital registration system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Vital registration system"]
["HIV/TB","HSS - Health information systems and M&E","Routine reporting","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Routine reporting"]
["HIV/TB","HSS - Health information systems and M&E","Analysis, review and transparency","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Analysis, review and transparency"]
["HIV/TB","HSS - Health information systems and M&E","Surveys","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Surveys"]
["HIV/TB","Program management","Policy, planning, coordination and management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Policy, planning, coordination and management"]
["HIV/TB","Program management","Grant management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Grant management"]
["HIV/TB","HSS - Health and community workforce","Scaling up health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Scaling up health and community workers"]
["HIV/TB","HSS - Health and community workforce","Retention and distribution of health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Retention and distribution of health and community workers"]
["HIV/TB","HSS - Procurement supply chain management (PSCM)","Operationalization of procurement and supply chain management system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  Operationalization of procurement and supply chain management system"]
["HIV/TB","HSS - Procurement supply chain management (PSCM)","PSM infrastructure and development of tools","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  PSM infrastructure and development of tools"]
["HIV/TB","HSS - Policy and governance","Development and implementation of health legislation, strategies and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Development and implementation of health legislation, strategies and policies"]
["HIV/TB","Program management","Supporting procurement and supply management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Supporting procurement and supply management"]
["HIV/TB","HSS - Policy and governance","Monitoring and reporting implementation of laws and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Monitoring and reporting implementation of laws and policies"]
["HIV/TB","HSS - Healthcare financing","Financial sustainability","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Financial sustainability"]
["HIV/TB","HSS - Healthcare financing","Equity of healthcare financing","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Equity of healthcare financing"]
["HIV/TB","HSS - Financial management","Performance,transparency&accountability of financial management system in health","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Financial management  -  Performance,transparency&accountability of financial management system in health"]
["HIV/TB","Removing legal barriers to access","Legal and policy environment assessment and law reform","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal and policy environment assessment and law reform"]
["HIV/TB","Removing legal barriers to access","Legal aid services and legal literacy","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal aid services and legal literacy"]
["HIV/TB","Removing legal barriers to access","Community-based monitoring of legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Community-based monitoring of legal rights"]
["HIV/TB","Removing legal barriers to access","Policy advocacy on legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Policy advocacy on legal rights"]
["HIV/AIDS","Community systems strengthening","Community-based monitoring for accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Community-based monitoring for accountability"]
["HIV/AIDS","Community systems strengthening","Advocacy for social accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Advocacy for social accountability"]
["HIV/AIDS","Community systems strengthening","Social mobilization, building community linkages, collaboration and coordination","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Social mobilization, building community linkages, collaboration and coordination"]
["HIV/AIDS","Community systems strengthening","Institutional capacity building, planning and leadership development","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Institutional capacity building, planning and leadership development"]
["HIV/AIDS","Results-based Financing","Results-based financing","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Results-based Financing  -  Results-based financing"]
["Tuberculosis","Community systems strengthening","Community-based monitoring for accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Community-based monitoring for accountability"]
["Tuberculosis","Community systems strengthening","Advocacy for social accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Advocacy for social accountability"]
["Tuberculosis","Community systems strengthening","Social mobilization, building community linkages, collaboration and coordination","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Social mobilization, building community linkages, collaboration and coordination"]
["Tuberculosis","Community systems strengthening","Institutional capacity building, planning and leadership development","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Institutional capacity building, planning and leadership development"]
["Tuberculosis","Results-based Financing","Results-based financing","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Results-based Financing  -  Results-based financing"]
["Malaria","Community systems strengthening","Community-based monitoring for accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Community-based monitoring for accountability"]
["Malaria","Community systems strengthening","Advocacy for social accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Advocacy for social accountability"]
["Malaria","Community systems strengthening","Social mobilization, building community linkages, collaboration and coordination","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Social mobilization, building community linkages, collaboration and coordination"]
["Malaria","Community systems strengthening","Institutional capacity building, planning and leadership development","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Institutional capacity building, planning and leadership development"]
["Malaria","Results-based Financing","Results-based financing","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Results-based Financing  -  Results-based financing"]
["HIV/TB","Community systems strengthening","Community-based monitoring for accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Community-based monitoring for accountability"]
["HIV/TB","Community systems strengthening","Advocacy for social accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Advocacy for social accountability"]
["HIV/TB","Community systems strengthening","Social mobilization, building community linkages, collaboration and coordination","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Social mobilization, building community linkages, collaboration and coordination"]
["HIV/TB","Community systems strengthening","Institutional capacity building, planning and leadership development","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Institutional capacity building, planning and leadership development"]
["HIV/TB","Results-based Financing","Results-based financing","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Results-based Financing  -  Results-based financing"]

{"sheet":"Impact Outcome Indicators_1A","index":2,"n_rows":51,"n_cols":32,"rows_kept":51,"cut":false,"hidden":false,"merged":[[41,1,41,5],[41,13,41,15],[50,1,50,5],[50,13,50,15],[46,1,46,5],[46,13,46,15],[47,1,47,5],[47,13,47,15],[48,1,48,5],[48,13,48,15],[42,1,42,5],[42,13,42,15],[43,1,43,5],[43,13,43,15],[44,1,44,5],[44,13,44,15],[45,1,45,5],[45,13,45,15],[49,1,49,5],[49,13,49,15],[36,1,36,5],[36,13,36,15],[37,1,37,5],[37,13,37,15],[38,1,38,5],[38,13,38,15],[39,1,39,5],[39,13,39,15],[40,1,40,5],[40,13,40,15],[31,1,31,5],[31,13,31,15],[32,1,32,5],[32,13,32,15],[33,1,33,5],[33,13,33,15],[34,1,34,5],[34,13,34,15],[35,1,35,5],[35,13,35,15],[26,13,26,15],[28,1,28,5],[28,13,28,15],[29,1,29,5],[29,13,29,15],[27,1,27,5],[27,13,27,15],[26,1,26,5],[30,1,30,5],[30,13,30,15],[19,0,19,15],[23,14,23,15],[24,0,25,0],[24,1,25,5],[24,6,24,7],[24,8,25,8],[24,9,25,9],[24,10,25,10],[24,11,25,11],[24,12,25,12],[24,13,25,15],[5,2,5,5],[7,0,7,1],[7,2,7,5],[8,0,8,1],[8,2,8,5],[9,0,9,1],[9,2,9,5],[13,2,13,5],[17,2,17,5],[49,23,49,27],[50,23,50,27],[26,23,26,27],[42,23,42,27],[43,23,43,27],[44,23,44,27],[45,23,45,27],[46,23,46,27],[37,23,37,27],[38,23,38,27],[39,23,39,27],[40,23,40,27],[41,23,41,27],[32,23,32,27],[33,23,33,27],[34,23,34,27],[35,23,35,27],[36,23,36,27],[27,23,27,27],[28,23,28,27],[29,23,29,27],[30,23,30,27],[31,23,31,27],[50,29,50,33],[33,29,33,33],[34,29,34,33],[35,29,35,33],[36,29,36,33],[37,29,37,33],[38,29,38,33],[39,29,39,33],[40,29,40,33],[41,29,41,33],[49,29,49,33],[24,28,25,28],[24,29,25,33],[26,29,26,33],[27,29,27,33],[28,29,28,33],[29,29,29,33],[30,29,30,33],[31,29,31,33],[32,29,32,33],[0,0,0,5],[23,28,23,33],[42,29,42,33],[43,29,43,33],[44,29,44,33],[45,29,45,33],[46,29,46,33],[47,29,47,33],[48,29,48,33],[24,16,24,17],[24,18,25,18],[24,19,25,19],[24,20,25,20],[23,16,23,27],[47,23,47,27],[48,23,48,27],[24,21,25,21],[24,22,25,22],[24,23,25,27],[6,0,6,1],[6,2,6,5],[4,0,4,1],[4,2,4,5],[5,0,5,1]]}
["On-going Progress Update and Disbursement Request"]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"AIS (AIDS Indicator Survey)",null,null,null,null,null,"AIS (AIDS Indicator Survey)"]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"BSS (Behavioral and Surveillance Survey)",null,null,null,null,null,"BSS (Behavioral and Surveillance Survey)"]
["GENERAL GRANT INFORMATION",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Census",null,null,null,null,null,"Census"]
["Country:",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Clinical cohort follow-up studies",null,null,null,null,null,"Clinical cohort follow-up studies"]
["Disease:",null,"Select",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"DHS/DHS+ (Demographic and Health Survey)",null,null,null,null,null,"DHS/DHS+ (Demographic and Health Survey)"]
["Grant Number:",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"MICS (Multiple Indicator Cluster Survey)",null,null,null,null,null,"MICS (Multiple Indicator Cluster Survey)"]
["Principal Recipient:",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"MIS (Malaria Indicator Survey)",null,null,null,null,null,"MIS (Malaria Indicator Survey)"]
["Program Start Date:",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"WHO Global report/estimates",null,null,null,null,null,"WHO Global report/estimates"]
["Currency:",null,"Select",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Other (type as appropriate)",null,null,null,null,null,"Other (type as appropriate)"]
["PROGRESS UPDATE "]
["Progress Update - Reporting Period:",null,"Cycle:","Select","Number:"]
["Progress Update - Period Covered:",null,"Beginning Date:",null,"End Date:"]
["Progress Update - Number:"]
["DISBURSEMENT REQUEST "]
["Disbursement Request  - Disbursement Period:",null,"Cycle:","Select","Number:"]
["Disbursement Request  - Period Covered:",null,"Beginning Date:",null,"End Date:"]
["Disbursement Request  - Number:"]
[]
[]
[]
["Section 1:  Programmatic Progress"]
["Note: The table below should contain those Impact/Outcome indicators that are (1) due for reporting during the current year of a grant and (2) those reporting on which is overdue from the previous periods."]
["A.  Impact / Outcome Indicators",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"For LFA Use Only",null,null,null,null,null,null,null,null,null,null,null,"For the Global Fund Use Only"]
["Impact / Outcome ","Indicator Description",null,null,null,null,"Baseline \n(if applicable)",null,"Year of Target","Intended Target","Report Due Date","Actual Result","Data Source of Results","Comments on results on Impact/Outcome indicators and data sources, and any other comments",null,null,"Baseline \n(if applicable)",null,"Year of Target","Intended Target","Report Due Date","Verification Method","Verified Result","LFA comments on (a) verified result, (b) source of information used by the PR to report results, including the status of completion of surveys and other methods to measure Impact/Outcome, as applicable,  ",null,null,null,null,"Validated Result","Country Team comments on validated results"]
[null,null,null,null,null,null,"Value","Year",null,null,null,null,null,null,null,null,"Value","Year"]
["Impact","TB mortality rate\nNumber of deaths attributable to TB (all forms) registered in a specified period per 100,000 populations",null,null,null,null,7,2014,"2015",6.5,"2016-02-15",6.6,"WHO Global report/estimates","The source of the baseline value is WHO Global TB Report",null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,{"$f":"W27","v":0}]
["Outcome","Case notification rate per 100,000 population- all forms of TB i.e. bacteriologically confirmed + clinically diagnosed*\n*Case notification rate indicators include new and relapse cases",null,null,null,null,88,2012,"2015",86,"2016-02-15",84,"Other (type as appropriate)","Overall number of TB cases has a tendency to decrease. The latter was articulated in the new NSP post 2016",null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,{"$f":"W28","v":0}]
["Outcome","Treatment success rate -  bacteriologically confirmed: Percentage of bacteriologically cobfirmed TB cases successfully treated (cured plus treatment completed)",null,null,null,null,0.76,2011,"2013",0.85,"2016-02-15",0.77,"Other (type as appropriate)","Overall treatment outcomes for regular TB patients remain sufficient",null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Outcome","Treatment success rate- laboratory confirmed RR TB and/or MDR-TB:\nPercentage of bacteriologically-confirmed RR and/or MDR-TB cases successfully treated (cured plus completed treatment) among those enrolled on second-line anti-TB treatment during the year of assessment ",null,null,null,null,0.52,2010,"2012",0.75,"2016-02-15",0.46,"Other (type as appropriate)","High rates of lost to follow-up contributes to poor treatment outcomes",null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Outcome","Case notification rate per 100,000 population- bacteriologically confirmed (new and relapse cases)",null,null,null,null,55,2012,"2015",53,"2016-02-15",58,"Other (type as appropriate)","Overall number of TB cases has a tendency to decrease. The latter was articulated in the new NSP post 2016",null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]

{"sheet":"Coverage Indicators_1B","index":3,"n_rows":51,"n_cols":42,"rows_kept":51,"cut":false,"hidden":false,"merged":[[10,38,10,40],[9,38,9,45],[22,41,22,45],[23,41,23,45],[24,41,24,45],[25,41,25,45],[45,0,45,45],[10,41,11,45],[12,41,12,45],[13,41,13,45],[14,41,14,45],[15,41,15,45],[16,41,16,45],[17,41,17,45],[18,41,18,45],[19,41,19,45],[20,41,20,45],[21,41,21,45],[28,41,28,45],[37,41,37,45],[39,41,39,45],[26,41,26,45],[27,41,27,45],[20,2,20,5],[46,2,46,5],[39,19,39,20],[43,2,43,5],[43,19,43,20],[44,2,44,5],[44,19,44,20],[23,2,23,5],[23,19,23,20],[28,19,28,20],[46,19,46,20],[40,2,40,5],[40,19,40,20],[41,2,41,5],[41,19,41,20],[42,2,42,5],[42,19,42,20],[25,2,25,5],[25,19,25,20],[26,2,26,5],[26,19,26,20],[27,2,27,5],[27,19,27,20],[24,2,24,5],[24,19,24,20],[21,2,21,5],[21,19,21,20],[22,2,22,5],[22,19,22,20],[17,2,17,5],[17,19,17,20],[18,2,18,5],[18,19,18,20],[19,2,19,5],[19,19,19,20],[20,19,20,20],[14,2,14,5],[14,19,14,20],[15,2,15,5],[15,19,15,20],[16,2,16,5],[16,19,16,20],[10,13,10,15],[12,19,12,20],[13,2,13,5],[13,19,13,20],[0,0,0,8],[10,30,10,32],[10,33,11,37],[12,33,12,37],[10,19,11,20],[2,0,2,2],[2,3,2,6],[5,3,5,6],[9,0,9,20],[10,0,11,0],[10,1,11,1],[10,2,11,5],[10,6,11,6],[10,7,11,7],[10,8,11,8],[12,2,12,5],[9,21,9,37],[10,16,10,18],[10,21,11,21],[10,22,11,22],[10,27,10,29],[10,9,10,12],[10,23,10,26],[37,2,37,5],[37,19,37,20],[39,2,39,5],[28,2,28,5],[23,33,23,37],[24,33,24,37],[25,33,25,37],[26,33,26,37],[41,33,41,37],[27,33,27,37],[28,33,28,37],[37,33,37,37],[39,33,39,37],[22,33,22,37],[13,33,13,37],[14,33,14,37],[15,33,15,37],[16,33,16,37],[17,33,17,37],[18,33,18,37],[19,33,19,37],[20,33,20,37],[21,33,21,37]]}
["On-going Progress Update and Disbursement Request"]
["PROGRESS UPDATE PERIOD"]
["Grant number:",null,null,{"$f":"IF('[6]PR_Programmatic Progress_1A'!C7=\"\",\"\",'[6]PR_Programmatic Progress_1A'!C7)","v":""}]
["Progress Update - Reporting Period:",null,null,"Cycle:",{"$f":"IF('[6]PR_Programmatic Progress_1A'!D12=\"Select\",\"\",'[6]PR_Programmatic Progress_1A'!D12)","v":""},"Number:",{"$f":"IF('[6]PR_Programmatic Progress_1A'!F12=\"Select\",\"\",'[6]PR_Programmatic Progress_1A'!F12)","v":0}]
["Progress Update - Period Covered:",null,null,"Beginning Date:",{"$f":"IF('[6]PR_Programmatic Progress_1A'!D13=\"\",\"\",'[6]PR_Programmatic Progress_1A'!D13)","v":""},"End Date:",{"$f":"IF('[6]PR_Programmatic Progress_1A'!F13=\"\",\"\",'[6]PR_Programmatic Progress_1A'!F13)","v":""}]
["Progress Update - Number:",null,null,{"$f":"IF('[6]PR_Programmatic Progress_1A'!C14=\"Select\",\"\",'[6]PR_Programmatic Progress_1A'!C14)","v":0}]
[]
["Section 1:  Programmatic Progress"]
["Note: All programmatic indicators contained in the current Performance Framework should be listed, regardless of whether there are targets/results for the period covered by the Progress Update or whether the targets have been met in previous periods.  "]
["B.  Coverage Indicators",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"For LFA Use Only",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"For the Global Fund Use Only"]
["Objective\nNo.","* Indicator No.","Indicator Description",null,null,null,"Tied To","Targets cumulative?\n","Top 10 indicator?","Baseline",null,null,null,"Target",null,null,"Result",null,null,"Reasons for programmatic deviation from intended target and deviations from the related workplan activities",null,"Targets cumulative?\n","Top 10 indicator?","Baseline",null,null,null,"Target",null,null,"Verified Result",null,null,"LFA analysis on progress to date and any variance between targets and results, and any other comments\n(this should not be a “Copy and Paste” of the reasons provided by the PR)",null,null,null,null,"Validated Result",null,null,"Country Team comments on validated results"]
[null,null,null,null,null,null,null,null,null,"Year","N#","D#","%","N#","D#","%","N#","D#","%",null,null,null,null,"Year","N#","D#","%","N#","D#","%","N#","D#","%",null,null,null,null,null,"N#","D#","%"]
[2,1,"Percentage of TB patients who had an HIV test result recorded in the TB register ",null,null,null,"Current grant","N-not cumulative","Yes - Top 10",2013,2535,4184,{"$f":"IFERROR(K13/L13,\"\")","v":0.60587954110898656},1850,2467,{"$f":"IFERROR(N13/O13,\"\")","v":0.74989866234292668},1435,1623,{"$f":"IFERROR(Q13/R13,\"\")","v":0.88416512630930377},"The indicator is overachieved. The numerator and denominator values are based on the TB Centre database for the said reporting period. The joint effort of PR/SR resulted in the substantial scale-up of HIV testing",null,"Select","Select",null,null,null,{"$f":"IFERROR(Y13/Z13,\"\")","v":""},null,null,{"$f":"IFERROR(AB13/AC13,\"\")","v":""},null,null,{"$f":"IFERROR(AE13/AF13,\"\")","v":""},null,null,null,null,null,{"$f":"AE13","v":0},{"$f":"AF13","v":0},{"$f":"IFERROR(AM13/AN13,\"\")","v":""}]
[2,2,"Number of notified cases of bacteriologically confirmed TB, (new and relapse)",null,null,null,"Current grant","Y-cumulative annually","Yes - Top 10",2012,2464,null,{"$f":"IFERROR(K14/L14,\"\")","v":""},2844,2844,{"$f":"IFERROR(N14/O14,\"\")","v":1},2168,2844,{"$f":"IFERROR(Q14/R14,\"\")","v":0.76230661040787628},"The number comes from the TB Centre database for the said reporting period. Overall number of TB cases has a tendency to decrease. The latter was addressed in the new NSP post 2016.",null,"Select","Select",null,null,null,{"$f":"IFERROR(Y14/Z14,\"\")","v":""},null,null,{"$f":"IFERROR(AB14/AC14,\"\")","v":""},null,null,{"$f":"IFERROR(AE14/AF14,\"\")","v":""},null,null,null,null,null,{"$f":"AE14","v":0},{"$f":"AF14","v":0},{"$f":"IFERROR(AM14/AN14,\"\")","v":""}]
[2,3,"Percentage of laboratories showing adequate performance in external quality assurance for smear microscopy among the total number of laboratories that undertake smear microscopy during the reporting period ",null,null,null,"Current grant","N-not cumulative","Yes - Top 10",2013,9,11,{"$f":"IFERROR(K15/L15,\"\")","v":0.81818181818181823},11,11,1,9,11,0.81818181818181823,"The result is based on the samples of slides collected randomly in April - March, 2015 (Q2) and checked for QA purposes in Q3. Smear testing is suspended in Gori (Shida Kartli) laboratory due to the absence of the lab-specialist. At the moment, the new technician is on board (starting January, 2016).",null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[3,1,"\nNumber of notified cases of all forms of TB - (i.e. bacteriologically confirmed +clinically diagnosed) (new and relapse)",null,null,null,"National Program","Y-cumulative annually","Yes - Top 10",2012,3939,null,{"$f":"IFERROR(K16/L16,\"\")","v":""},4063,4063,1,3136,4063,0.77184346541964066,"The number comes from the TB Centre database for the said reporting period. The value can slightly increase as culture results might be pending for the patients registered/tested in December, 2015. Overall number of TB cases has a tendency to decrease.",null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[3,2,"Number of bacteriologically confirmed  TB cases in a specified period who subsequently were successfully treated (sum of WHO outcome categories \"cured” plus \"treatment completed”)",null,null,null,"National Program","Y-cumulative annually","Yes - Top 10",2011,1917,null,"",2417,2417,1,1754,{"$f":"N17","v":2417},0.72569300786098467,"1754 bacteriologically confirmed TB cases were successfully treated during January-December, 2013. \n74 out of 102 of the reported cases relate to the penitentiary sector",null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[3,3,"Number of TB patients enrolled on standardized 1st line treatment in the specified calendar year",null,null,null,"National Program","Y-cumulative annually","Yes - Top 10",2012,4933,null,"",4423,4423,1,3352,{"$f":"N18","v":4423},0.75785665837666738,"The number comes from the TB Centre database for the said reporting period. The relatively low indicator relates to the actual (decreased) number of TB patients in the country",null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[3,4,"Laboratory-confirmed X/MDR-TB patients enrolled on second line anti-TB treatment in the specified calendar year",null,null,null,"National Program","Y-cumulative annually","Yes - Top 10",2013,659,null,"",519,519,1,457,{"$f":"N19","v":519},0.88053949903660889,"457 X/MDR-TB patients were enrolled on second line anti-TB treatment during  2015.  The data is derived from the TB Centre Database",null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[3,5,"Percentage of previously treated TB patients receiving DST",null,null,null,"National Program","Y-cumulative annually","Yes - Top 10",2012,569,632,0.90031645569620256,600,630,0.95238095238095233,494,558,0.88530465949820791,"494 previously treated TB patients received DST in July-December, 2014  and  January - June, 2015 as the latest available DST results for culture positive patients are from the same period.",null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[3,6,"Percentage of cases with drug resistant TB (RR-TB and/or MDR-TB) started on treatment for MDR-TB who were lost to follow up during the first six months of treatment",null,null,null,"National Program","N-not cumulative","Yes - Top 10",2013,31,253,0.1225296442687747,27,260,0.10384615384615385,26,222,0.11711711711711711,"This is a reverse indicator. 12% of the cohort from January-June, 2015 were lost to follow-up during the first six months of treatment. The data is derived from the TB Centre Database. The cohort was evaluated by PR and issue brought to the CCM's attention. The recommendation is to follow-up the cohort.",null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[4,1,"Number of and percentage of TB patients on 1st line treatment receiving cash incentives for better adherence to treatment ",null,null,null,"Current grant","Y-cumulative annually","Yes - Top 10",2012,3217,4675,0.68812834224598929,3096,4423,0.6999773909111463,3113,3924,0.79332313965341483,"The indicator is overachieved. Actual result reported (79% meaning that 3113 patients, out of 3924 received cash incentives for adequate compliance) includes transactions held in January-November 2015. As per December, 2015 compliance – incentives will be transferred in February 2016.",null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[4,2,"Number and percentage of M/XDR-TB patients on treatment receiving cash incentives for better adherence to treatment during out-patient phase",null,null,null,"Current grant","Y-cumulative annually","Yes - Top 10",2012,405,548,0.73905109489051091,389,519,0.74951830443159928,702,842,0.833729216152019,"The indicator is overachieved. Actual result reported (83% meaning that 702 patients, out of 842 received cash incentives for adequate compliance) includes transactions held in January-November 2015. As per December, 2015 compliance – incentives were transferred on February, 2016",null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,null,null,null,0]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,null,null,null,0]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,null,null,null,0]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,null,null,null,0]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,null,null,null,0]
[]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-"]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-"]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-"]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-"]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-"]

{"sheet":"ImpactOutcomeDisaggData","index":4,"n_rows":33,"n_cols":9,"rows_kept":33,"cut":false,"hidden":true,"merged":[[0,1,0,8]]}
[null,"Impact/outcome disaggregation Data "]
[]
[null,"HIV I-1: Percentage of young people aged 15–24 who are living with HIV","HIVI1","Sex",{"$f":"CONCATENATE(C3,D3)","v":"HIVI1Sex"},"Male","Female",null,"Impact"]
[null,"HIV I-2: HIV incidence among 15-49 age group","HIVI2","Sex",{"$f":"CONCATENATE(C4,D4)","v":"HIVI2Sex"},"Male","Female",null,"Impact"]
[null,"HIV I-2: HIV incidence among 15-49 age group","HIVI2","Age",{"$f":"CONCATENATE(C5,D5)","v":"HIVI2Age"},"15-24"]
[null,"HIV I-4: AIDS related mortality per 100,000 population","HIVI4","Sex","HIVI4Sex","Male","Female",null,"Impact"]
[null,"HIV I-4: AIDS related mortality per 100,000 population","HIVI4","Age","HIVI4Age","<15","15+","15-24","Impact"]
[null,"HIV I-9a: Percentage of men who have sex with men who are living with HIV","HIVI9a","Age","HIVI9aAge","<25","25+",null,"Impact"]
[null,"HIV I-9b: Percentage of transgender people who are living with HIV","HIVI9b","Age","HIVI9bAge","<25","25+",null,"Impact"]
[null,"Malaria I-1: Reported malaria cases - presumed and confirmed","MalariaI1","Sex","MalariaI1Sex","Male","Female",null,"Impact"]
[null,"Malaria I-1: Reported malaria cases - presumed and confirmed","MalariaI1","Age","MalariaI1Age","<5","5+",null,"Impact"]
[null,"Malaria I-2: Confirmed malaria cases (microscopy or RDT) per 1000 persons per year","MalariaI2","Sex","MalariaI2Sex","Male","Female",null,"Impact"]
[null,"Malaria I-2: Confirmed malaria cases (microscopy or RDT) per 1000 persons per year","MalariaI2","Age","MalariaI2Age","<5","5+",null,"Impact"]
[null,"Malaria I-2: Confirmed malaria cases (microscopy or RDT) per 1000 persons per year","MalariaI2","Species","MalariaI2Species","P. Vivax","P. Falciparum","Other - specify","Impact"]
[null,"Malaria I-3: Inpatient malaria deaths per 1000 persons per year","MalariaI3","Sex","MalariaI3Sex","Male","Female",null,"Impact"]
[null,"Malaria I-3: Inpatient malaria deaths per 1000 persons per year","MalariaI3","Age","MalariaI3Age","<5","5+",null,"Impact"]
[null,"Malaria I-4: Malaria test positivity rate","MalariaI4","Species","MalariaI4Species","P. Vivax","P. Falciparum","Other - specify","Impact"]
[null,"Malaria I-4: Malaria test positivity rate","MalariaI4","Type of testing",{"$f":"SUBSTITUTE(CONCATENATE(C18,D18),\" \",\"\")","v":"MalariaI4Typeoftesting"},"Microscopy","RDT",null,"Impact"]
[null,"Malaria I-5: Parasite prevalence: Proportion of children aged 6-59 months with malaria infection","MalariaI5","Sex","MalariaI5Sex","Male","Female",null,"Impact"]
[null,"Malaria I-5: Parasite prevalence: Proportion of children aged 6-59 months with malaria infection","MalariaI5","Species","MalariaI5Species","P. Vivax","P. Falciparum","Other - specify"]
[null,"Malaria I-6: All-cause under-5 mortality rate per 1000 live births","MalariaI6","Sex","MalariaI6Sex","Male","Female",null,"Impact"]
[null,"HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy","HIVO1","Sex","HIVO1Sex","Male","Female",null,"Outcome"]
[null,"HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy","HIVO1","Age","HIVO1Age","<15","15+",null,"Outcome"]
[null,"HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy","HIVO1","Duration of treatment",{"$f":"SUBSTITUTE(CONCATENATE(C24,D24),\" \",\"\")","v":"HIVO1Durationoftreatment"},"24 months","36 months",null,"Outcome"]
[null,"HIV O-2: Percentage of women and men aged 15-49 who have had sexual intercourse with more than one partner in the past 12 months","HIVO2","Sex","HIVO2Sex","Male","Female",null,"Outcome"]
[null,"HIV O-2: Percentage of women and men aged 15-49 who have had sexual intercourse with more than one partner in the past 12 months","HIVO2","Age","HIVO2Age","15-19","20-24",null,"Outcome"]
[null,"HIV O-3: Percentage of women and men aged 15-49 who had more than one partner in the past 12 months who used a condom during their last sexual intercourse","HIVO3","Sex","HIVO3Sex","Male","Female",null,"Outcome"]
[null,"HIV O-3: Percentage of women and men aged 15-49 who had more than one partner in the past 12 months who used a condom during their last sexual intercourse","HIVO3","Age","HIVO3Age","15-19","20-24",null,"Outcome"]
[null,"HIV O-5: Percentage of sex workers reporting the use of a condom with their most recent client","HIVO5","Sex","HIVO5Sex","Male","Female",null,"Outcome"]
[null,"HIV O-6: Percentage of people who inject drugs reporting the use of sterile injecting equipment the last time they injected","HIVO6","Sex","HIVO6Sex","Male","Female",null,"Outcome"]
[null,"HIV O-8: Current school attendance rate among orphans compared to non-orphans","HIVO8","Sex","HIVO8Sex","Male","Female",null,"Outcome"]
[null,"Malaria O-1a: Proportion of population that slept under an insecticide-treated net* the previous night","MalariaO1a","Sex","MalariaO1aSex","Male","Female",null,"Outcome"]
[null,"Malaria O-3: Proportion of population using an insecticide-treated net* among the population with access to an insecticide-treated net","MalariaO3","Sex","MalariaO3Sex","Male","Female",null,"Outcome"]

{"sheet":"Impactoutcome","index":5,"n_rows":28,"n_cols":11,"rows_kept":28,"cut":false,"hidden":true,"merged":[]}
[]
[null,"Type1","Type2","Type3","Type4","Type5","Type6","Type7","Type8","Type9","Type10"]
[null,"Malaria I-1: Reported malaria cases - presumed and confirmed","TB I-1: TB prevalence rate (per 100,000 population)","HIV I-1: Percentage of young people aged 15–24 who are living with HIV","HIV I-1: Percentage of young people aged 15–24 who are living with HIV","HSS I-1: Under 5 mortality rate per 1000 live births","Malaria O-1a: Proportion of population that slept under an insecticide-treated net* the previous night","TB O-1a: Case notification rate of all forms of TB per 100,000 population - bacteriologically confirmed plus clinically diagnosed, new and relapse cases","HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy","HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy","HSS O-1: Percentage of women attending antenatal care"]
[null,"Malaria I-2: Confirmed malaria cases (microscopy or RDT) per 1000 persons per year","TB I-2: TB incidence rate (per 100,000 population)","HIV I-2: HIV incidence among 15-49 age group","HIV I-2: HIV incidence among 15-49 age group","HSS I-2: Neonatal mortality rate, per 100,000 population","Malaria O-1b: Proportion of children under five years old who slept under an insecticide-treated net* the previous night","TB O-1b: Case notification rate per 100,000 population- bacteriologically-confirmed TB, new and relapse","HIV O-2: Percentage of women and men aged 15-49 who have had sexual intercourse with more than one partner in the past 12 months","HIV O-2: Percentage of women and men aged 15-49 who have had sexual intercourse with more than one partner in the past 12 months","HSS O-2: Percentage of births attended by skilled health professional"]
[null,"Malaria I-3: Inpatient malaria deaths per 1000 persons per year","TB I-3: TB mortality rate (per 100,000 population)","HIV I-3a: Percentage of antenatal care attendees who were positive for syphilis","HIV I-3a: Percentage of antenatal care attendees who were positive for syphilis","HSS I-3: Maternal mortality ratio, per 100,000 population","Malaria O-1c: Proportion of pregnant women who slept under an insecticide-treated net* the previous night","TB O-2a: Treatment success rate - all forms of TB","HIV O-3: Percentage of women and men aged 15-49 who had more than one partner in the past 12 months who used a condom during their last sexual intercourse","HIV O-3: Percentage of women and men aged 15-49 who had more than one partner in the past 12 months who used a condom during their last sexual intercourse","HSS O-3: Ratio of household out-of-pocket payments for health to total expenditure on health"]
[null,"Malaria I-4: Malaria test positivity rate","TB I-4: MDR-TB prevalence among new TB patients","HIV I-3b: Percentage of men who have sex with men with active syphilis","HIV I-3b: Percentage of men who have sex with men with active syphilis","Custom","Malaria O-2: Proportion of population with access to an ITN within their household","TB O-2b: Treatment success rate - bacteriologically confirmed TB cases","HIV O-4a: Percentage of men reporting the use of a condom the last time they had anal sex with a male partner","HIV O-4a: Percentage of men reporting the use of a condom the last time they had anal sex with a male partner","HSS O-4: General service readiness score for health facilities"]
[null,"Malaria I-5: Parasite prevalence: Proportion of children aged 6-59 months with malaria infection","TB I-5: Modelled lives saved based on latest epidemiological data","HIV I-3c: Percentage of sex workers with active syphilis","HIV I-3c: Percentage of sex workers with active syphilis",null,"Malaria O-3: Proportion of population using an insecticide-treated net* among the population with access to an insecticide-treated net","TB O-3: Notification of RR-TB and/or MDR-TB cases - Percentage of notified cases of bacteriologically confirmed, drug resistant RR-TB and/or MDR-TB? as a proportion of the estimated number of RR-TB and/or MDR-TB cases among notified TB cases","HIV O-4b: Percentage of transgender people who sell sex reporting the use of a condom with their most recent client","HIV O-4b: Percentage of transgender people who sell sex reporting the use of a condom with their most recent client","Custom"]
[null,"Malaria I-6: All-cause under-5 mortality rate per 1000 live births","TB I-6: Modelled infections averted based on latest epidemiological data","HIV I-4: AIDS related mortality per 100,000 population","HIV I-4: AIDS related mortality per 100,000 population",null,"Malaria O-4: Proportion of households with at least one insecticide-treated net for every two people and/or sprayed by IRS within the last 12 months","TB O-4: Treatment success rate of MDR-TB: Percentage of bacteriologically confirmed drug resistant TB cases (RR-TB and/or MDR-TB) successfully treated","HIV O-5: Percentage of sex workers reporting the use of a condom with their most recent client","HIV O-5: Percentage of sex workers reporting the use of a condom with their most recent client"]
[null,"Malaria I-7: Modelled lives saved (based on latest epidemiological data)","TB/HIV I-1: TB/HIV mortality rate, per 100,000 population","HIV I-5: New HIV infections among children","HIV I-5: New HIV infections among children",null,"Malaria O-6: Proportion of households with at least one insecticide-treated net* for every two people","HSS O-1: Percentage of women attending antenatal care","HIV O-6: Percentage of people who inject drugs reporting the use of sterile injecting equipment the last time they injected","HIV O-6: Percentage of people who inject drugs reporting the use of sterile injecting equipment the last time they injected"]
[null,"Malaria I-8: Modelled infections averted (based on latest epidemiological data)","HSS I-1: Under 5 mortality rate per 1000 live births","HIV I-6: Estimated percentage of child HIV infections from HIV-positive women delivering in the past 12 months","HIV I-6: Estimated percentage of child HIV infections from HIV-positive women delivering in the past 12 months",null,"HSS O-1: Percentage of women attending antenatal care","HSS O-2: Percentage of births attended by skilled health professional","HIV O-7: Percentage of other vulnerable populations who report the use of a condom at last sexual intercourse","HIV O-7: Percentage of other vulnerable populations who report the use of a condom at last sexual intercourse"]
[null,"HSS I-1: Under 5 mortality rate per 1000 live births","HSS I-2: Neonatal mortality rate, per 100,000 population","HIV I-7: Modelled lives saved based on latest epidemiological data","HIV I-7: Modelled lives saved based on latest epidemiological data",null,"Malaria O-5: Proportion of households with at least one insecticide-treated net","HSS O-3: Ratio of household out-of-pocket payments for health to total expenditure on health","HIV O-8: Current school attendance rate among orphans compared to non-orphans","HIV O-8: Current school attendance rate among orphans compared to non-orphans"]
[null,"HSS I-2: Neonatal mortality rate, per 100,000 population","HSS I-3: Maternal mortality ratio, per 100,000 population","HIV I-8: Modelled infections averted based on latest epidemiological data","HIV I-8: Modelled infections averted based on latest epidemiological data",null,"HSS O-2: Percentage of births attended by skilled health professional","HSS O-5: Specific services readiness score for health facilities","TB O-1a: Case notification rate of all forms of TB per 100,000 population - bacteriologically confirmed plus clinically diagnosed, new and relapse cases","TB O-1a: Case notification rate of all forms of TB per 100,000 population - bacteriologically confirmed plus clinically diagnosed, new and relapse cases"]
[null,"HSS I-3: Maternal mortality ratio, per 100,000 population","Custom","HIV I-9a: Percentage of men who have sex with men who are living with HIV","HIV I-9a: Percentage of men who have sex with men who are living with HIV",null,"HSS O-3: Ratio of household out-of-pocket payments for health to total expenditure on health","Custom","TB O-1b: Case notification rate per 100,000 population- bacteriologically-confirmed TB, new and relapse","TB O-1b: Case notification rate per 100,000 population- bacteriologically-confirmed TB, new and relapse"]
[null,"Custom",null,"HIV I-9b: Percentage of transgender people who are living with HIV","HIV I-9b: Percentage of transgender people who are living with HIV",null,"HSS O-5: Specific services readiness score for health facilities",null,"TB O-2a: Treatment success rate - all forms of TB","TB O-2a: Treatment success rate - all forms of TB"]
[null,null,null,"HIV I-10: Percentage of sex workers who are living with HIV","HIV I-10: Percentage of sex workers who are living with HIV",null,"Custom",null,"TB O-2b: Treatment success rate - bacteriologically confirmed TB cases","TB O-2b: Treatment success rate - bacteriologically confirmed TB cases"]
[null,null,null,"HIV I-11: Percentage of people who inject drugs who are living with HIV","HIV I-11: Percentage of people who inject drugs who are living with HIV",null,null,null,"TB O-3: Notification of RR-TB and/or MDR-TB cases - Percentage of notified cases of bacteriologically confirmed, drug resistant RR-TB and/or MDR-TB? as a proportion of the estimated number of RR-TB and/or MDR-TB cases among notified TB cases","TB O-3: Notification of RR-TB and/or MDR-TB cases - Percentage of notified cases of bacteriologically confirmed, drug resistant RR-TB and/or MDR-TB? as a proportion of the estimated number of RR-TB and/or MDR-TB cases among notified TB cases"]
[null,null,null,"HIV I-12: Percentage of other vulnerable populations (specify) who are living with HIV","HIV I-12: Percentage of other vulnerable populations (specify) who are living with HIV",null,null,null,"TB O-4: Treatment success rate of MDR-TB: Percentage of bacteriologically confirmed drug resistant TB cases (RR-TB and/or MDR-TB) successfully treated","TB O-4: Treatment success rate of MDR-TB: Percentage of bacteriologically confirmed drug resistant TB cases (RR-TB and/or MDR-TB) successfully treated"]
[null,null,null,"TB I-1: TB prevalence rate (per 100,000 population)","TB/HIV I-1: TB/HIV mortality rate, per 100,000 population",null,null,null,"HSS O-1: Percentage of women attending antenatal care","HSS O-1: Percentage of women attending antenatal care"]
[null,null,null,"TB I-2: TB incidence rate (per 100,000 population)","HSS I-1: Under 5 mortality rate per 1000 live births",null,null,null,"HSS O-2: Percentage of births attended by skilled health professional","HSS O-2: Percentage of births attended by skilled health professional"]
[null,null,null,"TB I-3: TB mortality rate (per 100,000 population)","HSS I-2: Neonatal mortality rate, per 100,000 population",null,null,null,"HSS O-3: Ratio of household out-of-pocket payments for health to total expenditure on health","HSS O-3: Ratio of household out-of-pocket payments for health to total expenditure on health"]
[null,null,null,"TB I-4: MDR-TB prevalence among new TB patients","HSS I-3: Maternal mortality ratio, per 100,000 population",null,null,null,"HSS O-5: Specific services readiness score for health facilities","HSS O-5: Specific services readiness score for health facilities"]
[null,null,null,"TB I-5: Modelled lives saved based on latest epidemiological data","Custom",null,null,null,"Custom","Custom"]
[null,null,null,"TB I-6: Modelled infections averted based on latest epidemiological data"]
[null,null,null,"TB/HIV I-1: TB/HIV mortality rate, per 100,000 population"]
[null,null,null,"HSS I-1: Under 5 mortality rate per 1000 live births"]
[null,null,null,"HSS I-2: Neonatal mortality rate, per 100,000 population"]
[null,null,null,"HSS I-3: Maternal mortality ratio, per 100,000 population"]
[null,null,null,"Custom"]

{"sheet":"Coverage Indicators","index":6,"n_rows":20,"n_cols":26,"rows_kept":20,"cut":false,"hidden":true,"merged":[]}
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS"]
[null,null," ",null,null,null,null,null,null,null,null,null,null,null,null,"Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","HIV/AIDS"]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,"HIV/AIDS","Malaria","Malaria","Malaria","Malaria","Malaria","Malaria","Malaria","Malaria","Malaria","HIV/AIDS","Tuberculosis"]
[null,null,null,null,null,"Tuberculosis","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","Tuberculosis","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","HIV/TB","Malaria"]
[null,"Malaria","Malaria","Malaria","Tuberculosis","HIV/TB","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","Malaria","HIV/TB"]
[null,"Specific prevention interventions (SPI)","Vector control","Case management","TB care and prevention","MDR-TB","Prevention programs for general population","Prevention programs for MSM and TGs","Prevention programs for people who inject drugs (PWID) and their partners","Prevention programs for other vulnerable populations (please specify)","Prevention programs for adolescents and youth, in and out of school","Prevention programs for sex workers and their clients","PMTCT","HIV/AIDS","TB/HIV","Removing legal barriers to access","HSS - Service delivery","HSS - Health and community workforce","HSS - Health information systems and M&E","Program management","HSS - Procurement supply chain management (PSCM)","HSS - Policy and governance","HSS - Healthcare financing","HSS - Financial management","Community systems strengthening","Results based Financing"]
[null,"Module1","Module2","Module3","Module4","Module5","Module8","Module9","Module10","Module11","Module12","Module13","Module14","Module15","Module24","Module27","Module28","Module29","Module30","Module31","Module32","Module33","Module34","Module35","Module72","Module73"]
[null,"SPI-1: Proportion of pregnant women attending antenatal clinics who received three or more doses of intermittent preventive treatment (IPTp) for malaria","VC-1: Number of long-lasting insecticidal nets distributed to at-risk populations through mass campaigns","CM-1a: Proportion of suspected malaria cases that receive a parasitological test at public sector health facilities","DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses","MDR TB-1: Percentage of previously treated TB patients receiving DST (bacteriologically positive cases only)","GP-1: Number of women and men aged 15+ who received an HIV test and know their results","KP-1a: Percentage of MSM reached with HIV prevention programs - defined package of services","KP-1d: Percentage of PWID reached with HIV prevention programs - defined package of services","KP-1e: Percentage of other vulnerable populations reached with HIV prevention programs - defined package of services","YP-1: Percentage of young people aged 10?24 years reached by life skills?based HIV education in schools","KP-1c: Percentage of sex workers reached with HIV prevention programs - defined package of services","PMTCT-1: Percentage of pregnant women who know their HIV status","TCS-1: Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV","TB/HIV-1: Percentage of TB patients who had an HIV test result recorded in the TB register","Custom ","SD-1: Number of health facilities per 10,000 population","HW-1: Number of health workers per 10,000 population (report on community health workers as applicable)","M&E-1: Percentage of HMIS or other routine reporting units submitting timely reports according to national guidelines","Custom","PSM-1: Percentage of health facilities reporting no stock-outs of essential drugs","Custom","HF-1: Government expenditure on health as percentage of general government expenditure","Custom","Custom","Custom"]
[null,"Custom","VC-2: Proportion of population at risk potentially covered by long lasting insecticidal nets distributed","CM-1b: Proportion of suspected malaria cases that receive a parasitological test in the community","DOTS-1b: Number of notified cases of bacteriologically confirmed TB, new and relapses","MDR TB-2: Number of bacteriologically confirmed, drug resistant TB cases (RR-TB and/or MDR-TB) notified","GP-2: Percentage of individuals from targeted population reached through community outreach with standardized HIV prevention interventions","KP-1b: Percentage of TG reached with HIV prevention programs - defined package of services","KP-2d: Percentage of PWID reached with HIV prevention programs - individual and/or smaller group level interventions","KP-2e: Percentage of other vulnerable populations reached with HIV prevention programs - individual and/or smaller group level interventions","Custom","KP-2c: Percentage of sex workers reached with HIV prevention programs - individual and/or smaller group level interventions","PMTCT-2: Percentage of HIV-positive pregnant women who received antiretrovirals to reduce the risk of mother-to-child transmission","TCS-2: Percentage of people living with HIV that initiated ART with CD4 count of <200 cells/mm³","TB/HIV-4: Percentage of new HIV-positive patients starting IPT during the reporting period",null,"SD-2: Number of outpatients visits per 10,000 population","HW-2: Distribution of health workers","M&E-2: Proportion of facility reports received over the reports expected during the reporting period",null,"Custom",null,"Custom"]
[null,null,"VC-3: Number of long-lasting insecticidal nets distributed to targeted risk groups through continuous distribution","CM-1c: Proportion of suspected malaria cases that receive a parasitological test at private sector sites","DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all TB cases registered for treatment during a specified period","MDR TB-3: Number of cases with drug resistant TB (RR-TB and/or MDR-TB) that began second-line treatment","GP-3: Proportion of new individuals who test positive for HIV, enrolled in care (pre-ART or ART) services","KP-2a: Percentage of MSM reached with HIV prevention programs - individual and/or smaller group level interventions","KP-3d: Percentage of PWID that have received an HIV test during the reporting period and know their results","KP-3e: Percentage of other vulnerable populations that have received an HIV test during the reporting period and know their results",null,"KP-3c: Percentage of sex workers that have received an HIV test during the reporting period and know their results","PMTCT-3: Percentage of infants born to HIV-positive women receiving a virological test for HIV within 2 months of birth","TCS-3: Percentage of adults and children that initiated ART, with an undetectable viral load at 12 months (<1000 copies/ml)","TB/HIV-3: Percentage of HIV-positive patients who were screened for TB in HIV care or treatment settings",null,"Custom","HW-3: Number of health workers newly recruited at primary health care facilities in the past 12 months, expressed as a percentage of planned recruitment targets","M&E-3: Percentage of deaths registered (as reported by civil or sample registration systems, hospitals, community-based reporting systems) among the total deaths for the same period and geographical region"]
[null,null,"VC-4: Proportion of targeted risk groups receiving long-lasting insecticidal-nets","CM-2a: Proportion of confirmed malaria cases that received first-line antimalarial treatment according to national policy at public sector health facilities","DOTS-2b: Percentage of bacteriologically confirmed TB cases successfully treated (cured plus completed treatment) among the bacteriologically confirmed TB cases registered during a specified period","MDR TB-4: Percentage of cases with drug resistant TB (RR-TB and/or MDR-TB) started on treatment for MDR-TB who were lost to follow up at six months","GP-4: Percentage of antenatal care attendees tested for syphilis","KP-2b: Percentage of TG reached with HIV prevention programs - individual and/or smaller group level interventions","KP-4: Number of needles and syringes distributed per person who injects drugs per year by needle and syringe programs","Custom",null,"Custom","Custom","TCS-4: Percentage of health facilities dispensing antiretroviral therapy that experienced a stock-out of at least one required antiretroviral drug in the last 12 month","TB/HIV-2: Percentage of HIV-positive registered TB patients given anti-retroviral therapy during TB treatment",null,null,"HW-4: Annual rate of retention of service providers at primary health care facilities","Custom"]
[null,null,"VC-5: Proportion of households in targeted areas that received Indoor Residual Spraying during the reporting period","CM-2b: Proportion of confirmed malaria cases that received first-line antimalarial treatment according to national policy in the community","DOTS-3: Percentage of laboratories showing adequate performance in external quality assurance for smear microscopy among the total number of laboratories that undertake smear microscopy during the reporting period","MDR TB-5: Percentage of DST laboratories showing adequate performance on External Quality Assurance","GP-5: Number of male circumcisions performed according to national standards","KP-3a: Percentage of MSM that have received an HIV test during the reporting period and know their results","KP-5: Percentage of individuals receiving Opioid Substitution Therapy who received treatment for at least 6 months",null,null,null,null,"TCS-5: Proportion of undernourished PLHIV that received therapeutic or supplementary food at any point during the reporting period","Custom",null,null,"Custom"]
[null,null,"VC-6: Proportion of population protected by Indoor Residual Spraying within the last 12 months","CM-2c: Proportion of confirmed malaria cases that received first-line antimalarial treatment according to national policy at private sector sites","DOTS-4: Percentage of reporting units reporting no stock-out of first-line anti-TB drugs on the last day of the quarter","Custom","GP-6: Percentage of orphaned and vulnerable children aged 0?17 years whose households received free basic external support in caring for the child according to national guidelines","KP-3b: Percentage of TG that have received an HIV test during the reporting period and know their results","Custom",null,null,null,null,"Custom"]
[null,null,"Custom","CM-3a: Proportion of estimated malaria cases (presumed and confirmed) that received first line antimalarial treatment at public sector health facilities","DOTS-5: Number of children <5 in contact with TB patients who began IPT",null,"Custom","Custom"]
[null,null,null,"CM-3b: Proportion of estimated malaria cases (presumed and confirmed) that received first line anti-malarial treatment in the community","DOTS-6: Number of TB cases (all forms) notified among key affected populations/high risk groups"]
[null,null,null,"CM-3c: Proportion of estimated malaria cases (presumed and confirmed) that received first line anti-malarial treatment at private sector sites","DOTS-7a: Percentage of notified TB cases, all forms, contributed by non-NTP providers - private/non-governmental facilities"]
[null,null,null,"CM-4: Proportion of health facilities without stock-outs of key commodities during the reporting period","DOTS-7b: Percentage of notified TB cases, all forms, contributed by non-NTP providers - public sector"]
[null,null,null,"CM-5: Percentage of confirmed cases fully investigated (malaria elimination phase)","DOTS-7c: Percentage of notified TB cases, all forms, contributed by non-NTP providers - community referrals"]
[null,null,null,"CM-6: Percentage of foci fully investigated (malaria elimination phase)","Custom"]
[null,null,null,"Custom"]

{"sheet":"CoverageDisaggregationData","index":7,"n_rows":37,"n_cols":10,"rows_kept":37,"cut":false,"hidden":true,"merged":[]}
[null,"Coverage disaggregation Data "]
[null,"Name of Indicator","ShortName","Disaggregation ","Concatenatedcode","Module","Categories"]
[null,"GP-1: Number of women and men aged 15+ who received an HIV test and know their results","GP1D","Sex",{"$f":"SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(CONCATENATE(C3,D3),\" \",\"\"),\"/\",\"\"),\"-\",\"\")","v":"GP1DSex"},"Prevention programs for general population","Male","Female"]
[null,"GP-1: Number of women and men aged 15+ who received an HIV test and know their results","GP1D","HIV status","GP1DHIVstatus","Prevention programs for general population","Positive","Negative"]
[null,"GP-1: Number of women and men aged 15+ who received an HIV test and know their results","GP1D","Age",{"$f":"SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(CONCATENATE(C5,D5),\" \",\"\"),\"/\",\"\"),\"-\",\"\")","v":"GP1DAge"},"Prevention programs for general population","15-24"]
[null,"PMTCT-1: Percentage of pregnant women who know their HIV status","PMTCT1","HIV status-pregnant women","PMTCT1HIVstatuspregnantwomen","PMTCT","Known positive HIV infection at ANC","Newly identified as HIV positive","Testing HIV negative"]
[null,"TCS-1: Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV","TCS1a","Sex","TCS1aSex","Treatment, care and support","Male","Female"]
[null,"TCS-1: Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV","TCS1a","Age","TCS1aAge","Treatment, care and support","<15","15+","15-24"]
[null,"TCS-2: Percentage of people living with HIV that initiated ART with CD4 count of <200 cells/mm³","TCS2a","Sex","TCS2aSex","Treatment, care and support","Male","Female"]
[null,"TCS-3: Percentage of adults and children that initiated ART, with an undetectable viral load at 12 months (<1000 copies/ml)","TCS3a","Sex","TCS3aSex","Treatment, care and support","Male","Female"]
[null,"TCS-3: Percentage of adults and children that initiated ART, with an undetectable viral load at 12 months (<1000 copies/ml)","TCS3a","Age","TCS3aAge","Treatment, care and support","15-24"]
[null,"DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses","DOTS1a","Sex","DOTS1aSex","TB care and prevention","Male","Female"]
[null,"DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses","DOTS1a","HIV test result","DOTS1aHIVtestresult","TB care and prevention","Positive","Negative","Not documented"]
[null,"DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses","DOTS1a","Age","DOTS1aAge","TB care and prevention","<15","15+"]
[null,"DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all TB cases registered for treatment during a specified period","DOTS2a","Sex","DOTS2aSex","TB care and prevention","Male","Female"]
[null,"DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all TB cases registered for treatment during a specified period","DOTS2a","Age","DOTS2aAge","TB care and prevention","<15","15+"]
[null,"DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all TB cases registered for treatment during a specified period","DOTS2a","HIV test result","DOTS2aHIVtestresult","TB care and prevention","Positive","Negative","Not documented"]
[null,"DOTS-6: Number of TB cases (all forms) notified among key affected populations/high risk groups","DOTS6","KAPs/high risk groups","DOTS6KAPshighriskgroups","TB care and prevention","Prisoners","Migrants/ Refugees/ IDPs","Others - specify"]
[null,"MDR TB-2: Number of bacteriologically confirmed, drug resistant TB cases (RR-TB and/or MDR-TB) notified","MDRTB2","Sex","MDRTB2Sex","MDR-TB","Male","Female"]
[null,"MDR TB-2: Number of bacteriologically confirmed, drug resistant TB cases (RR-TB and/or MDR-TB) notified","MDRTB2","Age","MDRTB2Age","MDR-TB","<15","15+"]
[null,"MDR TB-3: Number of cases with drug resistant TB (RR-TB and/or MDR-TB) that began second-line treatment","MDRTB3","Sex","MDRTB3Sex","MDR-TB","Male","Female"]
[null,"MDR TB-3: Number of cases with drug resistant TB (RR-TB and/or MDR-TB) that began second-line treatment","MDRTB3","Age","MDRTB3Age","MDR-TB","<15","15+"]
[null,"VC-3: Number of long-lasting insecticidal nets distributed to targeted risk groups through continuous distribution","VC3a","Targeted risk group","VC3aTargetedriskgroup","Vector control","Pregnant women","Children <5","Migrant workers/ refugees/ IDPs","Others - specify"]
[null,"VC-4: Proportion of targeted risk groups receiving long-lasting insecticidal-nets","VC4a","Targeted risk group","VC4aTargetedriskgroup","Vector control","Pregnant women","Children <5","Migrant workers/ refugees/ IDPs","Others - specify"]
[null,"CM-1a: Proportion of suspected malaria cases that receive a parasitological test at public sector health facilities","CM1a","Age","CM1aAge","Case management","<5","5+"]
[null,"CM-1a: Proportion of suspected malaria cases that receive a parasitological test at public sector health facilities","CM1a","Type of testing","CM1aTypeoftesting","Case management","Microscopy","RDTs"]
[null,"CM-1b: Proportion of suspected malaria cases that receive a parasitological test in the community","CM1b","Age","CM1bAge","Case management","<5","5+"]
[null,"CM-1b: Proportion of suspected malaria cases that receive a parasitological test in the community","CM1b","Type of testing","CM1bTypeoftesting","Case management","Microscopy","RDTs"]
[null,"CM-1c: Proportion of suspected malaria cases that receive a parasitological test at private sector sites","CM1c","Age","CM1cAge","Case management","<5","5+"]
[null,"CM-1c: Proportion of suspected malaria cases that receive a parasitological test at private sector sites","CM1c","Type of testing","CM1cTypeoftesting","Case management","Microscopy","RDTs"]
[null,"CM-2a: Proportion of confirmed malaria cases that received first-line antimalarial treatment according to national policy at public sector health facilities","CM2a","Age","CM2aAge","Case management","<5","5+"]
[null,"CM-2b: Proportion of confirmed malaria cases that received first-line antimalarial treatment according to national policy in the community","CM2b","Age","CM2bAge","Case management","<5","5+"]
[null,"CM-2c: Proportion of confirmed malaria cases that received first-line antimalarial treatment according to national policy at private sector sites","CM2c","Age","CM2cAge","Case management","<5","5+"]
[null,"CM-3a: Proportion of estimated malaria cases (presumed and confirmed) that received first line antimalarial treatment at public sector health facilities","CM3a","Age","CM3aAge","Case management","<5","5+"]
[null,"CM-3b: Proportion of estimated malaria cases (presumed and confirmed) that received first line anti-malarial treatment in the community","CM3b","Age","CM3bAge","Case management","<5","5+"]
[null,"CM-3c: Proportion of estimated malaria cases (presumed and confirmed) that received first line anti-malarial treatment at private sector sites","CM3c","Age","CM3cAge","Case management","<5","5+"]
[null,"HW-1: Number of health workers per 10,000 population (report on community health workers as applicable)","HW1a","Specialization","HW1aSpecialization","HSS - Health and community workforce","Doctors","Nurses","Lab technicians","Other - specify"]

{"sheet":"WPTM_1C","index":8,"n_rows":41,"n_cols":28,"rows_kept":41,"cut":false,"hidden":false,"merged":[[14,12,14,18],[14,20,14,21],[6,2,6,5],[10,2,10,5],[0,0,0,11],[14,0,14,11]]}
["Ongoing Progress Update and Disbursement Request"]
["Grant number:",null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Component",null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["PROGRESS UPDATE "]
["Progress Update - Reporting Period:",null,"Cycle:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}},null,null,null,null,null,null,"Number:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Period Covered:",null,"Beginning Date:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}},null,null,null,null,null,null,"End Date:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Number:"]
["DISBURSEMENT REQUEST "]
["Disbursement Request  - Disbursement Period:",null,"Cycle:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}},null,null,null,null,null,null,"Number:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Disbursement Request  - Period Covered:",null,"Beginning Date:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}},null,null,null,null,null,null,"End Date:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Disbursement Request  - Number:"]
[{"$f":"#REF!","v":{"$error":"#REF!"}}]
[null,null,null,"Section 1:  Programmatic Progress"]
[null,null,null,"Note: Enter only the Workplan Tracking Measures that are due for the reporting period "]
["C- Workplan Tracking Measures ",null,null,null,null,null,null,null,null,null,null,null,"LFA Use Only",null,null,null,null,null,null,null,"For the Global Fund Use Only"]
["Module",null,"Intervention","Activity","Activity details- milestones/ targets","Criterion for completion","Milestones/Target for the Current Period ","Country (relevant for multi-country grants)","Target","Progress Status","Score","Reasons for deviation from workplan activities and milestones","Activity details- milestones/ targets","Criterion for completion","Milestones/Target for the Current Period ","Country (relevant for multi-country grants)","Progress Status","Verified Score","LFA analysis of progress and any variance between targets and results, and any other comments\n(this should not be a “Copy and Paste” of the reasons provided by the PR)","Progress Status","Validated Score","Country Team Comments on Validated Score"]
[null,{"$f":"SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(A17,\" \",\"\"),\"-\",\"\"),\"&\",\"\"),\",\",\"\"),\"/\",\"\"),\")\",\"\"),\"(\",\"\")","v":""},null,null,null,null,null,null,null,null,{"$f":"IFERROR(VLOOKUP(J17,$AA$19:$AB$22,2,FALSE),\"\")","v":""},null," "," ",null," ",null,{"$f":"IFERROR(VLOOKUP(Q17,$AA$19:$AB$22,2,FALSE),\"\")","v":""},null,null,{"$f":"IFERROR(VLOOKUP(T17,$AA$19:$AB$22,2,FALSE),\"\")","v":""}]
[null,{"$f":"SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(A18,\" \",\"\"),\"-\",\"\"),\"&\",\"\"),\",\",\"\"),\"/\",\"\"),\")\",\"\"),\"(\",\"\")","v":""},null,null,null,null,null,null,"-",null,{"$f":"IFERROR(VLOOKUP(J18,$AA$19:$AB$22,2,FALSE),\"\")","v":""},null,null,null,null,null,null,{"$f":"IFERROR(VLOOKUP(Q18,$AA$19:$AB$22,2,FALSE),\"\")","v":""},null,null,{"$f":"IFERROR(VLOOKUP(T18,$AA$19:$AB$22,2,FALSE),\"\")","v":""}]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,"",null,null,null,null,null,"Not Started",0]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,"",null,null,null,null,null,"Started",1]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,"",null,null,null,null,null,"Advancing",2]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,"",null,null,null,null,null,"Completed",3]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]

{"sheet":"Intervention By Modules old","index":9,"n_rows":20,"n_cols":80,"rows_kept":20,"cut":false,"hidden":true,"merged":[]}
[]
[null,null," "]
[]
[]
[]
[null,"Specific prevention interventions (SPI)","Vector control","Case management","TBcareandprevention","MDR-TB","TB care and prevention","MDR-TB","Prevention programs for general population","Prevention programs for MSM and TGs","Prevention programs for people who inject drugs (PWID) and their partners","Prevention programs for other vulnerable populations (please specify)","Prevention programs for adolescents and youth, in and out of school","Prevention programs for sex workers and their clients","PMTCT","Treatment, care and support","Prevention programs for general population","Prevention programs for MSM and TGs","Prevention programs for people who inject drugs (PWID) and their partners","Prevention programs for other vulnerable populations (please specify)","Prevention programs for adolescents and youth, in and out of school","Prevention programs for sex workers and their clients","PMTCT","Treatment, care and support","TB/HIV","TB/HIV","TB/HIV","Removing legal barriers to access","HSS - Service delivery","HSS - Health and community workforce","HSS - Health information systems and M&E","Program management","HSS - Procurement supply chain management (PSCM)","HSS - Policy and governance","HSS - Healthcare financing","HSS - Financial management","Removing legal barriers to access","HSS - Service delivery","HSS - Health and community workforce","HSS - Health information systems and M&E","Program management","HSS - Procurement supply chain management (PSCM)","HSS - Policy and governance","HSS - Healthcare financing","HSS - Financial management","Removing legal barriers to access","HSS - Service delivery","HSS - Health and community workforce","HSS - Health information systems and M&E","Program management","HSS - Procurement supply chain management (PSCM)","HSS - Policy and governance","HSS - Healthcare financing","HSS - Financial management","Removing legal barriers to access","HSS - Service delivery","HSS - Health and community workforce","HSS - Health information systems and M&E","Program management","HSS - Procurement supply chain management (PSCM)","HSS - Policy and governance","HSS - Healthcare financing","HSS - Financial management","Removing legal barriers to access","HSS - Service delivery","HSS - Health and community workforce","HSS - Health information systems and M&E","Program management","HSS - Procurement supply chain management (PSCM)","HSS - Policy and governance","HSS - Healthcare financing","HSS - Financial management","Community systems strengthening","Results-based Financing","Community systems strengthening","Results-based Financing","Community systems strengthening","Results-based Financing","Community systems strengthening","Results-based Financing"]
[null,"MalariaModule1","MalariaModule2","MalariaModule3","TuberculosisModule4","TuberculosisModule5","HIV/TBModule6","HIV/TBModule7","HIV/TBModule8","HIV/TBModule9","HIV/TBModule10","HIV/TBModule11","HIV/TBModule12","HIV/TBModule13","HIV/TBModule14","HIV/TBModule15","HIV/AIDSModule16","HIV/AIDSModule17","HIV/AIDSModule18","\nHIV/AIDSModule19","HIV/AIDSModule20","HIV/AIDSModule21","HIV/AIDSModule22","\nHIV/AIDSModule23","HIV/AIDSModule24","\nTuberculosisModule25","\nHIV/TBModule26","\nHIV/AIDSModule27","HIV/AIDSModule28","HIV/AIDSModule29","HIV/AIDSModule30","HIV/AIDSModule31","HIV/AIDSModule32","HIV/AIDSModule33","HIV/AIDSModule34","HIV/AIDSModule35","TuberculosisModule36","TuberculosisModule37","TuberculosisModule38","TuberculosisModule39","TuberculosisModule40","TuberculosisModule41","TuberculosisModule42","TuberculosisModule43","TuberculosisModule44","Module45","MalariaModule46","MalariaModule47","MalariaModule48","MalariaModule49","MalariaModule50","MalariaModule51","MalariaModule52","MalariaModule53","Health Systems StrengtheningModule54","Health Systems StrengtheningModule55","Health Systems StrengtheningModule56","Health Systems StrengtheningModule57","Health Systems StrengtheningModule58","Health Systems StrengtheningModule59","Health Systems StrengtheningModule60","Health Systems StrengtheningModule61","Health Systems StrengtheningModule62","HIV/TBModule63","HIV/TBModule64","HIV/TBModule65","HIV/TBModule66","HIV/TBModule67","HIV/TBModule68","HIV/TBModule69","HIV/TBModule70","HIV/TBModule71","HIV/AIDSModule72","HIV/AIDSModule73","TuberculosisModule74","TuberculosisModule75","MalariaModule76","MalariaModule77","HIV/TBModule78","HIV/TBModule79"]
[null,"Intermittent preventive treatment (IPT) - In pregnancy","Long-lasting insecticidal nets (LLIN) - Mass campaign","Facility-based treatment","Case detection and diagnosis","Case detection and diagnosis: MDR-TB","Case detection and diagnosis","Case detection and diagnosis: MDR-TB","RMNCH linkages and gender-based violence (GBV)","Behavioral change as part of programs for MSM and TGs","Needle and Syringe programs as part of programs for PWID and their partners","Condoms as part of programs for other vulnerable populations","Behavioral change as part of programs for adolescent and youth","Behavioral change as part of programs for sex workers and their clients","Prong 1: Primary prevention of HIV infection among women of childbearing age","Pre-ART care","RMNCH linkages and gender-based violence (GBV)","Behavioral change as part of programs for MSM and TGs","Needle and Syringe programs as part of programs for PWID and their partners","Condoms as part of programs for other vulnerable populations","Behavioral change as part of programs for adolescent and youth","Behavioral change as part of programs for sex workers and their clients","Prong 1: Primary prevention of HIV infection among women of childbearing age","Pre-ART care","TB/HIV collaborative interventions","TB/HIV collaborative interventions","TB/HIV collaborative interventions","Legal and policy environment assessment and law reform","Service organization and facility management","Health and community workers capacity building","Administrative and finance data sources","Policy, planning, coordination and management","Operationalization of procurement and supply chain management system","Development and implementation of health legislation, strategies and policies","Financial sustainability","Performance,transparency&accountability of financial management system in health","Legal and policy environment assessment and law reform","Service organization and facility management","Health and community workers capacity building","Administrative and finance data sources","Policy, planning, coordination and management","Operationalization of procurement and supply chain management system","Development and implementation of health legislation, strategies and policies","Financial sustainability","Performance,transparency&accountability of financial management system in health","Legal and policy environment assessment and law reform","Service organization and facility management","Health and community workers capacity building","Administrative and finance data sources","Policy, planning, coordination and management","Operationalization of procurement and supply chain management system","Development and implementation of health legislation, strategies and policies","Financial sustainability","Performance,transparency&accountability of financial management system in health","Legal and policy environment assessment and law reform","Service organization and facility management","Health and community workers capacity building","Administrative and finance data sources","Policy, planning, coordination and management","Operationalization of procurement and supply chain management system","Development and implementation of health legislation, strategies and policies","Financial sustainability","Performance,transparency&accountability of financial management system in health","Legal and policy environment assessment and law reform","Service organization and facility management","Health and community workers capacity building","Administrative and finance data sources","Policy, planning, coordination and management","Operationalization of procurement and supply chain management system","Development and implementation of health legislation, strategies and policies","Financial sustainability","Performance,transparency&accountability of financial management system in health","Community-based monitoring for accountability","Results-based financing","Community-based monitoring for accountability","Results-based financing","Community-based monitoring for accountability","Results-based financing","Community-based monitoring for accountability","Results-based financing"]
[null,"Intermittent preventive treatment (IPT) - In infancy","Long-lasting insecticidal nets (LLIN) - Continuous distribution","Epidemic preparedness and response","Treatment","Treatment: MDR-TB","Treatment","Treatment: MDR-TB","Other interventions for general population - Please specify","Condoms as part of programs for MSM and TGs","OST and other drug dependence treatment (PWIDs and their partners)","Behavioral change as part of programs for other vulnerable populations","Condoms part of programs for adolescent and youth","Condoms as part of programs for sex workers and their clients","Prong 2: Preventing unintended pregnancies among women living with HIV","Antiretroviral Therapy (ART)","Other interventions for general population - Please specify","Condoms as part of programs for MSM and TGs","OST and other drug dependence treatment (PWIDs and their partners)","Behavioral change as part of programs for other vulnerable populations","Condoms part of programs for adolescent and youth","Condoms as part of programs for sex workers and their clients","Prong 2: Preventing unintended pregnancies among women living with HIV","Antiretroviral Therapy (ART)","Engaging all care providers","Engaging all care providers","Engaging all care providers","Legal aid services and legal literacy","Improving laboratory systems","Scaling up health and community workers","Vital registration system","Grant management","PSM infrastructure and development of tools","Monitoring and reporting implementation of laws and policies","Equity of healthcare financing",null,"Legal aid services and legal literacy","Improving laboratory systems","Scaling up health and community workers","Vital registration system","Grant management","PSM infrastructure and development of tools","Monitoring and reporting implementation of laws and policies","Equity of healthcare financing",null,"Legal aid services and legal literacy","Improving laboratory systems","Scaling up health and community workers","Vital registration system","Grant management","PSM infrastructure and development of tools","Monitoring and reporting implementation of laws and policies","Equity of healthcare financing",null,"Legal aid services and legal literacy","Improving laboratory systems","Scaling up health and community workers","Vital registration system","Grant management","PSM infrastructure and development of tools","Monitoring and reporting implementation of laws and policies","Equity of healthcare financing",null,"Legal aid services and legal literacy","Improving laboratory systems","Scaling up health and community workers","Vital registration system","Grant management","PSM infrastructure and development of tools","Monitoring and reporting implementation of laws and policies","Equity of healthcare financing",null,"Advocacy for social accountability",null,"Advocacy for social accountability",null,"Advocacy for social accountability",null,"Advocacy for social accountability"]
[null,"Seasonal malaria chemoprevention","Indoor residual spraying (IRS)","Integrated community case management (ICCM)","Prevention","Prevention for MDR-TB","Prevention","Prevention for MDR-TB","Behavioral change as part of programs for general population","HIV testing and counseling as part of programs for MSM and TGs","Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","Diagnosis and treatment of STIs (other vulnerable populations)","HIV testing and counseling as part of programs for adolescent and youth","HIV testing and counseling as part of programs for sex workers and their clients","Prong 3: Preventing vertical HIV transmission","Treatment monitoring","Behavioral change as part of programs for general population","HIV testing and counseling as part of programs for MSM and TGs","Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","Diagnosis and treatment of STIs (other vulnerable populations)","HIV testing and counseling as part of programs for adolescent and youth","HIV testing and counseling as part of programs for sex workers and their clients","Prong 3: Preventing vertical HIV transmission","Treatment monitoring","Community TB care delivery","Community TB care delivery","Community TB care delivery","Community-based monitoring of legal rights","Improving service delivery infrastructure","Retention and distribution of health and community workers","Routine reporting","Supporting procurement and supply management",null,null,null,null,"Community-based monitoring of legal rights","Improving service delivery infrastructure","Retention and distribution of health and community workers","Routine reporting","Supporting procurement and supply management",null,null,null,null,"Community-based monitoring of legal rights","Improving service delivery infrastructure","Retention and distribution of health and community workers","Routine reporting","Supporting procurement and supply management",null,null,null,null,"Community-based monitoring of legal rights","Improving service delivery infrastructure","Retention and distribution of health and community workers","Routine reporting","Supporting procurement and supply management",null,null,null,null,"Community-based monitoring of legal rights","Improving service delivery infrastructure","Retention and distribution of health and community workers","Routine reporting","Supporting procurement and supply management",null,null,null,null,"Social mobilization, building community linkages, collaboration and coordination",null,"Social mobilization, building community linkages, collaboration and coordination",null,"Social mobilization, building community linkages, collaboration and coordination",null,"Social mobilization, building community linkages, collaboration and coordination"]
[null,"IEC/BCC","Other vector control measures","Active case detection and investigation (elimination phase)","Other","Other","Other","Other","Condoms as part of programs for general population","Diagnosis and treatment of STIs as part of programs for MSM and TGs","Other interventions for IDUs and their partners - Please specify","Other interventions for other vulnerable populations - Please specify","RMNCH linkages and GBV as part of programs for adolescent youth","Diagnosis and treatment of STIs (sex workers and their clients)","Prong 4: Treatment, care & support to mothers living with HIV, their children &","Treatment adherence","Condoms as part of programs for general population","Diagnosis and treatment of STIs as part of programs for MSM and TGs","Other interventions for IDUs and their partners - Please specify","Other interventions for other vulnerable populations - Please specify","RMNCH linkages and GBV as part of programs for adolescent youth","Diagnosis and treatment of STIs (sex workers and their clients)","Prong 4: Treatment, care & support to mothers living with HIV, their children &","Treatment adherence","Key Affected Populations","Key Affected Populations","Key Affected Populations","Policy advocacy on legal rights","Other",null,"Analysis, review and transparency",null,null,null,null,null,"Policy advocacy on legal rights","Other",null,"Analysis, review and transparency",null,null,null,null,null,"Policy advocacy on legal rights","Other",null,"Analysis, review and transparency",null,null,null,null,null,"Policy advocacy on legal rights","Other",null,"Analysis, review and transparency",null,null,null,null,null,"Policy advocacy on legal rights","Other",null,"Analysis, review and transparency",null,null,null,null,null,"Institutional capacity building, planning and leadership development",null,"Institutional capacity building, planning and leadership development",null,"Institutional capacity building, planning and leadership development",null,"Institutional capacity building, planning and leadership development"]
[null,"Other","Entomological monitoring","Therapeutic efficacy surveillance",null,null,null,null,"Male circumcision","Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs","Behavioural change as part of programs for PWID and their partners","HIV testing and counseling as part of programs for other vulnerable populations","Young Key Population interventions as part of programs for adolescent and youth","Harm reduction as part of programs for sex workers and their clients","Other interventions for PMTCT- Please specify","Prevention, diagnosis and treatment of opportunistic infections","Male circumcision","Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs","Behavioural change as part of programs for PWID and their partners","HIV testing and counseling as part of programs for other vulnerable populations","Young Key Population interventions as part of programs for adolescent and youth","Harm reduction as part of programs for sex workers and their clients","Other interventions for PMTCT- Please specify","Prevention, diagnosis and treatment of opportunistic infections","Collaborative activities with other programs and sectors","Collaborative activities with other programs and sectors","Collaborative activities with other programs and sectors","Training on rights for officials, health workers and police",null,null,"Surveys",null,null,null,null,null,"Training on rights for officials, health workers and police",null,null,"Surveys",null,null,null,null,null,"Training on rights for officials, health workers and police",null,null,"Surveys",null,null,null,null,null,"Training on rights for officials, health workers and police",null,null,"Surveys",null,null,null,null,null,"Training on rights for officials, health workers and police",null,null,"Surveys"]
[null,null,"Other  ","Severe malaria",null,null,null,null,"HIV testing and counseling as part of programs for general population","Other interventions for MSM and TGs - Please specify","Condoms as part of programs for PWID and their partners","Condoms as part of programs for other vulnerable populations","Other interventions for adolescent and youth","Other interventions for sex workers and their clients - Please specify",null,"Counseling and psycho-social support","HIV testing and counseling as part of programs for general population","Other interventions for MSM and TGs - Please specify","Condoms as part of programs for PWID and their partners","Condoms as part of programs for other vulnerable populations","Other interventions for adolescent and youth","Other interventions for sex workers and their clients - Please specify",null,"Counseling and psycho-social support"]
[null,null,null,"Private sector co-payment mechanism",null,null,null,null,"Diagnosis and treatment of STIs as part of programs for general population",null,"Diagnosis and treatment of STIs as part of programs for PWID and their partners","Behavioral change as part of programs for other vulnerable populations",null,null,null,"Out-patient care","Diagnosis and treatment of STIs as part of programs for general population",null,"Diagnosis and treatment of STIs as part of programs for PWID and their partners","Behavioral change as part of programs for other vulnerable populations",null,null,null,"Out-patient care"]
[null,null,null,"Private sector case management (other)",null,null,null,null,"Blood safety",null,"Needle and Syringe programs as part of programs for PWID and their partners","Diagnosis and treatment of STIs (other vulnerable populations)",null,null,null,"In-patient care","Blood safety",null,"Needle and Syringe programs as part of programs for PWID and their partners","Diagnosis and treatment of STIs (other vulnerable populations)",null,null,null,"In-patient care"]
[null,null,null,null,null,null,null,null,null,null,"OST and other drug dependence treatment (PWIDs and their partners)","Other interventions for other vulnerable populations - Please specify",null,null,null,"Other interventions for treatment - Please specify",null,null,"OST and other drug dependence treatment (PWIDs and their partners)","Other interventions for other vulnerable populations - Please specify",null,null,null,"Other interventions for treatment - Please specify"]
[null,null,null,null,null,null,null,null,null,null,"Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","HIV testing and counseling as part of programs for other vulnerable populations",null,null,null,null,null,null,"Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","HIV testing and counseling as part of programs for other vulnerable populations"]
[null,null,null,null,null,null,null,null,null,null,"Behavioural change as part of programs for PWID and their partners",null,null,null,null,null,null,null,"Behavioural change as part of programs for PWID and their partners"]
[null,null,null,null,null,null,null,null,null,null,"Condoms as part of programs for PWID and their partners",null,null,null,null,null,null,null,"Condoms as part of programs for PWID and their partners"]
[null,null,null,null,null,null,null,null,null,null,"Diagnosis and treatment of STIs as part of programs for PWID and their partners",null,null,null,null,null,null,null,"Diagnosis and treatment of STIs as part of programs for PWID and their partners"]

{"sheet":"Intervention By Modules","index":10,"n_rows":17,"n_cols":26,"rows_kept":17,"cut":false,"hidden":true,"merged":[]}
[]
[]
[null,"SpecificpreventioninterventionsSPI","Vectorcontrol","Casemanagement","TBcareandprevention","MDR-TB","Preventionprogramsforgeneralpopulation","PreventionprogramsforMSMandTGs","PreventionprogramsforpeoplewhoinjectdrugsPWIDandtheirpartners","Preventionprogramsforothervulnerablepopulationspleasespecify","Preventionprogramsforadolescentsandyouthinandoutofschool","Preventionprogramsforsexworkersandtheirclients","PMTCT","Treatmentcareandsupport","TBHIV","Removinglegalbarrierstoaccess","HSSServicedelivery","HSSHealthandcommunityworkforce","HSSHealthinformationsystemsandME","Programmanagement","HSSProcurementsupplychainmanagementPSCM","HSSPolicyandgovernance","HSS-Healthcarefinancing","HSSFinancialmanagement","Communitysystemsstrengthening","Results basedFinancing"]
[null,"Intermittent preventive treatment (IPT) - In pregnancy","Long-lasting insecticidal nets (LLIN) - Mass campaign","Facility-based treatment","Case detection and diagnosis","Case detection and diagnosis: MDR-TB","RMNCH linkages and gender-based violence (GBV)","Behavioral change as part of programs for MSM and TGs","Needle and Syringe programs as part of programs for PWID and their partners","Condoms as part of programs for other vulnerable populations","Behavioral change as part of programs for adolescent and youth","Behavioral change as part of programs for sex workers and their clients","Prong 1: Primary prevention of HIV infection among women of childbearing age","Pre-ART care","TB/HIV collaborative interventions","Legal and policy environment assessment and law reform","Service organization and facility management","Health and community workers capacity building","Administrative and finance data sources","Policy, planning, coordination and management","Operationalization of procurement and supply chain management system","Development and implementation of health legislation, strategies and policies","Financial sustainability","Performance,transparency&accountability of financial management system in health","Community-based monitoring for accountability","Results-based financing"]
[null,"Intermittent preventive treatment (IPT) - In infancy","Long-lasting insecticidal nets (LLIN) - Continuous distribution","Epidemic preparedness and response","Treatment","Treatment: MDR-TB","Other interventions for general population - Please specify","Condoms as part of programs for MSM and TGs","OST and other drug dependence treatment (PWIDs and their partners)","Behavioral change as part of programs for other vulnerable populations","Condoms part of programs for adolescent and youth","Condoms as part of programs for sex workers and their clients","Prong 2: Preventing unintended pregnancies among women living with HIV","Antiretroviral Therapy (ART)","Engaging all care providers","Legal aid services and legal literacy","Improving laboratory systems","Scaling up health and community workers","Vital registration system","Grant management","PSM infrastructure and development of tools","Monitoring and reporting implementation of laws and policies","Equity of healthcare financing",null,"Advocacy for social accountability"]
[null,"Seasonal malaria chemoprevention","Indoor residual spraying (IRS)","Integrated community case management (ICCM)","Prevention","Prevention for MDR-TB","Behavioral change as part of programs for general population","HIV testing and counseling as part of programs for MSM and TGs","Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","Diagnosis and treatment of STIs (other vulnerable populations)","HIV testing and counseling as part of programs for adolescent and youth","HIV testing and counseling as part of programs for sex workers and their clients","Prong 3: Preventing vertical HIV transmission","Treatment monitoring","Community TB care delivery","Community-based monitoring of legal rights","Improving service delivery infrastructure","Retention and distribution of health and community workers","Routine reporting","Supporting procurement and supply management",null,null,null,null,"Social mobilization, building community linkages, collaboration and coordination"]
[null,"IEC/BCC","Other vector control measures","Active case detection and investigation (elimination phase)","Other","Other","Condoms as part of programs for general population","Diagnosis and treatment of STIs as part of programs for MSM and TGs","Other interventions for IDUs and their partners - Please specify","Other interventions for other vulnerable populations - Please specify","RMNCH linkages and GBV as part of programs for adolescent youth","Diagnosis and treatment of STIs (sex workers and their clients)","Prong 4: Treatment, care & support to mothers living with HIV, their children &","Treatment adherence","Key Affected Populations","Policy advocacy on legal rights","Other",null,"Analysis, review and transparency",null,null,null,null,null,"Institutional capacity building, planning and leadership development"]
[null,"Other","Entomological monitoring","Therapeutic efficacy surveillance",null,null,"Male circumcision","Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs","Behavioural change as part of programs for PWID and their partners","HIV testing and counseling as part of programs for other vulnerable populations","Young Key Population interventions as part of programs for adolescent and youth","Harm reduction as part of programs for sex workers and their clients","Other interventions for PMTCT- Please specify","Prevention, diagnosis and treatment of opportunistic infections","Collaborative activities with other programs and sectors","Training on rights for officials, health workers and police",null,null,"Surveys"]
[null,null,"Other  ","Severe malaria",null,null,"HIV testing and counseling as part of programs for general population","Other interventions for MSM and TGs - Please specify","Condoms as part of programs for PWID and their partners","Condoms as part of programs for other vulnerable populations","Other interventions for adolescent and youth","Other interventions for sex workers and their clients - Please specify",null,"Counseling and psycho-social support"]
[null,null,null,"Private sector co-payment mechanism",null,null,"Diagnosis and treatment of STIs as part of programs for general population",null,"Diagnosis and treatment of STIs as part of programs for PWID and their partners","Behavioral change as part of programs for other vulnerable populations",null,null,null,"Out-patient care"]
[null,null,null,"Private sector case management (other)",null,null,"Blood safety",null,"Needle and Syringe programs as part of programs for PWID and their partners","Diagnosis and treatment of STIs (other vulnerable populations)",null,null,null,"In-patient care"]
[null,null,null,null,null,null,null,null,"OST and other drug dependence treatment (PWIDs and their partners)","Other interventions for other vulnerable populations - Please specify",null,null,null,"Other interventions for treatment - Please specify"]
[null,null,null,null,null,null,null,null,"Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","HIV testing and counseling as part of programs for other vulnerable populations"]
[null,null,null,null,null,null,null,null,"Other interventions for IDUs and their partners - Please specify"]
[null,null,null,null,null,null,null,null,"Behavioural change as part of programs for PWID and their partners"]
[null,null,null,null,null,null,null,null,"Condoms as part of programs for PWID and their partners"]
[null,null,null,null,null,null,null,null,"Diagnosis and treatment of STIs as part of programs for PWID and their partners"]

{"sheet":"PR Cash Reconciliation_2A,B,C","index":11,"n_rows":73,"n_cols":18,"rows_kept":73,"cut":false,"hidden":false,"merged":[[59,9,59,11],[12,6,12,9],[17,6,17,9],[17,1,17,3],[10,1,10,3],[11,1,11,3],[12,1,12,3],[15,1,15,3],[16,1,16,3],[3,0,3,11],[48,1,48,11],[24,1,24,11],[59,5,59,8],[66,5,66,8],[65,1,65,11],[66,2,66,4],[66,9,66,11],[19,0,20,11],[21,0,21,11],[25,2,25,4],[25,5,25,8],[25,9,25,11],[58,1,58,11],[59,1,60,1],[59,2,59,4]]}
[]
[]
[]
["Ongoing Progress Update and Disbursement Request "]
[]
[null,"Grant Name:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"(Disease) Component",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"GA Number",{"$f":"#REF!","v":{"$error":"#REF!"}}]
[]
[null,"PROGRESS UPDATE "]
[null,"Progress Update - Reporting Period:",null,null,null,null,"Cycle:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"Number:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Progress Update - Period Covered:",null,null,null,null,"Beginning Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"End Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Progress Update - Number:"]
[]
[null,"DISBURSEMENT REQUEST "]
[null,"Disbursement Request  - Disbursement Period:",null,null,null,null,"Cycle:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"Number:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Disbursement Request  - Period Covered:",null,null,null,null,"Beginning Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"End Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Disbursement Request  - Number:"]
[]
["Section 2: Financial Information"]
[]
[]
[]
[]
[null,"A. Principal Recipient Cash Reconciliation Statement in Grant Currency"]
[null,null,"Principal Recipient",null,null,"For LFA Use Only ",null,null,null,"For the Global Fund Use Only"]
["Item No.","Description","Cumulative for Previous Periods","Current Period","Comments","Cumulative for Previous Periods as validated by Global Fund","LFA Adjustments on current Period","As verified by LFA","Comments","CT Adjustments (incl. External Audit adjustments)","The Global Fund Validated Figures","Comments"]
[1.1000000000000001,"Cash Balance: Beginning of the Period",0,40921.766591933439,null,null,0,{"$f":"D28+G28","v":40921.766591933439},null,null,{"$f":"H28+J28","v":40921.766591933439}]
[null,"2. Grant Income"]
[null,"Add: "]
[2.1,"Disbursement made to the Principal Recipient ",{"$f":"691821+664842","v":1356663},1319553.6000000001,null,0,0,{"$f":"D31+G31","v":1319553.6000000001},null,0,{"$f":"H31+J31","v":1319553.6000000001}]
[2.2000000000000002,"Disbursement to third parties by the Global Fund on behalf of the Principal Recipient ",{"$f":"36528.5+2391463.03+43994.7","v":2471986.23},49343.839999999997,null,0,0,{"$f":"D32+G32","v":49343.839999999997},null,0,{"$f":"H32+J32","v":49343.839999999997}]
[2.2999999999999998,"Interest received on bank accounts",0,0,null,0,0,{"$f":"D33+G33","v":0},null,0,0]
[2.4,"Revenue from income-generating activities (if applicable)",0,0,null,0,0,{"$f":"D34+G34","v":0},null,0,0]
[2.5,"Other income, if applicable (e.g. VAT/Other Tax returns, income from disposal of assets etc.)",0,{"$f":"17678.86+52847/2.6872","v":37345.055296219114},"VAT refund ",0,0,{"$f":"D35+G35","v":37345.055296219114},null,0,37345.055296219114,null,null,null,null,null,null," "]
[2.6,"Total Grant Income",{"$f":"SUM(C31:C35)","v":3828649.23},{"$f":"SUM(D31:D35)","v":1406242.4952962194},null,{"$f":"SUM(F31:F35)","v":0},{"$f":"SUM(G31:G35)","v":0},{"$f":"SUM(H31:H35)","v":1406242.4952962194},null,{"$f":"SUM(J31:J35)","v":0},{"$f":"SUM(K31:K35)","v":1406242.4952962194}]
[null,"3. Grant Cash Outflows"]
[null,"Less:"]
[3.1,"Principal Recipient Expenditure (including payments and other advance payments)",889926.670753791,756345.11684841302,null,{"$f":"F32","v":0},0,{"$f":"D39+G39","v":756345.11684841302},null,{"$f":"J32","v":0},{"$f":"H39+J39","v":756345.11684841302}]
[3.2,"Disbursement to third parties by the Global Fund on behalf of the Principal Recipient ",{"$f":"C32","v":2471986.23},{"$f":"D32","v":49343.839999999997},null,0,0,{"$f":"D40+G40","v":49343.839999999997},null,0,{"$f":"H40+J40","v":49343.839999999997}]
[3.3,"Principal Recipient disbursement to sub-recipients",{"$f":"231696.54+180732.8","v":412429.33999999997},164245.387294952,null,0,0,{"$f":"D41+G41","v":164245.387294952},null,0,{"$f":"H41+J41","v":164245.387294952}]
[3.4,"Bank charges on disbursements and payments",200,0,null,0,0,{"$f":"D42+G42","v":0},null,0,0]
[3.5,"Total Grant Cash Outflows",{"$f":"SUM(C39:C42)","v":3774542.2407537908},{"$f":"SUM(D39:D42)","v":969934.34414336504},null,{"$f":"SUM(F39:F42)","v":0},{"$f":"SUM(G39:G42)","v":0},{"$f":"SUM(H39:H42)","v":969934.34414336504},null,{"$f":"SUM(J39:J42)","v":0},{"$f":"SUM(K39:K42)","v":969934.34414336504}]
[null,"4. Reconciling Adjustments"]
[4.0999999999999996,"Other reconciliation adjustments (including for prior periods)",0,0,null,0,0,{"$f":"D45+G45","v":0},null,0,{"$f":"H45+J45","v":0}]
[4.2,"Net exchange gains/losses on translation of balances",{"$f":"-34128.06+50604.48","v":16476.420000000006},-20048.61,null,0,0,{"$f":"D46+G46","v":-20048.61},null,0,{"$f":"H46+J46","v":-20048.61}]
[4.3,"Ineligible transactions from previous periods for which justification was approved by the Global Fund",0,0,null,0,0,{"$f":"D47+G47","v":0},null,0,0]
[4.4000000000000004,"Reimbursement of ineligible transaction from previous periods",0,0,null,0,0,{"$f":"D48+G48","v":0},null,0,0]
[null,"5. Total Cash Balances: End of the reporting period"]
[5.0999999999999996,"Principal Recipient Cash Balance",0,{"$f":"(D28+D36-D43)+D45+D46+D48","v":457181.30774478789},null,null,{"$f":"(G36-G43)+G46+G48+G45","v":0},{"$f":"(H28+H36-H43)+H45+H46-H47","v":457181.30774478789},null,{"$f":"J28+J36-J43+J46+J45","v":0},{"$f":"K28+K36-K43+K46+K45-K47","v":457181.30774478789}]
[5.2,"Sub-Recipient Cash Balance",0,{"$f":"'SR_Cash Reconciliation_2D'!H54","v":27185.978578383641},null,null,{"$f":"'SR_Cash Reconciliation_2D'!K54","v":0},{"$f":"'SR_Cash Reconciliation_2D'!L54","v":27185.978578383641},null,0,{"$f":"+H51+J51","v":27185.978578383641}]
[5.3,"Total Cash Balance",{"$f":"C50+C51","v":0},{"$f":"D50+D51","v":484367.28632317152},null,{"$f":"F50+F51","v":0},{"$f":"G50+G51","v":0},{"$f":"H50+H51","v":484367.28632317152},null,{"$f":"J50+J51","v":0},{"$f":"K50+K51","v":484367.28632317152}]
[null,"6. Commitments & Other Obligations"]
[6.1,"Unpaid invoices, accrued expenditure for severance pay, leave and other liabilities ",0,{"$f":"(7218+73621.83)/2.6169","v":30891.447896365931},null,0,0,{"$f":"D54+G54","v":30891.447896365931},null,0,{"$f":"H54+J54","v":30891.447896365931}]
[6.2,"Open legal obligations (including signed contracts not yet invoiced) ",0,{"$f":"(23980/2+300+248430/3+24554/2)/2.6169","v":41032.137261645461},null,0,0,{"$f":"D55+G55","v":41032.137261645461},null,0,{"$f":"H55+J55","v":41032.137261645461}]
[6.3,"Tenders and/or procurement contracts initiated but not yet signed as contracts",0,0,null,0,0,{"$f":"D56+G56","v":0},null,0,{"$f":"H56+J56","v":0}]
[6.4,"Total Commitments & Other Obligations",{"$f":"SUM(C54:C56)","v":0},{"$f":"SUM(D54:D56)","v":71923.585158011396},null,{"$f":"SUM(F54:F56)","v":0},{"$f":"SUM(G54:G56)","v":0},{"$f":"SUM(H54:H56)","v":71923.585158011396},null,{"$f":"SUM(J54:J56)","v":0},{"$f":"SUM(K54:K56)","v":71923.585158011396}]
[]
[null,"B. Principal Recipient Bank Statement Balance & Cash In Transit in Grant Currency"]
[null,null,"Principal Recipient",null,null,"For LFA Use Only ",null,null,null,"For the Global Fund Use Only"]
[null,null,null,"End of Period","Comments",null,"LFA Adjustments on current Period","As verified by LFA","Comments","CT Adjustments","The Global Fund Validated Figures","Comments"]
[7.1,"Principal Recipient Cash Balance as per bank statements (For Information Only):",null,457181.30612556799,"EUR (The amount consists of GEL 1,196,397.76)",null,0,{"$f":"D62+G62","v":457181.30612556799},null,0,{"$f":"H62+J62","v":457181.30612556799}]
[7.2,"Cash in Transit for the reporting period",null,0,null,null,0,{"$f":"D63+G63","v":0},null,0,{"$f":"H63+J63","v":0}]
[7.3,"Cash in Transit after the current reporting period",null,{"$f":"1831327.48+45685+140600.42","v":2017612.9},"notifications received on 14/03/2016",null,0,{"$f":"D64+G64","v":2017612.9},null,0,2017612.9]
[]
[null,"C. Principal Recipient Ineligible Transactions in Grant Currency "]
[null,null,"Principal Recipient",null,null,"For LFA Use Only ",null,null,null,"For the Global Fund Use Only"]
[null,null,"Cumulative for Previous Periods","End of Period","Comments","Cumulative for Previous Periods as validated by Global Fund","LFA Adjustments on current Period","As verified by LFA","Comments","CT Adjustments","The Global Fund Validated Figures","Comments"]
[8.1,"Ineligible transactions validated for the reporting period",0,0,null,0,{"$f":"G52","v":0},{"$f":"D69+G69","v":0},null,{"$f":"J41","v":0},{"$f":"H69+J69","v":0}]
[8.1999999999999993,"Ineligible transactions from previous periods for which justification was approved by the Global Fund",{"$f":"C47","v":0},{"$f":"D47","v":0},null,{"$f":"F47","v":0},{"$f":"G47","v":0},{"$f":"D70+G70","v":0},null,0,{"$f":"H70+J70","v":0}]
[8.3000000000000007,"Reimbursement of ineligible transactions from previous periods",{"$f":"C48","v":0},{"$f":"D48","v":0},null,{"$f":"F48","v":0},{"$f":"G48","v":0},{"$f":"D71+G71","v":0},null,{"$f":"J48","v":0},0]
[8.4,"Cumulative ineligible transactions for the implementation period",0,{"$f":"D69+C72","v":0},null,0,0,{"$f":"D72+G72","v":0},null,0,{"$f":"K69+C72","v":0}]
[8.5,"Open ineligible transactions to be justified and/or reimbursed",{"$f":"C69-C70-C71","v":0},{"$f":"C73+D69-D70-D71","v":0},null,0,0,{"$f":"D73+H69-H70-H71","v":0},null,0,{"$f":"H73+J69-J70-J71","v":0}]

{"sheet":"SR_Cash Reconciliation_2D","index":12,"n_rows":56,"n_cols":16,"rows_kept":56,"cut":false,"hidden":false,"merged":[[21,13,21,15],[16,0,17,11],[19,0,19,15],[6,0,6,2],[7,0,7,2],[8,0,8,2],[11,0,11,2],[12,0,12,2],[8,3,8,6],[13,3,13,6],[13,0,13,2],[21,0,21,9],[21,10,21,12]]}
["Ongoing Progress Update and Disbursement Request "]
[]
["Grant Name:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
["(Disease) Component",{"$f":"#REF!","v":{"$error":"#REF!"}}]
[]
["PROGRESS UPDATE "]
["Progress Update - Reporting Period:",null,null,"Cycle:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"Number:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
["Progress Update - Period Covered:",null,null,"Beginning Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"End Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
["Progress Update - Number:"]
[]
["DISBURSEMENT REQUEST "]
["Disbursement Request  - Disbursement Period:",null,null,"Cycle:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"Number:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
["Disbursement Request  - Period Covered:",null,null,"Beginning Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"End Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
["Disbursement Request  - Number:"]
[]
[]
["Section 2: Financial Information"]
[]
[]
["D. Principal Recipient Reconciliation of funds provided to Sub-Recipients for the Current Implementation Period"]
[]
["Principal Recipient",null,null,null,null,null,null,null,null,null,"For Local Fund Agent Use Only ",null,null,"For the Global Fund Use Only"]
["(1) \nSub-Recipient Name","(2) \n Cumulative Sub-Recipient expenses for prior periods at Principal Recipient level","(3) \nSub-Recipient Open Advances at Principal Recipient Level","(4) \nDisbursements made by Principal Recipient during the Reporting Period","(5) \nOther Income* during the Reporting Period ","(6) \nExpenditure validated by Principal Recipient during the Reporting Period","(7) \nSub-Recipient Closing Balance at Principal Recipient Level","(8) \nActual Sub-Recipient Cash Balance (if applicable)"," (9)\nVariances on Sub-Recipient Balances","Comments","LFA Adjustments","As verified by LFA","Comments","Country Team Adjustments (incl. External Audit adjustments)","The Global Fund Validated Figures","Comments"]
["TB Center",0,0,0,0,0,{"$f":"+C24+D24+E24-F24","v":0},27185.978578383641,{"$f":"+H24-G24","v":27185.978578383641},"Advance payment to TB Center",null,{"$f":"H24+K24","v":27185.978578383641},null,null,{"$f":"L24+N24","v":27185.978578383641}]
[null,0,0,0,0,0,{"$f":"+C25+D25+E25-F25","v":0},0,0,null,null,{"$f":"H25+K25","v":0},null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,{"$f":"+H38-G38","v":0},null,null,{"$f":"H38+K38","v":0},null,null,{"$f":"L38+N38","v":0}]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,{"$f":"+H51-G51","v":0},null,null,{"$f":"H51+K51","v":0},null,null,{"$f":"L51+N51","v":0}]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
["Total for the Reporting Period",{"$f":"SUM(B24:B53)","v":0},0,0,0,0,0,27185.978578383641,27185.978578383641,null,null,27185.978578383641,null,null,27185.978578383641]
[]
["* Includes interest income, income generating activites etc."]

{"sheet":"Budget Variance_2E","index":13,"n_rows":43,"n_cols":14,"rows_kept":43,"cut":false,"hidden":false,"merged":[[39,7,39,8],[41,7,41,8],[42,7,42,8],[18,3,18,13],[33,3,33,13],[27,7,27,8],[34,7,34,8],[35,7,35,8],[36,7,36,8],[37,7,37,8],[21,7,21,8],[22,7,22,8],[24,7,24,8],[25,7,25,8],[26,7,26,8],[21,1,21,2],[34,1,34,2],[22,1,22,2],[26,1,26,2],[27,1,27,2],[24,1,24,2],[31,0,31,11],[25,1,25,2],[12,1,12,3],[19,1,19,2],[20,1,20,2],[19,7,19,8],[20,7,20,8],[14,0,14,13],[16,0,16,13],[6,1,6,3],[7,1,7,3],[8,1,8,3],[8,5,8,8],[11,1,11,3],[36,1,36,2],[35,1,35,2],[39,1,39,2],[40,1,40,2],[42,1,42,2],[41,1,41,2],[37,1,37,2]]}
["Ongoing Progress Update and Disbursement Request"]
[]
[null,"Grant Name:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"(Disease) Component",{"$f":"#REF!","v":{"$error":"#REF!"}}]
[]
[null,"PROGRESS UPDATE "]
[null,"Progress Update - Reporting Period:",null,null,null,"Cycle:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"Number:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Progress Update - Period Covered:",null,null,null,"Beginning Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"End Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Progress Update - Number:"]
[]
[null,"DISBURSEMENT REQUEST "]
[null,"Disbursement Request  - Disbursement Period:",null,null,null,"Cycle:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"Number:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Disbursement Request  - Period Covered:",null,null,null,"Beginning Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"End Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[]
["Section 2: Financial Information"]
[]
["E. Total Principal Recipient Budget Variance and Funding Absorption Analysis"]
[]
[null,null,null,"Principal Recipient"]
[null,null,null,"Budget for Reporting Period","Actual Grant Cash Out-Flow - Cash Basis for Reporting Period","Budget Vs Actual Variances","Absorption Capacity","Reasons for Variance",null,"Cumulative Budget through period of Progress Update","Cumulative Actual Grant Cash-Outflow - Cash Basis through period of Progress Update","Cumulative Budget Vs Actuals Variances","Absorption Capacity","Reasons for Variance"]
[null,"1. Total Principal Recipient cash outflow vs. budget",null,{"$f":"SUM(D22:D23)","v":584565.06816807995},{"$f":"SUM(E22:E23)","v":969934.34414336504},{"$f":"IF(D21=\"\",IF(E21=\"\",\"\",D21-E21),D21-E21)","v":-385369.2759752851},{"$f":"E21/D21","v":1.6592410271502571},null,null,{"$f":"SUM(J22:J23)","v":8858606.882074343},{"$f":"SUM(K22:K23)","v":4744476.5848971559},{"$f":"IF(J21=\"\",IF(K21=\"\",\"\",J21-K21),J21-K21)","v":4114130.2971771872},{"$f":"K21/J21","v":0.53557818379972888}]
[null,"    1a. Principal Recipient's total expenditures (including any direct-disbursements to third-parties)",null,362123.79053793201,{"$f":"'PR Cash Reconciliation_2A,B,C'!D39+'PR Cash Reconciliation_2A,B,C'!D40+'PR Cash Reconciliation_2A,B,C'!D42","v":805688.95684841298},{"$f":"IF(D22=\"\",IF(E22=\"\",0,D22-E22),D22-E22)","v":-443565.16631048097},{"$f":"E22/D22","v":2.2248992689808325},"The net variance of EUR (443,565) consists of positive (EUR 166,312) and negative variances (EUR 609,877) \n \nPositive variance EUR 166,312 - derived from the activities that were budgeted for the current reporting period and represents either saving, commitment or postponed activity \n\nSaving -Total EUR 142,943 includes: \n\nEUR 9,626 - Actual unit price of fuel turned to be less than projected/budgeted. From the programmatic point of view, activities were performed as planned, though required quantity of fuel was less.\n\nEUR 10,451 – GenXpert actual calibration cost (part of the contract/invoice) was less than budgeted\n\nEUR 83,705- Actual cost for Cash Incentives (Sensitive & MDR) was less than budgeted due to actual number of patients (slightly less than projected). Most importantly, budget was made assuming max (100%) compliance to treatment. Reimbursed period covers June 2015- November 2015\n\nEUR 39,161 - Project management actual costs, such as HR costs, fuel, tender announcement fee, TA were found to be less than budgeted and FX rate change effect.\n\nPostponed activities and commitments - Total EUR 23,369 includes:\n\nEUR 2,377 – SRs fuel costs for December, payment transferred to next reporting period.\n\nEUR 20,635 – Committed payment for Cash Incentives (Sensitive & MDR) for December 2015 (Q4); \n\nEUR 357 – Project Management costs delayed to next reporting period, including fuel, postal cost, mobile service.\n \nNegative Variance EUR 609,877 – derived from activities that were budgeted in the previous reporting period and postponed to Q3Q4 period: \n\nEUR 250,186 – Procurement of Lab supplies and equipment carried to the current reporting period.\n\nEUR 301,195 – Procurement of GeneXpert cartridges for 2016-2017 period, part of the amount was budgeted in the previous reporting period and the other part in the year 2016.\n\nEUR 2,898 – Procurement of drugs for side effects carried out in current reporting period and budgeted in the previous period.\n\nEUR 55,598 – Procurement of SLD and local PSM costs for pharmaceuticals procured in previous year. These activities were budgeted in the previous reporting periods.\n",null,8042499.3232110096,{"$f":"'PR Cash Reconciliation_2A,B,C'!D39+'PR Cash Reconciliation_2A,B,C'!D40+'PR Cash Reconciliation_2A,B,C'!D42+'PR Cash Reconciliation_2A,B,C'!C39+'PR Cash Reconciliation_2A,B,C'!C40+'PR Cash Reconciliation_2A,B,C'!C42","v":4167801.8576022042},{"$f":"IF(J22=\"\",IF(K22=\"\",0,J22-K22),J22-K22)","v":3874697.4656088054},{"$f":"K22/J22","v":0.51822222049478361},"The net variance of EUR 3,874,698 consists of the positive (EUR 4,030,130) and negative variances (EUR 155,432)\n\nPositive Variance EUR 4,030,130 – derived from the savings, commitments or postponed activities.\n \nSaving – Total EUR 3,866,846 includes: \n \nEUR 52,542 - Actual unit price of fuel turned to be less than projected/budgeted. From the programmatic point of view, activities were performed as planned, though required quantity of fuel was less; Fuel cost budgeted under line 4.7 (b) was cancelled due to the following factor: the adherence data is collected and monitored on a regular basis by regional coordinators with further submission to the TB Centre. Activity related to the monitoring of the cash incentive scheme was abolished, considering that it is being performed under the current set-up of the scheme\n\nEUR 721,034 - Procurement of lab supplies, including PSM costs and respirators caused saving, due to the following factors: 1. Local procurement with competitive bidding with preceding market assessment derived significantly cheaper unit costs compared to the budgeted amounts; 2. Available stock; 3. Re-calculation of average consumption rates;\n\nEUR 700,681 - Actual cost of Cash incentives  (Sensitive & MDR) covered period June 2014 – November 2015 and was less than budgeted. The following are the reasons for saving:\nSensitive - budgeted amount was calculated for 1 year period covering 70% of all sensitive patients with100% adherence (both installments). Actually patients enrolled in January - May, 2014 did not fit for being beneficiary of the scheme as approved scheme was enrolling patients starting June 1. \nMDR - budgeted amount was calculated for the entire treatment course (15 months) covering 75% of MDR patients from the 2012, 2013, 2014 cohorts, with100% adherence (all weeks on outpatient treatment).  Actually, 5 months were covered, payments started in August, there was no 100% compliance in many cases and number of patients was less than projected/budgeted. \n\nEUR 4,276 – Payments to the staff were initiated only after scheme operationalization, though were budgeted to start earlier. Exchange rate impact also caused additional savings \n\nEUR 2,132,924 – Net saving in procurement of SLD include several reasons: recalculation of needs; tendency of decreasing prevalence of TB; \nBDQ Donation program provided the medicine free-of-charge; General tendency of decreasing cost of TB medicines through GDF; some savings from the SLD line were reallocated to activities as equipment by TB center. These reallocation requests were approved by the GF in January-February 2016, as well as in 2015.\n\nEUR 1,230 – Lines 3.10/3.11 were cancelled (ref. PR letter to GF19/11/2014), as the pharmaceutical was included in the GDF Order (Act. 3.1.a)\n\nEUR 2997 –The activity was canceled. Procurement (water for injectable) was carried out by TB Centre.\n\nEUR 55,908 – Cost of Procurement side effects drugs was less than budgeted due to the decreasing number of patients and low prices derived through the local procurement (tender).\n\nEUR 1,151 – Saving in printing of statistical forms due to lower unit price derived through tender;\n\nEUR 194,103 – Saving in Project Management costs such as TA, Audit cost, Fuel, HR due to vacant position, less unit costs than budgeted, FX rate Change, As for the TA saving – amount was spent to cover WHO Review mission that was performed last year, though the costs related to the exercise was less than budgeted.\n   \nPostponed activities and commitments - Total EUR 163,284 includes:\n\nEUR 139,915 – Payment for Procurement of SLDs and local PSM costs postponed to the next reporting period\n\nEUR 2,377 – SRs fuel costs for December, payment transferred to next reporting period.\n\nEUR 20,635 – Committed payment for Cash Incentives (Sensitive & MDR) for December 2015 (Q4); \n\nEUR 357 – Project Management costs delayed to next reporting period, including fuel, postal cost, mobile service.\n  \nNegative Variance EUR 155,432 – derived from the activities not budgeted in the cumulative period and actual costs that were greater than budgeted: \n\nEUR 40,649 - FX rate change for FLDs and GLC Mission payment. \n\nEUR 67,030 - Procurement of GeneXpert cartridges to meet the need for 2016-2017 years, part of the amount was budgeted in the previous reporting period and the other part in the year 2016.\n\nEUR 47,753 – Actual cost and quantity for lab supplies budgeted under the line 2.7 (a) was greater than projected; also Procurement of GeneXperts resulted in negative variance due to FX rate change\n"]
[null,"    1b. Disbursements to sub-recipients",null,222441.27763014799,{"$f":"'PR Cash Reconciliation_2A,B,C'!D41","v":164245.387294952},{"$f":"IF(D23=\"\",IF(E23=\"\",0,D23-E23),D23-E23)","v":58195.890335195989},0.73837638879256029,"The reporting period relates to the activities performed by the TB center for July 2015-December 2015, but according to the contract, SR received reimbursement for June 2015-November 2015 services (EUR 164,245).\n\nPositive variance - EUR 58,196 includes: \n\nSaving EUR 37,658 - mainly unspent HR costs; less transportation incentives for patients;\n\nCommitments EUR 28,133 - December service cost reimbursed in January 2016.\n\nNegative Variance EUR 7,595 – The actual Training, vehicle maintenance and monitoring/supervision costs were greater in the current reporting period, due to postponed activities from the previous period.\n",null,816107.55886333401,{"$f":"'PR Cash Reconciliation_2A,B,C'!D41+'PR Cash Reconciliation_2A,B,C'!C41","v":576674.72729495191},{"$f":"IF(J23=\"\",IF(K23=\"\",0,J23-K23),J23-K23)","v":239432.8315683821},0.70661608391195196,"The Budget relates to the activities performed by the TB Center in April 2014-December 2015.  During the cumulative period SR received payment for April 2014-Novemebr 2015 services in the amount of EUR 549,489 and advance payment with remaining balance of EUR 27,186, available till the end of the contract 30/06/2016.\n\nThe net variance in the amount of EUR 239,433 related to TB Center performance includes: \n\nSaving of EUR 238,486 (mainly unspent HR costs; less transportation incentives to patients; cheaper operational research rather than budgeted; unspent TA amount during the year 2014-2015, as all the needs were met through PR financing, including GLC/GDF missions, WHO Programme Review, etc.) \n\nCommitment for December service - EUR 28,133. \n\nAdvance Payment reduces the positive variance by EUR 27,186.\n\n"]
[]
[null,"Procurement data for analytical purposes",null,"Budget for Reporting Period","Actual Grant Cash Out-Flow - Cash Basis for Reporting Period","Budget Vs Actual Variances","Absorption Capacity","Reasons for Variance",null,"Cumulative Budget through period of Progress Update","Cumulative Actual Grant Cash-Outflow - Cash Basis through period of Progress Update","Cumulative Budget Vs Actuals Variances","Absorption Capacity","Reasons for Variance"]
[null,"2. Total pharmaceutical & non-pharmaceutical incl. equipment expenditures vs.    budget",null,{"$f":"D27+D28","v":11700},{"$f":"E27+E28","v":593754.71408463654},{"$f":"IF(D26=\"\",IF(E26=\"\",\"\",D26-E26),D26-E26)","v":-582054.71408463654},{"$f":"E26/D26","v":50.748266161080046},null,null,{"$f":"J27+J28","v":5738450.61689323},{"$f":"K27+K28","v":3057751.3645656174},{"$f":"IF(J26=\"\",IF(K26=\"\",\"\",J26-K26),J26-K26)","v":2680699.2523276126},{"$f":"K26/J26","v":0.53285312860652789}]
[null,"    2a.  Health Products- Pharmaceutical Products",null,0,52241.724084636597,{"$f":"IF(D27=\"\",IF(E27=\"\",0,D27-E27),D27-E27)","v":-52241.724084636597},{"$f":"E27/D27","v":{"$error":"#DIV/0!"}},"The budget relates to pharmaceuticals procured locally as well as through the GDF.\nThe Negative variance EUR 52,242 is due to activities that were budgeted in the previous reporting period and postponed to Q3Q4 period: \nEUR 2,898 – Procurement of drugs for side effects carried out in current reporting period and budgeted in the previous period.\n\nEUR 49,344 – Payment for SLD order placed in December 2015, but budgeted in the previous reporting period.\n",null,4358024.9702597596,2258875.4433946302,{"$f":"IF(J27=\"\",IF(K27=\"\",0,J27-K27),J27-K27)","v":2099149.5268651294},{"$f":"K27/J27","v":0.51832549349986634},"The budget relates to pharmaceuticals procured locally as well as through the GDF.\n\nThe variance is due to several reasons:\n\nSaving – Total EUR 1,988,277 includes: \n\nEUR 1,928,303 – Net saving in procurement of SLD include several reasons: recalculation of needs; tendency of decreasing prevalence of TB; \nBDQ Donation program provided the medicine free-of-charge; General tendency of decreasing cost of TB medicines through GDF;\n\nEUR 1,069 – Lines3.10 was cancelled (ref. PR letter to GF19/11/2014) as the pharmaceutical was included in the GDF Order (Act. 3.1.a)\n\nEUR 2997 –The activity was canceled. Procurement (water for injectibles) was carried out by TB Centre.\n\nEUR 55,908 – Cost of Procurement side effects drugs was less than budgeted due to the decreasing number of patients and low prices derived through the local procurement (tender).\n\nCommitment EUR 139,891 for SLD order placed in December 2015 \n\nOverspending: EUR 29,019 - FX rate change FLD order placed in 2014.\n"]
[null,"    2b.  Health Products - Non-Pharmaceuticals & Equipment",null,11700,541512.99,{"$f":"IF(D28=\"\",IF(E28=\"\",0,D28-E28),D28-E28)","v":-529812.99},46.283161538461535,"The budget relates to internationally and locally procured lab supplies, consumables and equipment. \n\nReasons for variance are following: \n\nSaving EUR 10,451 - GeneXpert actual calibration cost (part of the contract/invoice) was less than budgeted\n\nNegative Variance EUR 540,264 includes: \n\nEUR 249,878 – Procurement of Lab supplies and equipment carried to the current reporting period.\n\nEUR 290,386 – Procurement of GeneXpert cartridges to meet need for 2016-2017 years, part of the amount was budgeted in the previous reporting period and the other part in the year 2016.\n",null,1380425.64663347,798875.92117098696,{"$f":"IF(J28=\"\",IF(K28=\"\",0,J28-K28),J28-K28)","v":581549.72546248301},0.57871709578799513,"The budget relates to internationally and locally procured lab supplies, consumables and equipment. \n\nReasons for variance are following: \n\nSaving EUR 696,333 is derived from procurement of lab supplies and respirators 1. Local procurement with competitive bidding with preceding market assessment derived significantly cheaper unit costs compared to the budgeted amounts; 2. Available stocks; 3. Re-calculation of average consumption rates;\n\nOverspending EUR 114,783 includes:\n\nEUR 67,030 - Procurement of GeneXpert cartridges to meet need for 2016-2017 years, part of the amount was budgeted in the previous reporting period and the other part in the year 2016.\n\nEUR 47,753 – Actual cost and quantity for lab supplies budgeted under the line 2.7 (a) was greater than projected; also Procurement of GeneXperts resulted in negative variance due to FX rate change\n"]
[]
[]
["For LFA Use Only"]
["E. Total Principal Recipient Budget Variance and Absorption Analysis"]
[]
[null,null,null,"Local Fund Agent (LFA)"]
[null,null,null,"Budget for Reporting Period","Actual Grant Expenditure - Cash Basis for Reporting Period","Budget Vs Actual Variances","Absorption Capacity","LFA comments on thePrincipal Recipient's explanation of variances ",null,"Cumulative Budget through period of Progress Update","Cumulative Actual Grant Expenditure - Cash Basis through period of Progress Update","Cumulative Budget Vs Actuals Variances","Absorption Capacity","LFA comments on the Principal Recipient's explanation of variances "]
[null,"1. Total Principal Recipient cash outflow vs. budget",null,{"$f":"SUM(D37:D38)","v":0},{"$f":"SUM(E37:E38)","v":969934.34414336493},{"$f":"IF(D36=\"\",IF(E36=\"\",\"\",D36-E36),D36-E36)","v":-969934.34414336493},{"$f":"E36/D36","v":{"$error":"#DIV/0!"}},null,null,{"$f":"SUM(J37:J38)","v":0},969934.34414336493,{"$f":"IF(J36=\"\",IF(K36=\"\",\"\",J36-K36),J36-K36)","v":-969934.34414336493},{"$f":"K36/J36","v":{"$error":"#DIV/0!"}}]
[null,"    1a. Principal Recipient's total expenditures (including any direct-disbursements to third-parties)",null,0,{"$f":"'PR Cash Reconciliation_2A,B,C'!H39+'PR Cash Reconciliation_2A,B,C'!H41+'PR Cash Reconciliation_2A,B,C'!H42","v":920590.50414336496},{"$f":"IF(D37=\"\",IF(E37=\"\",0,D37-E37),D37-E37)","v":-920590.50414336496},{"$error":"#DIV/0!"},null,null,0,{"$f":"'PR Cash Reconciliation_2A,B,C'!F39+'PR Cash Reconciliation_2A,B,C'!F41+'PR Cash Reconciliation_2A,B,C'!F42+E37","v":920590.50414336496},{"$f":"IF(J37=\"\",IF(K37=\"\",0,J37-K37),J37-K37)","v":-920590.50414336496},{"$f":"K37/J37","v":{"$error":"#DIV/0!"}}]
[null,"    1b. Disbursements to sub-recipients",null,0,{"$f":"'PR Cash Reconciliation_2A,B,C'!H40","v":49343.839999999997},{"$f":"IF(D38=\"\",IF(E38=\"\",0,D38-E38),D38-E38)","v":-49343.839999999997},{"$error":"#DIV/0!"},null,null,0,{"$f":"'PR Cash Reconciliation_2A,B,C'!F40+E38","v":49343.839999999997},{"$f":"IF(J38=\"\",IF(K38=\"\",0,J38-K38),J38-K38)","v":-49343.839999999997},{"$error":"#DIV/0!"}]
[]
[null,"Procurement data for analytical purposes",null,"Budget for Reporting Period","Actual Grant Expenditure - Cash Basis for Reporting Period","Budget Vs Actual Variances","Absorption Capacity","LFA comments on the Principal Recipient's explanation of variances ",null,"Cumulative Budget through period of Progress Update","Cumulative Actual Grant Expenditure - Cash Basis through period of Progress Update","Cumulative Budget Vs Actuals Variances","Absorption Capacity","LFA comments on the Principal Recipient's explanation of variances "]
[null,"2. Total pharmaceutical & non-pharmaceutical incl. equipment expenditures vs. budget",null,{"$f":"D42+D43","v":0},{"$f":"E42+E43","v":0},{"$f":"IF(D41=\"\",IF(E41=\"\",\"\",D41-E41),D41-E41)","v":0},{"$f":"E41/D41","v":{"$error":"#DIV/0!"}},null,null,{"$f":"J42+J43","v":0},{"$f":"K42+K43","v":0},{"$f":"IF(J41=\"\",IF(K41=\"\",\"\",J41-K41),J41-K41)","v":0},{"$f":"K41/J41","v":{"$error":"#DIV/0!"}}]
[null,"    2a.  Health Products- Pharmaceutical Products",null,0,0,{"$f":"IF(D42=\"\",IF(E42=\"\",0,D42-E42),D42-E42)","v":0},{"$error":"#DIV/0!"},null,null,0,0,{"$f":"IF(J42=\"\",IF(K42=\"\",0,J42-K42),J42-K42)","v":0},{"$f":"K42/J42","v":{"$error":"#DIV/0!"}}]
[null,"    2b.  Health Products - Non-Pharmaceuticals & Equipment",null,0,0,{"$f":"IF(D43=\"\",IF(E43=\"\",0,D43-E43),D43-E43)","v":0},{"$error":"#DIV/0!"},null,null,0,0,{"$f":"IF(J43=\"\",IF(K43=\"\",0,J43-K43),J43-K43)","v":0},{"$error":"#DIV/0!"}]

{"sheet":"Procurement_3","index":14,"n_rows":63,"n_cols":23,"rows_kept":63,"cut":false,"hidden":false,"merged":[[5,14,5,20],[3,17,3,19],[4,17,4,19],[0,12,0,22],[2,12,2,13],[2,14,2,20],[3,15,3,16],[4,15,4,16],[8,12,8,21],[11,18,11,22],[12,18,12,22],[14,12,14,22],[15,12,15,13],[15,16,15,22],[12,12,12,16],[16,12,16,13],[16,16,16,22],[17,12,17,13],[17,16,17,22],[18,12,18,13],[18,16,18,22],[19,12,19,13],[19,16,19,22],[20,12,20,13],[20,16,20,22],[21,12,21,13],[21,16,21,22],[22,12,22,13],[23,12,23,13],[23,16,23,22],[24,12,24,13],[24,16,24,17],[22,16,22,22],[25,12,25,22],[26,12,26,22],[31,12,31,22],[34,16,34,22],[35,16,35,22],[35,12,35,13],[38,12,38,22],[39,12,39,13],[40,12,40,13],[40,17,40,18],[41,12,41,13],[41,17,41,18],[42,12,42,13],[42,17,42,18],[43,12,43,13],[43,17,43,18],[44,12,44,13],[44,17,44,18],[45,12,45,13],[45,17,45,18],[47,12,47,13],[47,17,47,18],[48,12,48,13],[48,17,48,18],[46,12,46,13],[46,17,46,18],[50,12,50,22],[51,12,51,13],[51,16,51,22],[52,12,52,13],[52,16,52,22],[53,12,53,13],[53,16,53,22],[54,12,54,13],[54,16,54,22],[55,12,55,13],[55,16,55,22],[62,12,62,22],[63,12,63,22],[56,12,56,13],[56,16,56,22],[57,12,57,13],[58,12,58,13],[59,12,59,13],[59,16,59,22],[57,16,57,22],[58,16,58,22]]}
[null,null,null,null,null,null,null,null,null,null,null,null,"Ongoing Progress Review and Disbursement Request"]
[null,null,null,null,null,null,null,null,null,null,null,null,"PROGRESS UPDATE PERIOD"]
[null,null,null,null,null,null,null,null,null,null,null,null,"Grant Name:",null,{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
[null,null,null,null,null,null,null,null,null,null,null,null,"Progress Update - Reporting Period:",null,"Cycle:",{"$f":"+#REF!","v":{"$error":"#REF!"}},null,"Number:",null,null,{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,null,null,null,null,null,null,null,null,null,null,null,"Progress Update - Period Covered:",null,"Beginning Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}},null,"End Date:",null,null,{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
[null,null,null,null,null,null,null,null,null,null,null,null,"Progress Update - Number:"]
[]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,"Section 3A:  PR - Procurement and Supply Management"]
[]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Comments"]
[null,null,null,null,null,null,null,null,null,null,null,null,"1.  Have you updated the Price Quality Reporting (PQR) with the required information on the pharmaceuticals and health products received during the period covered by this PU/DR’ (if applicable)?  If health products procurement information has not been entered into the PQR, please explain why.\n\n!  For further guidance on PQR data entry, please refer to the guidelines.",null,null,null,null,"Select","All the info on applicable health  products procurement within this reporting period was entered into the  PQR.  \nFollowing items procurement was processed and submitted accordingly:                        \nSecond line anti -Tb drugs  procured  through GDF/IDA:                                                                                                          1.  Moxifloxacin -PO# GF-T/SSP/G-56; inv no GEO/DP/14/4364-GS14440                                                                             2. Bedaquiline- PO#GF-T/SSP/G-56, inv no GEO/DP/14/4376-GS14441;                                                                            3.  Prothionamide 250mg tab ,Clarithromycin 500mg tab, Amoxicillin+Clavulanate - FDC 500mg/125mg tab, Capreomycin 1g powder for inj, PAS Sodium 5.52g (equiv 4g PAS) powder for oral sol/susp Sachet - 25 X 4g, Cycloserine 250mg Caps, Imipenem+Cilastatin inj. 1g (500mg+500mg) powder for inj., Bedaquiline 100mg tab, Linezolide 600mg tab, Clofazimine 100mg - PO #   GF-T/SSP/G-56, INV GEO/DP/14/4364-GS14440                                                                                                                                                         \n4. TB testing consumables/test kits BACTEC MGIT 960 Supplement Kit 100s [245124] \nBD Biosciences TB testing consumables/test kits BACTEC MGIT 960 SIRE Kit 40s [245123] \n BACTEC MGIT 960 PZA Drug Kit 50s [245128] \n BD Biosciences TB testing consumables/test kits BBL MGIT 7 ml Tube (100 tests) [245122] \n BD Biosciences TB testing consumables/test kits BACTEC MGIT 960 PZA Medium 25s [245115]- PO#GF-  T/ET/G-158/1;INV #ელ-0195724088;                                                                                                                           \n 5.TB molecular diagnostics -Hain Lifescience GmbH  -  GenoTypeMTBDR plus tests 12s, 96s [304A, 30496A], \n- GenoType MTBDRsl 12s, 96s [317, 31796] ;                                                                                                                                          6. TB testing consumables/test kits -SD BIOLINE TB Ag MPT64 Rapid [08FK50]"]
[]
[null,null,null,null,null,null,null,null,null,null,null,null," 2. Based on the most up-to-date stock situation, are there any risks of stock-outs or expiries for the key pharmaceuticals & health products, listed below, at the central level in the next period of implementation?  If yes, please comment."]
[null,null,null,null,null,null,null,null,null,null,null,null,"Key Pharmaceuticals & Health Products",null,"Risk of Stock-Out","Risk of Expiry","Comment (if yes, please provide information on the specific items that are at risk of stock-out or expiry)"]
[null,null,null,null,null,null,null,null,null,null,null,null,"1. Anti-malaria medicines",null,"N/A","N/A"," "]
[null,null,null,null,null,null,null,null,null,null,null,null,"2. Bed nets",null,"N/A","N/A"]
[null,null,null,null,null,null,null,null,null,null,null,null,"3. In-Vitro Diagnostic Products",null,"No","No"]
[null,null,null,null,null,null,null,null,null,null,null,null,"4. Condoms",null,"N/A","N/A"]
[null,null,null,null,null,null,null,null,null,null,null,null,"5. Anti-retrovirals",null,"N/A","N/A"]
[null,null,null,null,null,null,null,null,null,null,null,null,"6. Anti-TB medicines",null,"Yes","Yes","About 23,000 vials of Kanamycin will expire in coming 6 months. "]
[null,null,null,null,null,null,null,null,null,null,null,null,"7. Lab supplies (e.g. CD4, Viral Load, Cartridges…)",null,"No","No"]
[null,null,null,null,null,null,null,null,null,null,null,null,"8. Other (Please specify in the \"Comment\" column)",null,"No","No"]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,"3.  Comment on additional issues related to the procurement and supply management of pharmaceuticals and health products."]
[null,null,null,null,null,null,null,null,null,null,null,null,"\"Global test\"  was contracted for quality check of  5  Anti - TB drugs using the competitive selection (e-tender). Sampling was made in Tbilisi , Batumi  and Zugdidi TB facilities. \nFollowing products were tested:                                          \n1. Capreomycin for Injection . Pwder, 1g , Vianex S.A. Greec 4 0NA 2 0\n2. PAS , 5.52 g , Olainfarm, Latvia 15 0 NA 2 0\n3. Levofloxacin tabs, 250 mg , Micro Labs Hosur, india 1 0 NA 1 0\n4. Sinerdol ( Rifampicin) caps, \"Antibiotice S.A. Romania 1 0 NA 1 0\n5. Rifampicin 150mg/ Isoniazid 75 mg/ Pirazinamid 400 mg/ Ethambutol Hidrochlorid 275 mg, 24/28 2 0NA 2 0\nNo batches with out-of -specification results observed.\nPeriod of reporting: 1 Sept 2014 - 1 November 2015\n\n"]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,"For LFA Use Only"]
[]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,"Section 3B: LFA-Verified Procurement and Supply Management Information"]
[]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,"PR's response","LFA's response","LFA Comments/Analysis "]
[null,null,null,null,null,null,null,null,null,null,null,null,"1a.  Has the PR updated the Price Quality Reporting (PQR) with the required information on the pharmaceuticals and health products received during the period covered by this PU/DR’ (if applicable)?  (If health products procurement information has not been entered into the PQR, please explain why in comments box)    ",null,{"$f":"R13","v":"Select"},"Select"]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,"1b.  Value of Pharmaceuticals and Health Products in the PQR (6 categories only)"]
[null,null,null,null,null,null,null,null,null,null,null,null,"(!) This table is included in the PU/DR form with the aim to improve completeness of information in the PQR system and not for comparing PQR amounts vis-à-vis expenditure per se. NB: PQR and expenditure amounts on health products may not be equal due to a timelag between payments and delivery of pharmaceuticals/health products.\n(!)  For further guidance on PQR data entry, please refer to the guidelines."]
[null,null,null,null,null,null,null,null,null,null,null,null,"Reporting Currency"]
[null,null,null,null,null,null,null,null,null,null,null,null,"PQR Product Categories",null,"Value of  products received during reporting period","Value of products entered by the PR and verified as correct by the LFA in the PQR during reporting period","Variance","Reason for Variance",null,"Cumulative value of  products received since the start of the grant","Cumulative value of products verified as correct by the LFA in the PQR since the start of the grant","Variance","Reason for Variance"]
[null,null,null,null,null,null,null,null,null,null,null,null,"1. Anti-malaria medicines",null,null,null,{"$f":"IF(O42=\"\",IF(P42=\"\",\"\",O42-P42),O42-P42)","v":""},null,null,null,null,{"$f":"IF(T42=\"\",IF(U42=\"\",\"\",T42-U42),T42-U42)","v":""}]
[null,null,null,null,null,null,null,null,null,null,null,null,"2. Bed nets",null,null,null,"",null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,"3. In-Vitro Diagnostic Products",null,null,null,"",null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,"4. Condoms",null,null,null,"",null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,"5. Anti-retrovirals",null,null,null,"",null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,"6. Anti-TB medicines"]
[null,null,null,null,null,null,null,null,null,null,null,null,"7. Indoor Residual Spraying (IRS)",null,null,null,"",null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,"Total",null,{"$f":"SUM(O42:O48)","v":0},{"$f":"SUM(P42:P48)","v":0},{"$f":"SUM(Q42:Q48)","v":0},null,null,{"$f":"SUM(T42:T48)","v":0},{"$f":"SUM(U42:U48)","v":0},{"$f":"SUM(V42:V48)","v":0}]
[]
[null,null,null,null,null,null,null,null,null,null,null,null," 2. Based on best information available to the LFA, are there any risks of drug stock-out or expiries at the central level in the next period of implementation?  (If yes, please explain in comments box)\n! This section should be completed by the LFA based on best information on stock at the central level available to the LFA and should not require dedicated visits for on-site checks of stocks."]
[null,null,null,null,null,null,null,null,null,null,null,null,"Key Pharmaceuticals & Health Products",null,"Risk of Stock-Out","Risk of Expiry","Comment (if yes, please provide information on the specific items that are at risk of stock-out or expiry)"]
[null,null,null,null,null,null,null,null,null,null,null,null,"1. Anti-malaria medicines",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"2. Bed nets",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"3. In-Vitro Diagnostic Products",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"4. Condoms",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"5. Anti-retrovirals",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"6. Anti-TB medicines",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"7. Lab supplies (e.g. CD4, Viral Load, Cartridges…)",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"8. Other (Please specify in the \"Comment\" column)",null,"Select","Select"]
[]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,"3. LFA analysis of issues related to the procurement and supply management of pharmaceuticals and health products"]

{"sheet":"Grant Management_4","index":15,"n_rows":104,"n_cols":29,"rows_kept":104,"cut":false,"hidden":false,"merged":[[86,1,86,5],[86,7,86,12],[86,14,86,22],[86,24,86,32],[87,1,87,5],[87,7,87,12],[87,14,87,22],[87,24,87,32],[83,1,83,5],[83,7,83,12],[83,14,83,22],[83,24,83,32],[84,1,84,5],[84,7,84,12],[84,14,84,22],[84,24,84,32],[85,1,85,5],[85,7,85,12],[85,14,85,22],[85,24,85,32],[80,1,80,5],[80,7,80,12],[80,14,80,22],[80,24,80,32],[81,1,81,5],[81,7,81,12],[81,14,81,22],[81,24,81,32],[82,1,82,5],[82,7,82,12],[82,14,82,22],[82,24,82,32],[77,1,77,5],[77,7,77,12],[77,14,77,22],[77,24,77,32],[78,1,78,5],[78,7,78,12],[78,14,78,22],[78,24,78,32],[79,1,79,5],[79,7,79,12],[79,14,79,22],[79,24,79,32],[74,1,74,5],[74,7,74,12],[74,14,74,22],[74,24,74,32],[75,1,75,5],[75,7,75,12],[75,14,75,22],[75,24,75,32],[76,1,76,5],[76,7,76,12],[76,14,76,22],[76,24,76,32],[42,1,42,5],[42,7,42,12],[42,14,42,22],[42,24,42,32],[72,1,72,5],[72,7,72,12],[72,14,72,22],[72,24,72,32],[73,1,73,5],[73,7,73,12],[73,14,73,22],[73,24,73,32],[47,7,47,13],[48,1,48,5],[51,7,51,13],[48,7,48,13],[50,1,50,5],[44,14,44,20],[64,14,64,22],[62,7,62,12],[63,1,63,5],[61,1,61,5],[45,14,45,20],[50,14,50,20],[39,1,39,5],[39,7,39,12],[39,14,39,22],[39,24,39,32],[40,1,40,5],[40,7,40,12],[40,14,40,22],[40,24,40,32],[41,1,41,5],[41,7,41,12],[41,14,41,22],[41,24,41,32],[36,1,36,5],[36,7,36,12],[36,14,36,22],[36,24,36,32],[37,1,37,5],[37,7,37,12],[37,14,37,22],[37,24,37,32],[38,1,38,5],[38,7,38,12],[38,14,38,22],[38,24,38,32],[33,1,33,5],[33,7,33,12],[33,14,33,22],[33,24,33,32],[34,1,34,5],[34,7,34,12],[34,14,34,22],[34,24,34,32],[35,1,35,5],[35,7,35,12],[35,14,35,22],[35,24,35,32],[30,1,30,5],[30,7,30,12],[30,14,30,22],[30,24,30,32],[31,1,31,5],[31,7,31,12],[31,14,31,22],[31,24,31,32],[32,1,32,5],[32,7,32,12],[32,14,32,22],[32,24,32,32],[27,1,27,5],[27,7,27,12],[27,14,27,22],[27,24,27,32],[28,1,28,5],[28,7,28,12],[28,14,28,22],[28,24,28,32],[29,1,29,5],[29,7,29,12],[29,14,29,22],[29,24,29,32],[23,1,23,5],[23,7,23,12],[88,1,88,5],[57,7,57,12],[58,7,58,12],[59,7,59,12],[61,7,61,12],[68,7,68,12],[69,7,69,12],[70,7,70,12],[71,7,71,12],[88,7,88,12],[60,1,60,5],[60,7,60,12],[65,1,65,5],[65,7,65,12],[66,1,66,5],[66,7,66,12],[67,1,67,5],[67,7,67,12],[62,1,62,5],[44,7,44,13],[46,7,46,13],[47,1,47,5],[51,14,51,20],[52,14,52,20],[57,14,57,22],[58,14,58,22],[59,14,59,22],[61,14,61,22],[45,7,45,13],[46,1,46,5],[46,14,46,20],[47,14,47,20],[48,14,48,20],[19,7,19,12],[19,14,19,22],[18,1,18,5],[21,1,21,5],[18,7,18,12],[21,7,21,12],[20,7,20,12],[20,14,20,22],[22,1,22,5],[22,7,22,12],[22,14,22,22],[0,1,0,19],[9,1,9,13],[103,19,103,22],[55,1,55,22],[12,14,12,22],[13,14,13,22],[15,14,15,22],[24,14,24,22],[26,14,26,22],[25,14,25,22],[43,14,43,22],[49,1,49,22],[13,1,13,5],[24,1,24,5],[25,1,25,5],[15,1,15,5],[44,1,44,5],[45,1,45,5],[2,1,2,3],[2,4,2,7],[5,4,5,7],[12,1,12,5],[14,1,14,5],[14,7,14,12],[10,1,10,13],[26,1,26,5],[43,1,43,5],[12,7,12,12],[13,7,13,12],[15,7,15,12],[24,7,24,12],[25,7,25,12],[26,7,26,12],[43,7,43,12],[11,1,11,12],[11,13,11,22],[16,1,16,5],[16,7,16,12],[16,14,16,22],[20,1,20,5],[23,14,23,22],[21,14,21,22],[14,14,14,22],[17,1,17,5],[17,7,17,12],[17,14,17,22],[18,14,18,22],[19,1,19,5],[68,1,68,5],[69,1,69,5],[70,1,70,5],[71,1,71,5],[57,1,57,5],[58,1,58,5],[56,13,56,22],[60,14,60,22],[65,14,65,22],[66,14,66,22],[67,14,67,22],[62,14,62,22],[63,14,63,22],[64,1,64,5],[64,7,64,12],[63,7,63,12],[69,14,69,22],[70,14,70,22],[71,14,71,22],[101,19,101,22],[102,19,102,22],[91,1,91,4],[91,5,91,13],[68,14,68,22],[90,1,90,4],[90,5,90,13],[50,7,50,13],[51,1,51,5],[98,1,98,13],[52,1,52,5],[54,1,54,13],[59,1,59,5],[95,1,95,4],[52,7,52,13],[94,1,94,4],[94,5,94,13],[93,1,93,4],[93,5,93,13],[89,1,89,4],[89,5,89,13],[95,14,95,22],[89,14,89,22],[101,15,101,18],[102,13,102,14],[103,13,103,14],[103,1,103,4],[102,1,102,4],[101,1,101,4],[95,5,95,13],[101,7,101,12],[102,7,102,12],[103,7,103,12],[20,24,20,32],[21,24,21,32],[22,24,22,32],[23,24,23,32],[24,24,24,32],[25,24,25,32],[26,24,26,32],[43,24,43,32],[56,23,56,32],[11,23,11,32],[12,24,12,32],[13,24,13,32],[14,24,14,32],[15,24,15,32],[16,24,16,32],[17,24,17,32],[18,24,18,32],[19,24,19,32],[57,24,57,32],[58,24,58,32],[59,24,59,32],[60,24,60,32],[61,24,61,32],[62,24,62,32],[63,24,63,32],[64,24,64,32],[65,24,65,32],[102,24,102,27],[103,24,103,27],[100,23,100,32],[101,28,101,32],[102,28,102,32],[103,28,103,32],[103,15,103,18],[66,24,66,32],[67,24,67,32],[68,24,68,32],[69,24,69,32],[70,24,70,32],[71,24,71,32],[88,24,88,32],[101,24,101,27],[88,14,88,22],[90,14,90,22],[91,14,91,22],[92,14,92,22],[93,14,93,22],[94,14,94,22],[102,15,102,18],[100,13,100,22],[101,13,101,14]]}
[null,"On-going Progress Update and Disbursement Request"]
[null,"PROGRESS UPDATE PERIOD"]
[null,"Grant Name:",null,null,{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
[null,"Progress Update - Reporting Period:",null,null,"Cycle:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"Number:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Progress Update - Period Covered:",null,null,"Beginning Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
[null,"Progress Update - Number:"]
[]
[null,"Section 4:  Grant Management"]
[]
[null,"A.  PR and LFA Comments on the Fulfilment of Conditions Precedent and/or Special Conditions Under the Grant Agreement"]
[]
[null,"! Please include in this table the Condition Precedent number as per Grant Agreement and full text of Conditions Precedent and/or other special conditions due for fulfilment during this period or outstanding from previous periods. \n! Some Special Conditions may apply to more than one period of grant implementation.  Their fulfilment during one period does not automatically imply fulfilment in subsequent periods.  The LFA should verify that the status of such conditions is reported by the PR during each period concerned.",null,null,null,null,null,null,null,null,null,null,null,"For LFA Use Only",null,null,null,null,null,null,null,null,null,"For the Global Fund Use Only"]
[null,"Conditions Precedent and/or other special conditions\n",null,null,null,null,"Status","PR Comments on Progress of Implementation",null,null,null,null,null,"Status","LFA Analysis\n(this should not be a \"Copy and Paste\" of the comments provided by the PR)",null,null,null,null,null,null,null,null,"Validate Status","Country Team Comments"]
[null,"CP3.\nCondition Precedent  to Use of Funds for procurement of Second-Line\nAnti-Tuberculosis Drugs\n\nPrior to the use of Grant funds by the Principal Recipient to finance the procurement of second-line  anti-tuberculosis drugs,  the Principal Recipient shall deliver to the Global Fund the following items, each in form and substance satisfactory to the Global Fund:\n\na.  A current detailed  MDR-TB expansion   plan  (including  the number  of MDR-TB patients  to be treated  and the  list and quantifications of  the  medicines  to  be  procured  for  the  MDR-TB program reflecting the Principal Recipient's finalized forecast for the Grant implementation period covered by this Agreement); and\n\nb.   The  national   guidelines  for  programmatic  management  of MDR-TB, both of which have been developed in collaboration  with a technical partner acceptable to the Global Fund.\n",null,null,null,null,"Met","This condition is ongoing. \nThe condition was met for procurement of the SLDs for the year of 2015 (Orders to GDF as per approved quantifications by TGF, no. SLD GEO/DP/14/ 4356, GEOjDP/14/4364, GEO/DP/14/4376) \nAnd the new SLD Order (bi-laterally signed invoices #15000836SQ, and 15000837SQ were submitted to GDF on December 14, 2015). The Order reflects forecast for the years of 2016 -2017 with quantifications approved by TGF and WHO Euro. The next Order is scheduled to take place in March (BDQ) and  June, 2016\nBedaquiline Implementation Plan was developed and approved by the Global Fund on 2 April 2015.\nThe updated National Guideline for Programmatic  Management  of MDR-TB was approved on 6 August, 2015 by the MoLHSA Guideline Board.  ",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,{"$f":"N14","v":"Select"}]
[null,"SC1.\nNo later than 30 June 2016, the  CCM shall,  or  the  Principal\nRecipient shall cause the CCM to, submit a Budgeted Sustainability Plan\nfor governmental take-over of financing for the first line TB medicines during the second year of the implementation, and gradual take-over of financing for the NTP by the end of the second implementation period, which at a minimum  shall include the financing  of second-line  anti-\ntuberculosis medicines and patient support.",null,null,null,null,"Met","The calculations implying gradual handover of the financial responsibilities to the government in 2016-2019 were drafted and  integrated in the respective MTEF, as well as are stipulated under the National TB Strategy/Action Plan 2016-2020;\nThe state budget law, 2016 integrates additional governmental commitments at 996,000GEL. The amount covers funding for cash incentives for 225 beneficiaries (including the income tax), procurement of SLDs (fully) and co-funding of laboratory tests (bacterioscopy and solid media investigations) and supplies (masks/respirators). \nProcurement of FLDs was carried out in November, 2015 using the GDF mechanism and fully financed via the state budget with the total value of 153,880.38 USD.",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,{"$f":"N15","v":"Select"}]
[null,"SC2.\nNo later than 30 days prior to a scheduled cash transfer that includes funds  for  the  procurement  of  MDR-TB medicines,  the  Principal Recipient shall deliver to the Global Fund a pro forma invoice issued by\nthe  designated  Procurement  Agent of the  Global Drug Facility, as delegated by the Green Light Committee Initiative.",null,null,null,null,"Met","The condition was met for procurement of the medicines for the\nMDR-TB treatment for year 2015 (orders to GDF as per approved quantifications by the Global Fund, SLD GEO/ DP/14/ 4356, GEO/DP/14/4364, GEO/DP/14/4376).\n\nBi-laterally signed invoices #15000836SQ, and 15000837SQ related to the SLD procurement were submitted to GDF on December 14, 2015",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"SC3\nThe   Principal   Recipient  shall   cooperate   with  the   Green   Light\nCommittee (the \"GLC\") in GLC's efforts to provide technical support\nand assistance to the Principal Recipient with respect to monitoring and\nthe  scaling-up  of  MDR-TB-related services  provided  in  Georgia.\nAccordingly, the  Principal  Recipient  shall  budget  and  authorize  the Global Fund to disburse up to a maximum of US$ 5o,ooo, or such lower amount as may be agreed between the GLC and the Global Fund, each year to pay for the GLC services.",null,null,null,null,"Met","The GLC fees are reflected in the GEO-T-NCDC Budget. GLC mission to Georgia took place on October 26-31, 2015 (rGLC EUROPE/Europe consultant Dr. Manfred Danilovits)",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"SC4 \nNo later than 31 December,\n2015, the Government of Georgia shall, or the\nPrincipal Recipient shall cause the Government  of Georgia to, prepare and  provide a formal  document describing  the  tuberculosis  program coordination mechanisms, with clear segregation of the roles and responsibilities among the implementing entities in Georgia.\n",null,null,"Select",null,"Met","The National TB Strategy/Action Plan Post-2016 integrates proposed model of TB governance with costed operational strategies implying all necessary components of TB service delivery, including coordination mechanisms, with clear segregation of the roles and responsibilities among the implementing entities in Georgia, etc. The document represents an integral part of the NFM application package and was approved by CCM. before its submission to the TGF on July, 2015. At the moment the TB NSP is undergoing formal procedures required for approval by the Cabinet of Ministers, similarly to the HIV Strategy (the state chancellery requested to put the document in the specific format for further processing).\nThe National TB Council held three meetings in 2015. The latest meeting on July 15, 2015 was devoted to discussion on the final draft TB Law.  ",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"SC5\nNo later than 31 July 2015, the CCM shall, or the Principal Recipient\nshall cause  the  CCM to,  deliver  the  National  Tuberculosis  Strategy,\napproved by the relevant government bodies, which shall clearly specify\nand describe the full organizational structure, including a central body responsible for TB services in Georgia.",null,null,null,null,"Met","The National TB Strategy/Action Plan Post 2016 was developed and reviewed by WHO Euro. The positive feedback was obtained. The document was approved by CCM.\nThe NSP reflects and clearly describes the full organizational structure for TB service delivery in Georgia, including a central coordination and governing body (National TB Council).  \nAt the moment the TB NSP is undergoing formal procedures required for approval by the Cabinet of Ministers, similarly to the HIV Strategy (the state chancellery requested to put the document in the specific format for further processing).",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,{"$f":"N28","v":"Select"}]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[]
[null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[]
[null,"B.  PR & LFA Review of Progress on Implementation of Outstanding Management Actions from Previous Disbursements"]
[null,"! Please list all issues raised in the last Performance Letter from the Global Fund or outstanding from previous Performance Letters, and comment on the progress. Please include the date of the Performance Letter and the item number."]
[null,null,null,null,null,null,null,null,null,null,null,null,null,"For LFA Use Only",null,null,null,null,null,null,null,null,null,"For the Global Fund Use Only"]
[null,"Global Fund Management Actions",null,null,null,null,"Status","PR Comments on Progress of Implementation",null,null,null,null,null,"Status","LFA Review of PR Progress on Global Fund Management Actions",null,null,null,null,null,null,null,null,"Validate Status","Country Team Comments of PR Progress on Global Fund Management Actions"]
[null,"M&E Issue 1: Reporting results for the indicator 3•4  \"Laboratory-confirmed  X/MDR-TB\npatients enrolled on second line anti-TB treatment in the specified calendar year\"\n\nRequired action:\n\nThe PR is requested  to ensure that the reporting for the indicator 3-4 is based on the actual number of the XDR/MDR-TB patients' as registered in the admissions forms and these results are included in the next progress updates.\n\nTimeline: ongoing\n \n",null,null,null,null,"Met","PR worked with SR to ensure that the reporting on the said indicators is based on the actual number of the XDR/MDR-TB patients' as registered in the admissions forms. These results are included in the present progress update.\n",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,{"$f":"N59","v":"Select"}]
[null,"M&E Issue 2: Management of the patients' registry in the Health Management System\n\nRequired action:\n\nThe Global Fund notes with concern this data quality issue and requests the PR to follow up with the SR to ensure that the patients' registry is completed and all required  information  is entered into the system.\n\nTimeline: ongoing.The PR is requested  to update on the implementation of this management action with the next progress update by no later than 14 August 2015.\n\n",null,null,null,null,"Met","\nPR is working with SR to support improving data-entry processes, including communicating the issue with management, articulating the issue at the meetings with SR staff, as well as by using official correspondence. As a part of his weekly routine M&E officer checks the progress on data entry. It should be emphasized that the process had significantly been improved since initiation of the current grant, though the compliance will further improved as the TB module is fully operationalized.",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,{"$f":"N60","v":"Select"}]
[null,"M&E Issue 3: Reporting on  the Impact and Outcome Indicators; Revision of Performance\nFramework\n\nRequired action:\n\na)   The PR is requested to submit revised Performance Framework for the approval of the Global Fund which includes the targets set according to the latest methodology developed by the WHO.\nb)  The PR is requested to submit revised Performance Framework to update the definitions of the\nreporting for cohorts according to the WH0 guidelines.\nc)  The PR is requested to submit revised Performance Framework and exclude the line (3) \"other\nretreatment cases\" from the comments section of the indicator 3.1.\n\nTimeline: 15July 2015\n",null,null,null,null,"Met","\nAll required changes were reflected in the PF and submitted to the TGF for approval on July 15. The approval was obtained with the Implementation Letter 2 on August 12.",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"FM&S Issue 1: Recommendations to be addressed from the Audit of fiscal year 2014\nRequired Action:\n\nDuring the preparation for the Audit review of the financial statements for fiscal year 2015 we recommend the PR:\na)   To bring to the Secretariat's attention any specific regulations applied to the PR reporting and\npreparation of the financial statements, well in advance. The PR is requested to disclose these\nrequirements already  at the  stage  of review and  approval  of the  TORs for the  Audit of\nFinancial Statements for fiscal year 2015.\nb)  To further develop and refine the process of preparing the financial statements.\nc)   To ensure that the procedures  and related deadlines for all staff involved in preparation of\nthe financial statements are developed in advance and formally documented.\n\nTimeline: The PR should submit to the Secretariat  the TORs for the Audit review of the financial statements for fiscal year 2015 addressing the actions outlined by no later than 31July 2015.\n\n",null,null,null,null,"Met","\nThe required actions were taken/recommendations are considered and followed precisely. ToR was submitted to the TGF for review per indicated deadline. The actual service is procured and the Audit process is underway by BDO.\n\n \n",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"FM&S Issue 2: Recording the expenditures in existing bookkeeping system\n\nRequired Action:\n\na) The PR is expected to follow up on the integration of the new financial software  in existing accounting systems. While this activity should have been implemented during the last reporting period and was postponed, the PR is requested  to ensure that the transition  is completed  before the end of fiscal year 2015. Additionally, the Secretariat  recommends the PR and SRs to produce semi-annual and  monthly  reports  while  reconciling  between  the  financial  reports and  other accounting data, using MS Excel.\n\nb) The PR is requested to ensure that further automation process is taking place, to better facilitate the  process  of  gathering   information   for  the  preparation  of  the  grant   program   financial statements.\n\nAdditionally, the PR should explore options to incorporate the accounting of PP and HPHE in the new financial software during its integration with the existing accounting systems by the end of fiscal year 2015.\n\nTimeline: The  PR is requested  to report  on the progress  made concerning  the  management actions outlined  above with the submission of the next progress  update by no later than 14\nAugust 2015.\n",null,null,null,null,"Unmet - In Progress","PR and SR’s have  integrated budget categories and lines in their existing accounting software and reports are reconciled with the accounting data on regular basis.   \nSeries of meetings were conducted with almost all representatives of the ERP  market in Georgia, particularly Exact Georgia, Microsoft Georgia, UGT, Direct Solutions, Railway IT and IBS. Development of ERP has already been initiated. From October, 2015 for the phase 1 of ERP development the local  consultant was hired to develop a detailed system requirements. The tender documents will be finalized and announcement will be made during the Q1 of 2016 within the GEO-T-NCDC grant. Meanwhile, the ToR was placed at the state procurement website for the purpose of market assessment. Two companies espressed its interest to participate in the forthcoming tender. It is anticipated that the ERP development process will be completed and the system will be piloted at the end of 2016. The necessary adjustments will be made during the first semester of 2017. \n\nNCDC started using of the Software for logistic PP and HPHE from 2015. Information regarding GF PIU assets was provided to the LIMS software managers two times during the last year - as of January 1st positions and of Jane 1st positions. However, during the roll out period some technical issues raised by NCDC logistic staff regarding the system, which is now under review (DITRA GH2 project in collaboration with  USAD HSSP proved support to NCDC). PR made a decision to develop independent system from NCDC LIMS as a part of the ERP which will be piloted by the end of 2016. Meantime the excel based system is implied. \n\n",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"\nHIMS Issue 3: Health Management System Module and reporting on cash incentive scheme\nAction required:\n\nThe PR is invited to explore the options which will allow to enhance the HMIS module and the data recording mechanism currently being used, in order to facilitate the reporting on the indicators and to be able to generate  the updates  on the implementation of the cash incentive scheme. The PR is requested  to report  on the available options  and on possible solutions  which could enhance  the module.\n\nTimeline: with submission of the next progress update by no later than 14 August 2015.\n",null,null,null,null,"Met","\nThe required action was taken: issue was communicated with USAID/HSSP and the respective changes were made to the software, enabling it to generate the reports  on  the  number  of patients who had received cash incentives at given period of time",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"OSDV 2015 Issue 1 (moderate)\nThe contracts of most of TB treatment units being under management of private entities will expire next year and those private health institutions will not be obliged anymore to provide TB treatment services. As a result there is a risk that in 2016 the mentioned health institutions can change their profile and stop providing TB treatment services to their patients.\nTimeline: end of 2015\nRecommendation: PR should investigate this issue with the Ministry of Health and try to find a sustainable solution.\n",null,null,null,null,"Met","The issue goes far beyond the control of PIU. The rights of the private entities are regulated through the respective legislation. The MoLHSA is well aware with the topic and closely following processes using available legal mechanisms to address the issue.  Though we found minor inconsistency – as the agreements with private providers were signed back in  2011-2012 (double-checked). The providers committed to keep TB service points for the coming 7 years, i.e. minimum 2018. Though it was non-standard case of one TB service delivery point in Tbilisi located at the private institution. The management of the facility requested the TB point to move. The MoLHSA reacted immediately and the alternative venue (state-owned) for the TB service point was provided.\nIn-line with the NSP post-2016 over the next program period, a number of measures are planned under the NFM to facilitate the provision of TB services by private providers. To uphold universal access to essential TB care in all areas of the country, the tasks and responsibilities of private providers will be formalized in annual service contracts with MoLHSA / SSA. These agreements will stipulate in detail the scope and volume of services to be provided. The payment conditions will be clearly articulated in the contracts, according to the payments methods (see above under financing and allocation). Additionally, the modes of cooperation, related to referrals and other processes, between private medical centers and public institutions (NCDCPH territorial units and laboratories, public hospitals) will be elaborated.  \n",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"OSDV 2015 Issue 2 (minor)\nIn the drug inventory documents checked, the batch numbers and expiry dates for TB drugs were not specified (for both FLDs and SLDs).  Furthermore, the pharmacy of NCTBLD doesn't indicate the batch numbers and corresponding expiry dates in \"handling over documents/acts\" that accompany drugs when they are supplied to the regional facilities and SDPs.\n\nTimeline: 31 December, 2015\nRecommendation: All inventory documents should consistently carry the batch numbers and corresponding expiry dates for all TB drugs (both FLDs and SLDs) all along the distribution chain at all levels.\n",null,null,null,null,"Met","\nPR worked closely with SR to follow with the issue on the batch numbers. For all medicines procured through the GEO-T-NCDC – numbers were incorporated within the warehouse el. registry (starting date January 2015). So, the NCTBLD pharmacy indicates/marks the batch numbers and corresponding drug expiry dates in the handover documents/acts accompanying drugs. \nAs for the drugs delivered before the launch of the current Grant, SR is not able to incorporate it into the registry due to technical issues –the system does not allow entering data retrospectively. It was agreed with SR that the batch numbers will be entered manually into the handover documents/acts accompanying drugs at all levels - from central to regional and from regional to district/village level. \n",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"OSDV 2015 Issue 3 (minor)\n\nThere is no mechanism to allow for the redistribution of short-dated medicines.  This results in a wastage of significant amount of drugs.\nTimeline: 31 December, 2015\nRecommendation: \n1.       The PR should ensure that they routinely receive information on the shelf-life and stock-levels of TB medicines.\n2.       The PR should work with relevant stakeholders to develop a mechanism that enables either more frequent distribution with less stock-holding at SDPs or the redistribution of short-dated medicines in an effort to decrease wastage.   \n",null,null,null,null,"Met","PR has worked to identify the best mechanism to address this problem, such as short shelf-life drugs are ordered for shorter periods with zero buffer stock and with several shipments; monthly reports on stock at hand are obtained from SR including the information on expiration date; drugs are distributed on monthly basis, compared to the previously adopted quarterly based distribution. \n",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,{"$f":"N73","v":"Select"}]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[null,"C.  Comments on Annual Grant Reporting Requirements"]
[]
[null,"! Please indicate a date for the report due for submission.  If a report is overdue, indicate the original due date and explain the reason for delay.",null,null,null,null,null,null,null,null,null,null,null,"For LFA Use Only",null,null,null,null,null,null,null,null,null,"For the Global Fund Use Only"]
[null,"Required Documentation",null,null,null,"Due date \n(dd-mmm-yy)","Status","Comments",null,null,null,null,null,"Due date\n(dd-mmm-yy)",null,"Status",null,null,null,"Comments",null,null,null,"Due date\n(dd-mmm-yy)","Validate Status",null,null,null,"Country Team Comments"]
[null,"PR Audit Report",null,null,null,"2016-03-30","Preparation on track"]
[null,"Annual Financial Report (AFR) / Enhanced Financial Report (EFR)",null,null,null,"2016-03-15","Submitted to GF","Part of the current submission"]

{"sheet":"PR-LFA Evaluation_5","index":16,"n_rows":55,"n_cols":8,"rows_kept":55,"cut":false,"hidden":false,"merged":[[24,0,24,14],[11,0,15,14],[0,0,0,15],[18,0,22,14],[25,0,29,14],[10,0,10,10],[2,0,2,1],[2,2,2,5],[5,2,5,5],[17,0,17,14],[62,0,62,10],[46,0,51,14],[45,0,45,14],[55,0,60,14],[33,15,33,29],[38,0,43,14],[33,0,33,14],[34,0,34,10]]}
["Ongoing Progress Update and Disbursement Request"]
["PROGRESS UPDATE PERIOD"]
["Grant Name:",null,{"$f":"#REF!","v":{"$error":"#REF!"}}]
["Progress Update - Reporting Period:",null,"Cycle:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Period Covered:",null,"Beginning Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Number:",null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
[]
["Section 5: PR and LFA Evaluation of Overall Performance"]
[]
["A.  PR's Overall Self-Evaluation of Grant Performance (including a summary of how financial performance is linked to programmatic achievements)"]
["!  The self-evaluation should be undertaken by taking into account programmatic achievements, financial performance and program issues in various functional areas (M&E, Finance, Procurement, and Program Management, including management of Sub-Recipients).  See Guidelines for more detailed guidance."]
["The year of 2015 was groundbreaking for the National TB Program of Georgia in many ways, i.e.: \nunder the auspices of the CCM the National Strategy for TB control 2016-2020 was developed with following submission of TB Proposal for the New Funding Model (NFM) and Its approval by the Technical Review Committee (TRP). \nThe Government of Georgia carried out procurement of the 1st line anti-TB medicines (total budget 153,880.38 USD) through the State budget.  Meanwhile calculations implying gradual handover of the financial responsibilities to the Government of Georgia in 2016-2019 were drafted to be further integrated in the respective MTEF. The state budget law, 2016 comprising additional governmental commitments at 996,000 GEL was approved in December, 2015. The amount covers funding for cash incentive for 225 beneficiaries (including the income tax), procurement of FLDs (fully) and co-funding of laboratory tests (bacterioscopy and solid media investigations) and supplies (masks/respirators).\nFurthermore, the new law on the TB, integrating the concept of social support mechanisms for TB patients, using cash incentives was passed by the Parliament of Georgia on December 11, 2015. The deadline for development and mainstreaming of entire legislative acts under the law is stipulated as January 1, 2017.\nThe Decree of the Minister of Labour, Health and Social Affairs  requesting the TB service-providers country-wide to initiate data recording and reporting using the TB module starting  1 May, 2015 was issued. For the purpose of making the process of module mainstreaming smooth, individual work with TB providers throughout the country is underway (supported through the USAID/URC/TPP). The tool was handed-over to the MoLHSA and, at the moment, over 80% TB service delivery points country-wide are using the TB module. \nThe MoLHSA is strongly committed to mainstream the effective PV approaches within the system in-line with the Bedaquiline Development Plan. The PV working group was established at the NTBLD and together with Drug Regulation Agency, MSF and USAID DIAPS technical support, the country made decision on required PV type and elaborated respective forms. At the moment these documents are submitted to the MoLHSA and awaiting for being integrated into the Order by the Minister of Health #167ნ as of August 7, 2013 on ‘The Procedure of Information Channeling on the Drug Side Effects’. \nFor the purpose of strengthening capacity, the respective staff of the Drug Regulation Agency participated in the 17th international pharmacovigilance training course by UPSALA.\nThe National TB Program provided access to the new drugs in-line with the updated disease management guidelines per WHO recommendations in 2015.  Through the support of the USAID Donation Program, country received BDQ for the complete treatment course of 132 patients (at the moment we are awaiting for 34 patient treatment courses remaining under 2015 order). In order to ensure effective implementation of the new treatment regimens, the Mobile Consillium practice was introduced, thus enabling enrolment of Multidrug resistant (MDR) TB patients at the regional level. \nFurthermore, the National TB Program mainstreamed the monitoring scheme for patients under the new treatment regimens to improve management of treatment side effects. To ensure smooth operationalization of the monitoring scheme, TGF TB Program procured required equipment (ECGs, defibrillators, audiometers).   \nGeorgia has mainstreamed the nowel diagnostic methods recognized by the WHO: in 2015, nine GeneXpert machines were procured and operationalized at the penitentiary system and NCDC LSSs country-wide.  It is worth emphasizing that during the initial three quarters out of 626 cases diagnosed at NCDC regional labs (LSS/ZDL) 49% (308 cases) were reviled via GeneXpert technology. Microscopic examinations were not able to detect mycobacteria in these samples (smear negative cases).   \nAs mentioned earlier, procurement of the FLDs was fully covered via state budget law. As for the SLDs, procurement was carried out on December 14, 2015 with overall value at: 387,151.41USD. The said procurement was carried out through the GDF mechanism ensuing cost-effectiveness and compliance to the quality standards.\nThe Program provides cash incentives to patients that manifest full adherence to treatment, using funding from TGF and State Budget Law.  The preliminary assessment of the Cash Incentive Scheme for MDR TB patients shown 42% decrease in lost to follow-up rate (35% for 2013 cohort, 20% for 2014 cohort).  The last years’ trends for downsizing in appearance of new TB cases was maintained in 2015.  \nIn other words, implementation of the GEO-T-NCDC as an integral part of the National TB Program goes in-line with planned objectives, activities and time-lines. Uninterrupted supply of treatment and diagnostic services to TB patients is well-facilitated, as well as supervision and monitoring processes. The latter is reflected in the overall grant performance-the top 10 indicators. Furthermore, all management actions raised within the MA EECA/TS/218-01/07/2015 were taken into account as articulated in the respective section of the PU/DR (PR Grant Management 2).\nFinancial management: the two critical components of this work are a) external to Georgia - communication with the donor (GFATM), and b) internal to Georgia – communication and reporting with the Ministries of Health and Finance, with NCDC, state statistics department, tax authorities, state revenue service, suppliers, service providers, etc. The former is smooth and efficient, which helps the stable and robust operations. In 2015 year PR has timely completed the submission of the regular PU reporting. Also, met all of the donor’s additional ad-hoc requests on the provision of financial and/or operational data. This includes PR/SR end-of month balances/receivables/payables, grant fund receipts and payments to third parties, etc. The PR has successfully procured audit service for the year 2015 through tender and contract is signed with BDO. The Audit of Consolidated financial statements is ongoing and audit report will be submitted timely by the end of March.\nPR received Eur 1,319K worth of one transfer from GFATM during the current reporting period.  In addition, one direct payment to vendors, with total worth of Eur 49,3K was completed.\nPR paid total of Eur 920K to the vendors/providers/patients during the current reporting period.\nPR manages VAT smoothly. The first refund, followed by several refunds was completed in the second half of year 2015. The total refunded amount comprise EUR 37,345. The surplus of refundable VAT on the State Revenue Service system amounts EUR 2,740 as of 31/12/2015 and additional EUR 6000 is submitted as surplus in the year 2016.\nPR effectively manages TB Cash Incentive Scheme. Total cash incentives paid in the current reporting period is EUR 130 K (in addition EUR 65K was financed by the state budget- income tax and monthly 150 MDR patients) and covered period through May, 2015-November, 2015 for both MDR and sensitive TB patients.\n\n"]
[]
[]
[]
[]
[]
["B.  Planned Changes in the Program, if any"]
[]
[]
[]
[]
[]
[]
["C.  External factors beyond the control of the Principal Recipient that have impacted or may impact the Program"]
["NCDC initiated discussion with GDF/IDA in April, 2015 to make necessary amendments to the SLD Orders made back in 2014 (GEO/DP/14/4364, GEO/DP/14/4376). It was decided to reschedule delivery of some items (Linezolid, PAS, Cycloserine, Prothio, Amoxiclave and Clofazimine) and abolish Clarithromycin order as per the most recent WHO recommendation. The process was preceded with multiple consultations and situation analysis carried out together with NCTBLD and USAID TA and in coordination with TGF and GDF. The country was very careful in terms of receiving the full order as the preparation for introduction of the new MDR treatment regimens was underway. The roll-out of the new regimens was supposed to start by BDQ and Linezolid arrival in Georgia. So, the actual data/evidence on the consumption rates of drugs including both new and previously used, in the context of the new treatment regimens, was not available and at least 3 month evidence was needed to be precise in terms of projections. In other words, the context was unique compared to the previous period, as Georgia was initiating completely different approach to MDR management in Georgia. In other words, the orders were re-scheduled and lessons learned and experience gained through this exercise was worthy while making the recent SLD order in 2015."]
[]
[]
[]
[]
[]
["For LFA Use Only"]
[]
["A. LFA  Overall Evaluation and Rating of Grant Performance (including a summary of how financial performance is linked to programmatic achievements)"]
["!  The evaluation should be undertaken by taking into account programmatic achievements, financial performance and program issues in various functional areas (M&E, Finance, Procurement, and Program Management, including management of sub-recipients).  See Guidelines for more detailed guidance on the completion of this section."]
[]
["Indicator rating","Select",null,"Any major management issues resulting in downgrade?","Select",null,"Overall Grant Rating","Select"]
[]
[]
[]
[]
[]
[]
[]
[]
["B.  LFA comments on PR planned changes in the program, if any"]
[]
[]
[]
[]
[]
[]
[]
[]
["C.  LFA Comments on External Factors Beyond Control of the Principal Recipients that have impacted or may impact program"]

{"sheet":"LFA_Findings&Recommendations_6","index":17,"n_rows":39,"n_cols":10,"rows_kept":39,"cut":false,"hidden":false,"merged":[[0,0,0,9],[2,0,2,1],[2,2,2,5],[5,2,5,5],[26,0,26,1],[24,0,24,1],[13,2,13,4],[25,0,25,1],[17,2,17,4],[23,0,23,1],[15,2,15,4],[15,5,15,8],[18,5,18,8],[16,5,16,8],[10,0,10,9],[12,5,12,8],[17,5,17,8],[12,0,12,1],[13,5,13,8],[14,2,14,4],[14,5,14,8],[13,0,13,1],[16,2,16,4],[12,2,12,4],[16,0,16,1],[17,0,17,1],[14,0,14,1],[15,0,15,1],[26,2,26,4],[26,5,26,8],[25,2,25,4],[25,5,25,8],[23,5,23,8],[24,5,24,8],[23,2,23,4],[24,2,24,4],[21,0,21,1],[22,0,22,1],[18,2,18,4],[19,5,19,8],[20,5,20,8],[21,5,21,8],[22,5,22,8],[19,2,19,4],[20,2,20,4],[21,2,21,4],[22,2,22,4],[18,0,18,1],[19,0,19,1],[20,0,20,1]]}
[" Ongoing Progress Review and Disbursement Request"]
["DISBURSEMENT REQUEST"]
["Grant Name:",null,{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Reporting Period:",null,"Cycle:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Period Covered:",null,"Beginning Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Number:",null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
[]
["For LFA Use Only"]
["Section 6: LFA Findings & Recommendations  "]
[]
["! Based on the information provided in the previous sections and your understanding of the grant, please summarise any important management issues, proposing a recommendation for each.\nNB: an issue is considered as 'important' if it impacts or is likely to impact program implementation and results.                                                                                                                                                                                                          ! Instead of repeating detailed descriptions of issues covered in other sections, it is acceptable to state the issue and reference the section containing the details."]
[]
["Functional Areas",null,"Description of Identified Issues \n(in order of importance)",null,null,"LFA Recommendations \n(in order of importance)",null,null,null,"Country Team Comments"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
[]
[]
["Select"]
["Yes"]
["No"]
[]
["Select"]
["Program management (including SR management)"]
["Financial management and systems"]
["Monitoring and evaluation"]
["Pharmaceutical & health product management"]
["Other management issues, including: PR capacity to develop quality programmatic and financial reports"]

{"sheet":"PR EFR_7A","index":18,"n_rows":156,"n_cols":12,"rows_kept":156,"cut":false,"hidden":false,"merged":[[0,0,0,5],[3,0,3,1],[3,2,3,3],[3,5,4,7],[4,0,4,1],[4,2,4,3],[2,0,2,5],[1,0,1,5],[16,1,16,2],[5,0,5,1],[5,2,5,3],[6,0,6,1],[6,2,6,3],[7,0,7,1],[8,0,8,1],[7,2,7,3],[8,4,9,4],[8,8,9,8],[12,4,14,7],[15,4,15,7],[15,8,15,11],[28,1,28,3],[17,1,17,3],[18,1,18,3],[19,1,19,3],[20,1,20,3],[21,1,21,3],[22,1,22,3],[23,1,23,3],[24,1,24,3],[25,1,25,3],[26,1,26,3],[27,1,27,3],[29,1,29,3],[30,0,30,2],[33,4,33,7],[33,8,33,11],[90,0,90,3],[146,4,146,10],[91,0,93,4],[95,4,95,7],[95,8,95,11],[121,0,123,4],[128,0,128,11],[143,4,143,10],[144,4,144,10],[145,4,145,10],[130,0,134,11],[147,4,147,10],[129,0,129,11],[154,4,154,10],[136,4,136,11],[137,4,137,10],[138,4,138,10],[151,4,151,10],[152,4,152,10],[153,4,153,10],[148,4,148,10],[149,4,149,10],[150,4,150,10],[139,4,139,10],[140,4,140,10],[141,4,141,10],[142,4,142,10]]}
["Ongoing Progress Update and Disbursement Request"]
["Section 7A: PR - Enhanced Financial Reporting"]
[]
["Country",null,{"$f":"CoverSheet!D5","v":"Georgia"},null,null,"PLEASE REFER TO THE \"GUIDANCE FOR COMPLETION OF THE ENHANCED FINANCIAL REPORTING TEMPLATE\" DOCUMENT TO ASSIST YOU IN COMPLETING THE TEMPLATE"]
["Grant No.",null,{"$f":"CoverSheet!D7","v":"GEO-T-NCDC"}]
["PR",null,{"$f":"CoverSheet!D8","v":"NCDC"},null,null,"TO BE COMPLETED ONLY ONCE A YEAR EXCEPT AT MONTH 18 FOR PURPOSES OF PHASE 2 REVIEW"]
["Currency",null,{"$f":"CoverSheet!D11","v":"EUR"}]
["Disease(Component)",null,{"$f":"CoverSheet!D6","v":"Tuberculosis"},null,null,null,"dd-mm-yyyy",null,null,null,"dd-mm-yyyy"]
[null,null,null,null,"Current Reporting Period","Start Date:","2015-01-01",null,"Cumulative Reporting Period","Start Date:","2014-04-01"]
[null,null,null,null,null,"End Date:","2015-12-31",null,null,"End Date:","2015-12-31"]
[null,null,null,null,null,null,null,"The end date for the current reporting period and cumulative reporting period must be the same"]
[null,null,{"$f":"CONCATENATE(\"EFR\",SUBSTITUTE(SUBSTITUTE(C8,\"/\",\"\"),\" \",\"\"))","v":"EFRTuberculosis"}]
[null,null,{"$f":"CONCATENATE(\"SDA\",SUBSTITUTE(SUBSTITUTE(C8,\"/\",\"\"),\" \",\"\"))","v":"SDATuberculosis"},null,"The \"TOTAL\" rows in Table A, B and C will have a RED background if the amounts in each table do not agree. If the Totals for each Table agrees, these rows will have a YELLOW background. "]
[]
[]
["A- BREAKDOWN* BY  EXPENDITURE CATEGORY",null,null,null,"Current Reporting Period",null,null,null,"Cumulative Reporting Period"]
["#","Category",null,null," \nBudget","\nExpenditures","Variance","Reason for Variance","Cumulative Budget","Cumulative Expenditure","Variance","Reason for Variance"]
[1,"Human Resources",null,null,276458.28014192078,222965.89818537215,{"$f":"E18-F18","v":53492.381956548634},"PR level: (total saving: EUR 18,017) one vacant position and FX rate change cumulated the saving.\nSR level: (total saving: EUR 24,578) there was no need for recruiting additional staff (nurses at penitentiaries) also FX rates changes\nCommitment: EUR 10,897- payment for the Month of December took place in January.\n",509565.69807758031,422992.72818537214,{"$f":"I18-J18","v":86572.969892208173},"PR level: (total saving: EUR 29,570 euro) one vacant position and FX rate change cumulated the saving, Programme Department staff started receiving payroll payments only after operationalization of the Cash Insentive Scheme.\nSR level: (total saving: 46,106 Euro;) several staff recruired later (Finance Manager, Driver), or there was no need for recruiting additional staff (nurses at penitentiaries);\nCommitment: EUR 10,897 - payment for the Month of December took place in January.\n"]
[2,"Technical Assistance",null,null,21340,11438.797966617658,{"$f":"E19-F19","v":9901.2020333823421},"PR level: 0 \nSR level: Saving EUR 8,980 - needs were met through PR financing, e.g. GDF/GLC Missions, WHO Review; there was no need for recruiting additional (4th) person for database monitoring; \nCommitment: EUR 921 - TA for database monitoring in December, paid in January\n",173648,69429.327966617653,{"$f":"I19-J19","v":104218.67203338235},"PR level: saving – EUR 75,572 WHO review actual costs were less than budgeted.\nSR level: Saving EUR 27,726 - needs were met through PR financing, e.g. GDF/GLC missions, WHO Review; there was no need for recruiting additional (4th) person for database monitoring; \nCommitment: EUR 921 - TA for database monitoring in December, paid in January\n"]
[3,"Training",null,null,13000,21107.652875407206,-8107.652875407206,"PR: Overspending EUR 8,660 – training cost budgeted in 2014 was postponed to current reporting period.\nSR: Saving EUR 514 – all actual training costs for the year 2015 were paid by TB Center and the latter is saving.\nEUR 38 remaining December service to be reimbursed by TB Center in January 2016\n",57800,46906.742875407203,10893.257124592797,"PR: saving EUR 9,298 - Actual costs occured less than budgeted\nSR: Saving EUR 1,557 - Actual costs occured less than budgeted\nCommitment – EUR 38 remaining December service to be reimbursed by TB Center in January 2016\n"]
[4,"Health Products and Health Equipment",null,null,833371.99200956081,577220.82117098733,256151.17083857348,"PR: total saving EUR 416,041 - due to the following factors: \n1. Local procurement of lab supplies derived  cheaper unit costs; 2. Available stocks (incl. Genexpert cartriges); 3. Re-calcualtion of average consumption rates;\nOverspending EUR 159,890 – is mainly derived from Procurement of GeneXpert cartridges to meet need for 2016-2017 years, part of the amount was budgeted in the previous reporting period and the other part in the year 2016 \n",1380425.6466334672,798875.92117098731,581549.72546247987,"PR: Saving EUR 696,333 is derived from procurement of lab supplies and respirators 1. Local procurement with competitive bidding with preceding market assessment derived significantly cheaper unit costs compared to the budgeted amounts; 2. Available stocks; 3. Re-calculation of average consumption rates;\nOverspending EUR 114,783 includes:\nEUR 67,030 - Procurement of GeneXpert cartridges to meet need for 2016-2017 years, part of the amount was budgeted in the previous reporting period and the other part in the year 2016.\nEUR 47,753 – Actual cost and quantity for lab supplies budgeted under the line 2.7 (a) was greater than projected; also Procurement of GeneXperts resulted in negative variance due to FX rate change\n"]
[5,"Medicines and Pharmaceutical Products",null,null,2313316.7736080568,68678.983394627139,2244637.7902134298,"PR: Saving EUR 2,104,747 - Net saving in procurement of SLD include several reasons: recalculation of needs; tendency of decreasing prevalence of TB; \nBDQ Donation program provided the medicine free-of-charge; General tendency of decreasing cost of TB medicines through GDF; some savings from the SLD line were reallocated to activities as equipment by TB center. These reallocation requests were approved by the GF in January-February 2016, as well as in 2015\nCommitment: EUR 139,891- payment for SLD order placed in December 2015\n",4358024.9702597614,2258875.443394627,2099149.5268651345,"PR: Saving – Total EUR 1,988,277 includes: \nEUR 1,928,303 – Net saving in procurement of SLD include several reasons: recalculation of needs; tendency of decreasing prevalence of TB; \nBDQ Donation Program provided the medicine free-of-charge; General tendency of decreasing cost of TB medicines through GDF;\nEUR 1,069 – Lines3.10 was cancelled (ref. PR letter to GF19/11/2014) as the pharmaceutical was included in the GDF Order (Act. 3.1.a)\nEUR 2997 –The activity was canceled. Procurement (water for injectibles) was carried out by TB Centre.\nEUR 55,908 – Cost of Procurement side effects drugs was less than budgeted due to the decreasing number of patients and low prices derived through the local procurement (tender).\nCommitment -  EUR 139,891 for SLD order placed in December 2015 \nOverspending: EUR 29,019 - FX rate change FLD order placed in 2014.\n"]
[6,"Procurement and Supply Management Costs",null,null,247863.9913608057,19530.205790072105,228333.7855707336,"PR: Saving EUR 230,120 – due to savings in SLD order placed in 2015\nOverspending – EUR 1,786 – FLD local PSM costs occurred in 2015 per deliveries, budgeted in 2014 \n",480438.7793770798,254725.1157900721,225713.6635870077,"PR: Saving EUR 229,221 – due to savings in SLD order placed in 2014-2015 years;\nOverspending – EUR 3,507 – PSM cost for FLD order placed in 2014 was greater than budgeted due to FX rate Change \n"]
[7,"Infrastructure and Other Equipment",null,null,15519.867090060779,14098.81944037044,1421.0476496903393,"PR:  Saving EUR 1,963: The actual costs for the several activities such as vehicle maintenance, office furniture, vehicle insurance;\nCommitment -EUR 10: Domain fee for December paid in January\nOverspending EUR 2,734: IT equipment for TB Center was postponed from the year 2014 and  procured in 2015 ;\nSR level: Saving EUR 1,545  - actual insurance and vehicle meintenance costs were less than budgeted;\nCommitment - EUR 637 – December service to be reimbursed by TB Center in January 2016\n",80128.902539931471,41103.559440370445,39025.343099561025,"PR: Savings- EUR 33,355: The actual costs for the several activities such as office rehabilitation, computers were less than budgeted, also there was no need for procureing office furniture as it was handed-over from the previous PR. \nCommitment -EUR 10: Domain fee for December paid in January\nSR level: 5,023 EUR saving - actual insurance and vehicle meintenance costs were less than budgeted;\nCommitment - EUR 637 – December service to be reimbursed by TB Center in January 2016\n"]
[8,"Communication Materials",null,null,0,0,0,"-",0,0,0,"-"]
[9,"Monitoring & Evaluation",null,null,103117.18634683947,64190.57609009857,38926.610256740903,"PR: Saving EUR 15,217- Activities performed in accordance with the workplan, but actual costs were less than budgeted\nCommittment: EUR 423 - fuel cost for December provided to TB Center \nSR: Saving EUR 18,894- was due to the actual costs being less than projected, though Planned activities took place in-line with approved implementation plan\nCommittment: EUR 4,393 - December service reimbursed in January 2016\n",184789.51684984381,114327.24609009858,70462.270759745239,"PR: Saving EUR 26,835 -Activities performed in accordance with the workplan but actual costs were less than budgeted.\nCommitment : EUR 423 - fuel cost for December provided to TB Center.\nSR: Saving EUR 38,811 - was due to the actual costs being less than projected, though Planned activities took place in-line with approved implementation plan\nCommittment: EUR 4,393 - December service reimbursed in January 2016\n"]
[10,"Living Support to Clients/Target Populations",null,null,680581.84499999997,412396.96914627432,268184.87585372565,"PR: Saving EUR 180,604 - Sensitive patients: Saving (EUR 28,025): (a) budgeted amount was calculated for 1 year period covering 70% of all sensitive patients with 100% adherence (both installments), but actual adherence was less.   MDR patients: (EUR 138,699): (a) budgeted amount was calculated for the entire treatment course (15 months) covering 75% of  MDR patients, with 100% adherence (all weeks on outpatient treatment). Actually there was no 100% compliance and number of patients was less than projected/budgeted. The remaining amount is fuel cost 13,880 due to less than budgeted unit cost.\nCommitment: EUR 20,635 – December 2015 cash incentives for MDR and Sensitive patients (due to scheme set-up payment takes 1-2 months, including: data gathering, entry, treatment, cross-checking); EUR 1,954 - December fuel cost provided to TB Center paid in January \nSR level: Saving EUR 62,945 - less patients required transportation allowence, less DOT nurses were recruited; \nCommitment EUR 2,047 - payment for DOT nurses and transportation costs for December, paid in January 2016;\n",1493843.2199999997,615608.61914627429,878234.60085372545,"PR: Saving EUR 735,899 - Sensitive patients: Saving (185,986): (a) budgeted amount was calculated for 1 year period covering 70% of all sensitive patients with100% adherence (both installments). Actually patients enrolled in January - May, 2014 did not fit for being beneficiary of the scheme as approved scheme was enrolling patients starting June 1.   MDR patients: Saving (EUR 514,695 ): (a) budgeted amount was calculated for the entire treatment course (15 months) covering 75% of  MDR patients from the 2012, 2013, 2014 cohors, with100% adherence (all weeks on outpatient treatment).  Actually, 18 months were covered, payments started in August, there was no 100% compliance and number of patients was less than projected/budgeted. The remaining amount is fuel cost EUR 35,217 due to less than budgeted unit cost and available stock at SR level.\nCommitment: EUR 20,635 – December 2015 cash incentives for MDR and Sensitive patients (due to scheme set-up payment takes 1-2 months, including: data gathering, entry, treatment, cross-checking); EUR 1,954 - December fuel cost provided to TB Center paid in January \nSR level: Saving EUR 117,700 - less patients required transportation allowence, less DOT nurses were recruited; \nCommitment EUR 2,047 - payment for DOT nurses and transportation costs for December, paid in January 2016;\n"]
[11,"Planning and Administration",null,null,75540.374729783012,59190.405640387158,16349.969089395854,"PR level: PR level: Saving EUR 27,394 – project management actual costs were less than budgeted.\nCommitment : EUR 40 – postal costs for December paid in January 2016.\nOverspending – EUR 12,644- printing TB forms were budgeted in 2014 and payments postponed to 2015, also project management actual costs were less than budgeted, GLC payment/exchange rate impact.\nSR level: Saving EUR 1,560 – budgeted amount was not used by TB center.\n",124951.35998752345,98316.225640387158,26635.134347136292,"PR level: Saving EUR 33,159 – actual Printing costs for TB forms were less than budgeted, also project management actual costs were less than budgeted.\nCommitment : EUR 40 – postal costs for December paid in January 2016.\nOverspending – EUR 8,123 - GLC payment/exchange rate impact.\nSR level: Saving EUR 1,560 – budgeted amount was not used by TB center.\n"]
[12,"Overheads",null,null,8451.3829045240491,3238.371860385565,5213.0110441384841,"PR level: Saving EUR 4,906 - Fuel and Mobile Operator costs were less than budgeted; \nCommittment - EUR 307 - PR fuel and mobile service cost for December, paid in January.  \n",14990.78834915285,5331.2318603855656,9659.5564887672845,"PR level: Saving EUR 9,353 - Fuel and Mobile Operator costs were less than budgeted; \nCommittment - EUR 307 - PR fuel and mobile service cost for December, paid in January.  \n"]
[13,"Other",null,null,0,3.1011070577733335E-3,-3.1011070577733335E-3,"-",0,3.1011070577733335E-3,-3.1011070577733335E-3,"-"]
[null,null,null,"TOTAL",{"$f":"E18+E19+E20+E21+E22+E23+E24+E25+E27+E26+E28+E29+E30","v":4588561.6931915516},{"$f":"F18+F19+F21+F20+F22+F23+F24+F25+F26+F27+F28+F29+F30","v":1474057.5046617067},{"$f":"SUM(G18:G30)","v":3114504.1885298449},null,{"$f":"SUM(I18:I30)","v":8858606.8820743393},{"$f":"SUM(J18:J30)","v":4726492.1646617055},{"$f":"SUM(K18:K30)","v":4132114.7174126329}]
[]
[]
["B- BREAKDOWN* BY PROGRAM ACTIVITY",null,null,null,"Current Reporting Period",null,null,null,"Cumulative Reporting Period"]
["#","Macro-category","Objectives","Service Delivery Area"," \nBudget","\nExpenditures","Variance","Reason for Variance","Cumulative Budget","Cumulative Expenditure","Variance","Reason for Variance"]
[1,"Supportive Environment","To strengthen the National TB Control Program management, coordination, monitoring and evaluation","Program Management, M&E, Capacity Building",233521.77756213368,193430.43600034172,{"$f":"E36-F36","v":40091.341561791953},"Activities performed in-line with approved work plan. Unspent funds are as follows:\nSaving- EUR 30,761 (less actual costs, availability of stocks, SR TA cancelled) \nCommitment: EUR 14,179 (PR and SR December costs paid in January); \nOverspending: EUR 4,849 (printing of TB forms budgeted in 2014 and carried in 2015\n",424324.89789154928,328436.63600034174,{"$f":"I36-J36","v":95888.261891207541},"Activities performed in-line with approved work plan. Unspent funds are as follows: \nSaving- EUR 81,709(less actual costs, availability of stocks, SR TA cancelled) \nCommitment: EUR 14,179 (PR and SR December costs paid in January); \n"]
[2,"TB Detection","To improve diagnosis of TB including M/XDR-TB","Improving diagnosis",762957.19192676584,554269.81692869484,{"$f":"E37-F37","v":208687.374998071},"All activities were performed as planned. Savings occurred due to smaller actual costs of procurement; available stocks and average consumption rates at SR level, FX rate change\nSaving: EUR 369,141\nCommitment: EUR 2,263 December SR service cost paid in January\nOverspending: EUR 162,717 (exchange rate impact for GeneXpert procurement; Procurement of GeneXpert cartridges for 2016-2017 period, part of the amount was budgeted in the previous reporting period and the other part in the year 2016, procurement of IT equipment budgeted in 2014 carried forward to 2015)\n",1242279.0603301921,771316.76692869491,{"$f":"I37-J37","v":470962.29340149718},"All activities were performed as planned. Savings and delays occurred due to smaller actual costs of procurement; available stocks and average consumption rates at SR level, as well as cheaper actual cost for operational research (SR). \nSaving: EUR 583,482;\nCommitment: EUR 2,263 December SR service cost paid in January\nOverspending: EUR 114,783  (exchange rate impact for GeneXpert procurement; Procurement of GeneXpert cartridges for 2016-2017 period, part of the amount was budgeted in the previous reporting period and the other part in the year 2016)\n"]
[3,"TB Treatment","To ensure quality treatment of all forms of TB","Quality Treatment of all forms of TB, including M/XDR-TB",2703951.5427498203,175964.71489551096,{"$f":"E38-F38","v":2527986.8278543092},"All activities were performed. Savings occurred due to actual costs of procurement; available stocks and average consumption rates at SR level.  \nSaving: EUR 2,397,560 (SLD drugs and lab supplies)\nCommitment: EUR 139,915 (SLD order placed in December 2015)\nOverspending: EUR 9,488 (exchange rate impact for GDF/GLC procurement; FLD local PSM costs occurred in 2015 per deliveries, budgeted in 2014)\n",5123348.7857609829,2660920.924895511,{"$f":"I38-J38","v":2462427.8608654719},"All activities were performed. Savings and delays occurred due to actual costs of procurement; available stocks and average consumption rates at SR level,  \nSaving: EUR 2,363,162 (SLD drugs, side effect drugs and lab supplies)\nCommitment: EUR 139,915 (SLD order placed in December 2015)\nOverspending: EUR 40,649 (FX rate change for FLD order placed in 2014 and GLC)\n"]
[4,"TB Treatment","To ensure adherence to TB treatment by intensive patient support and follow up ","Patient Support",734703.47074675199,444827.34743116761,289876.12331558438,"Cash incentive scheme is functioning well. Savings occurred mainly due to budget assumptions used to project cash incentives. Actual compliance was not 100%, also number of patients was less than projected/budgeted. State budget participation (Cash incentives for 150 MDR patients) also was driver for saving. Actual Incentives paid by SR was also less than budgeted.\nSaving: 264,375;\nCommitment: EUR 25,501 – December cash incentive paid in January both by SR and PR. As well as December fuel cost provided to SR.\n",1576406.0650568157,668029.30743116757,908376.75762564817,"Cash incentive scheme is functioning well. Savings occurred mainly due to budget assumptions used to project cash incentives. Actual compliance was not 100%, also number of patients was less than budgeted. State budget participation (Cash incentives for 150 MDR patients) also was driver for saving. Actual Incentives paid by SR was also less than budgeted.\nSaving: 882,876;\nCommitment: EUR 25,501 – December cash incentive paid in January both by SR and PR. As well as December fuel cost provided to SR.\n"]
[5,"Supportive Environment","Project management - PR","Supportive environment: Program management and administration",153427.7102060797,105565.19129050331,{"$f":"E40-F40","v":47862.518915576395},"PR Office is fully functional.\nSaving: EUR 56,165 - Project management actual costs, such as HR costs, fuel, tender announcement fee were found to be less than budgeted and FX rate change effect.\nCommitted: EUR 357 - Project Management December costs paid in January including fuel, postal cost, and mobile service.\nOverspending: EUR 8,660 - training cost budgeted in 2014 was postponed to current reporting period.\n",492248.07303480053,297788.53129050334,{"$f":"I40-J40","v":194459.5417442972},"PR Office is fully functional. \nSaving: EUR 194,103  Project Management costs such as TA, Audit cost, Fuel, HR due to vacant position, less unit costs than budgeted, FX rate Change, As for the TA saving – amount was spent to cover WHO Review mission that was performed last year, though the costs related to the exercise was less than budgeted.\nCommitment: EUR 357 - Project Management December costs paid in January including fuel, postal cost, and mobile service.\n"]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E41-F41","v":0},null,0,0,{"$f":"I41-J41","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E42-F42","v":0},null,0,0,{"$f":"I42-J42","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E45-F45","v":0},null,0,0,{"$f":"I45-J45","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E46-F46","v":0},null,0,0,{"$f":"I46-J46","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E47-F47","v":0},null,0,0,{"$f":"I47-J47","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E52-F52","v":0},null,0,0,{"$f":"I52-J52","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E53-F53","v":0},null,0,0,{"$f":"I53-J53","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E54-F54","v":0},null,0,0,{"$f":"I54-J54","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E59-F59","v":0},null,0,0,{"$f":"I59-J59","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E60-F60","v":0},null,0,0,{"$f":"I60-J60","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E61-F61","v":0},null,0,0,{"$f":"I61-J61","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E69-F69","v":0},null,0,0,{"$f":"I69-J69","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E70-F70","v":0},null,0,0,{"$f":"I70-J70","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E71-F71","v":0},null,0,0,{"$f":"I71-J71","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E73-F73","v":0},null,0,0,{"$f":"I73-J73","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E74-F74","v":0},null,0,0,{"$f":"I74-J74","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E75-F75","v":0},null,0,0,{"$f":"I75-J75","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E77-F77","v":0},null,0,0,{"$f":"I77-J77","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E80-F80","v":0},null,0,0,{"$f":"I80-J80","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E81-F81","v":0},null,0,0,{"$f":"I81-J81","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E82-F82","v":0},null,0,0,{"$f":"I82-J82","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E85-F85","v":0},null,0,0,{"$f":"I85-J85","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E86-F86","v":0},null,0,0,{"$f":"I86-J86","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E87-F87","v":0},null,0,0,{"$f":"I87-J87","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
["TOTAL",null,null,null,{"$f":"SUM(E36:E90)","v":4588561.6931915507},{"$f":"SUM(F36:F90)","v":1474057.5065462184},{"$f":"SUM(G36:G90)","v":3114504.1866453327},null,{"$f":"SUM(I36:I90)","v":8858606.8820743412},{"$f":"SUM(J36:J90)","v":4726492.166546219},{"$f":"SUM(K36:K90)","v":4132114.7155281221}]
[]
[]
[]
[]
["C- BREAKDOWN* BY IMPLEMENTING ENTITY",null,null,null,"Current Reporting Period",null,null,null,"Cumulative Reporting Period"]
["#","PR/SR","Name","Type of\nImplementing Entity"," \nBudget","\nExpenditures","Variance","Reason for Variance","Cumulative Budget","Cumulative Expenditure","Variance","Reason for Variance"]
[1,"PR","National Center for Disease Control and Public Health","Other Government",4123179.1379312552,1147047.1876022047,{"$f":"E98-F98","v":2976131.9503290504},"The net variance of EUR 2,976,132 consists of positive (EUR 3,161,845) and negative variances (EUR 185,713) \n \nPositive variance EUR 3,161,845 - derived from the activities that were budgeted for the current reporting period and represents either saving, commitment or postponed activity \n\nSaving -Total EUR 2,998,561 includes: \n\nEUR 23,324 - Actual unit price of fuel turned to be less than projected/budgeted. From the programmatic point of view, activities were performed as planned, though required quantity of fuel was less.\n\nEUR 426,216 – Procurement of lab supplies, including PSM costs and respirators caused saving, due to the following factors: 1. Local procurement with competitive bidding with preceding market assessment derived significantly cheaper unit costs compared to the budgeted amounts; 2. Available stock; 3. Re-calculation of average consumption rates;\n\nEUR 25,182 - Cost of Procurement side effects drugs was less than budgeted due to the decreasing number of patients and low prices derived through the local procurement (tender) and one activity was canceled - Procurement (water for injectable) was carried out by TB Centre.\n\nEUR 2,299,486 – Net saving in procurement of SLD include several reasons: recalculation of needs; tendency of decreasing prevalence of TB; \nBDQ Donation program provided the medicine free-of-charge; General tendency of decreasing cost of TB medicines through GDF; some savings from the SLD line were reallocated to activities as equipment by TB center. These reallocation requests were approved by the GF in January-February 2016, as well as in 2015.\n\n\nEUR 166,724- Actual cost for Cash Incentives (Sensitive & MDR) was less than budgeted due to actual number of patients (slightly less than projected). Most importantly, budget was made assuming max (100%) compliance to treatment. Reimbursed period covers November 2014 - November 2015\n\nEUR 57,629 - Project management actual costs, such as HR costs, fuel, tender announcement fee, TA were found to be less than budgeted and FX rate change effect.\n\nPostponed activities and commitments - Total EUR 163,284 includes:\n\nEUR 2,377 – SRs fuel costs for December, payment transferred to next reporting period.\n\nEUR 139,915 – Payment for Procurement of SLDs and local PSM costs postponed to the next reporting period\n\nEUR 20,635 – Committed payment for Cash Incentives (Sensitive & MDR) for December 2015 (Q4); \n\nEUR 357 – Project Management costs delayed to next reporting period, including fuel, postal cost, mobile service.\n \nNegative Variance EUR 185,713 – derived from activities that were budgeted in the previous reporting period and postponed to Q3Q4 period or overspendings: \n\nEUR 35,675 – Procurement of Lab supplies and equipment carried to the current reporting period and procurement unit price and Quantities greater than budgeted.\n\nEUR 124,307 – Procurement of GeneXpert cartridges for 2016-2017 period, part of the amount was budgeted in the previous reporting period and the other part in the year 2016.\n\nEUR 7,583 – IT equipment and printing costs provided to TB center was budgeted in the year 2014 and carried forward to the current reporting period.\n\nEUR 1,693 – FLD local PSM costs occurred in 2015 per deliveries, budgeted in 2014\n\nEUR 7,795 - GLC payment/exchange rate impact.\n\nEUR 8,660- PR training costs carried from the year 2014.\n",8042499.3232110068,4167801.8576022047,{"$f":"I98-J98","v":3874697.4656088022},"The net variance of EUR 3,874,698 consists of the positive (EUR 4,030,130) and negative variances (EUR 155,432)\n\nPositive Variance EUR 4,030,130 – derived from the savings, commitments or postponed activities.\n \nSaving – Total EUR 3,866,846 includes: \n \nEUR 52,542 - Actual unit price of fuel turned to be less than projected/budgeted. From the programmatic point of view, activities were performed as planned, though required quantity of fuel was less; Fuel cost budgeted under line 4.7 (b) was cancelled due to the following factor: the adherence data is collected and monitored on a regular basis by regional coordinators with further submission to the TB Centre. Activity related to the monitoring of the cash incentive scheme was abolished, considering that it is being performed under the current set-up of the scheme\n\nEUR 721,034 - Procurement of lab supplies, including PSM costs and respirators caused saving, due to the following factors: 1. Local procurement with competitive bidding with preceding market assessment derived significantly cheaper unit costs compared to the budgeted amounts; 2. Available stock; 3. Re-calculation of average consumption rates;\n\nEUR 700,681 - Actual cost of Cash incentives  (Sensitive & MDR) covered period June 2014 – November 2015 and was less than budgeted. The following are the reasons for saving:\nSensitive - budgeted amount was calculated for 1 year period covering 70% of all sensitive patients with100% adherence (both installments). Actually patients enrolled in January - May, 2014 did not fit for being beneficiary of the scheme as approved scheme was enrolling patients starting June 1. \nMDR - budgeted amount was calculated for the entire treatment course (15 months) covering 75% of MDR patients from the 2012, 2013, 2014 cohorts, with100% adherence (all weeks on outpatient treatment).  Actually, 5 months were covered, payments started in August, there was no 100% compliance in many cases and number of patients was less than projected/budgeted. \n\nEUR 4,276 – Payments to the staff were initiated only after scheme operationalization, though were budgeted to start earlier. Exchange rate impact also caused additional savings \n\nEUR 2,132,924 – Net saving in procurement of SLD include several reasons: recalculation of needs; tendency of decreasing prevalence of TB; \nBDQ Donation program provided the medicine free-of-charge; General tendency of decreasing cost of TB medicines through GDF; some savings from the SLD line were reallocated to activities as equipment by TB center. These reallocation requests were approved by the GF in January-February 2016, as well as in 2015.\n\nEUR 1,230 – Lines 3.10/3.11 were cancelled (ref. PR letter to GF19/11/2014), as the pharmaceutical was included in the GDF Order (Act. 3.1.a)\n\nEUR 2997 –The activity was canceled. Procurement (water for injectable) was carried out by TB Centre.\n\nEUR 55,908 – Cost of Procurement side effects drugs was less than budgeted due to the decreasing number of patients and low prices derived through the local procurement (tender).\n\nEUR 1,151 – Saving in printing of statistical forms due to lower unit price derived through tender;\n\nEUR 194,103 – Saving in Project Management costs such as TA, Audit cost, Fuel, HR due to vacant position, less unit costs than budgeted, FX rate Change, As for the TA saving – amount was spent to cover WHO Review mission that was performed last year, though the costs related to the exercise was less than budgeted.\n   \nPostponed activities and commitments - Total EUR 163,284 includes:\n\nEUR 139,915 – Payment for Procurement of SLDs and local PSM costs postponed to the next reporting period\n\nEUR 2,377 – SRs fuel costs for December, payment transferred to next reporting period.\n\nEUR 20,635 – Committed payment for Cash Incentives (Sensitive & MDR) for December 2015 (Q4); \n\nEUR 357 – Project Management costs delayed to next reporting period, including fuel, postal cost, mobile service.\n  \nNegative Variance EUR 155,432 – derived from the activities not budgeted in the cumulative period and actual costs that were greater than budgeted: \n\nEUR 40,649 - FX rate change for FLDs and GLC Mission payment. \n\nEUR 67,030 - Procurement of GeneXpert cartridges to meet the need for 2016-2017 years, part of the amount was budgeted in the previous reporting period and the other part in the year 2016.\n\nEUR 47,753 – Actual cost and quantity for lab supplies budgeted under the line 2.7 (a) was greater than projected; also Procurement of GeneXperts resulted in negative variance due to FX rate change\n"]
[2,"SR","National Center for Tuberculosis and Lung Diseases","Other Government",465382.55526029645,327010.31894403632,{"$f":"E99-F99","v":138372.23631626013},"SR is well-performing vis-à-vis the approved implementation plan. PR has transferred to SR EUR 344,978 to cover services for the period December 2014-November 2015 and advance payment, which is carried forward to year 2016.  SRs expenditure during 2015 year is consists of the following :  previous year SR cash balance EUR 17, Expenditures covered by PR, December 2015 expenditures reimbursed by SR from the advance payments; remaining amount is TB Center cash balance per bank statement as of 31/12/2015\nTotal Savings comprise EUR 119,441: number of patients decreased, less transportation costs required, less cost of operational research, cancelled TA; Commitment for December service which is not reimbursed by TB center in December- EUR 18,931 \n",816107.55886333412,558690.30894403625,{"$f":"I99-J99","v":257417.24991929787},"The Budget relates to the activities performed by the TB Center in April 2014-December 2015.  During the cumulative period SR received payment for April 2014-Novemebr 2015 services in the amount of EUR 549,489 and advance payment with of EUR 27,186, available till the end of the contract 30/06/2016. SR actual expenditures differ from payments received from PR in the amount of EUR due to advance payment not fully utilized by the end of year, which represents the actual cash balance on Srs Bank account.  \nThe net variance in the amount of EUR 257,417 related to TB Center performance includes: \nSaving of EUR 238,486 (mainly unspent HR costs; less transportation incentives to patients; cheaper operational research rather than budgeted; unspent TA amount during the year 2014-2015, as all the needs were met through PR financing, including GLC/GDF missions, WHO Programme Review, etc.) \nCommitment for December service which is not reimbursed by TB center in December- EUR 18,931 \n "]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,{"$f":"E104-F104","v":0},null,0,0,{"$f":"I104-J104","v":0}]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,{"$f":"E111-F111","v":0},null,0,0,{"$f":"I111-J111","v":0}]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,{"$f":"E114-F114","v":0},null,0,0,{"$f":"I114-J114","v":0}]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,{"$f":"E117-F117","v":0},null,0,0,{"$f":"I117-J117","v":0}]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,null,null,"TOTAL",{"$f":"SUM(E98:E120)","v":4588561.6931915516},{"$f":"SUM(F98:F120)","v":1474057.506546241},{"$f":"SUM(G98:G120)","v":3114504.1866453104},null,{"$f":"SUM(I98:I120)","v":8858606.8820743412},{"$f":"SUM(J98:J120)","v":4726492.1665462404},{"$f":"SUM(K98:K120)","v":4132114.7155280998}]
[]
[]
[]
[]
["* The sum of all three breakdowns should be equal (A- Budget Line-item, B- Program Activity, C- Implementing Entity)."]
["** For the purposes of this report, the SDA Program management and administration should be included in the Supportive Environment Macro Category."]
[]
["D- ADDITIONAL INFORMATION"]
["Please disclose any relevant information concerning the information in the above tables. Refer to the Guidelines for Completing the Template if required."]
[]
[]
[]
[]
[]
[]
["E- DISBURSEMENTS BREAKDOWN BY IMPLEMENTING ENTITY",null,null,null,"Cumulative Reporting Period"]
["#","Name","Type of\nImplementing Entity","Cumulative Disbursements","Comments"]
[1,"National Center for Tuberculosis and Lung Diseases","Other Government",576674.72729495191,"The actual disbursements paid to SR covers period April 2014-November 2015 and advance payment carried forward to year 2016. Diff-ce between disbursed amount by PR and EFR expenditure spent by SR amounts EUR 17,984.42 is cash balance at SR level per Bank Statement"]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"TOTAL",{"$f":"SUM(D139:D155)","v":576674.72729495191}]

{"sheet":"LFA EFR_7B","index":19,"n_rows":156,"n_cols":26,"rows_kept":156,"cut":false,"hidden":false,"merged":[[8,0,8,1],[0,0,0,5],[3,0,3,1],[3,2,3,3],[3,5,4,7],[4,0,4,1],[4,2,4,3],[5,0,5,1],[5,2,5,3],[6,0,6,1],[6,2,6,3],[7,0,7,1],[8,4,9,4],[7,2,7,3],[8,8,9,8],[12,4,14,7],[15,4,15,7],[15,8,15,11],[15,20,15,21],[15,15,15,16],[16,1,16,2],[16,15,16,16],[16,20,16,21],[17,1,17,3],[17,15,17,16],[17,20,17,21],[18,1,18,3],[18,15,18,16],[18,20,18,21],[19,1,19,3],[20,1,20,3],[20,15,20,16],[20,20,20,21],[26,1,26,3],[21,1,21,3],[21,15,21,16],[21,20,21,21],[22,1,22,3],[22,15,22,16],[22,20,22,21],[23,1,23,3],[23,15,23,16],[23,20,23,21],[24,1,24,3],[25,1,25,3],[128,0,128,11],[27,1,27,3],[28,1,28,3],[29,1,29,3],[30,0,30,2],[33,4,33,7],[33,8,33,11],[90,0,90,3],[91,0,93,4],[95,4,95,7],[95,8,95,11],[121,0,123,4],[140,4,140,10],[141,4,141,10],[154,4,154,10],[129,0,129,11],[130,0,134,11],[136,4,136,11],[137,4,137,10],[138,4,138,10],[139,4,139,10],[142,4,142,10],[143,4,143,10],[153,4,153,10],[144,4,144,10],[145,4,145,10],[146,4,146,10],[147,4,147,10],[152,4,152,10],[148,4,148,10],[149,4,149,10],[150,4,150,10],[151,4,151,10]]}
["Ongoing Progress Update and Disbursement Request"]
["Section 7B: LFA - Enhanced Financial Reporting"]
[]
["Country",null,{"$f":"CoverSheet!D5","v":"Georgia"},null,null,"PLEASE REFER TO THE \"GUIDANCE FOR COMPLETION OF THE ENHANCED FINANCIAL REPORTING TEMPLATE\" DOCUMENT TO ASSIST YOU IN COMPLETING THE TEMPLATE"]
["Grant No.",null,{"$f":"CoverSheet!D7","v":"GEO-T-NCDC"}]
["PR",null,{"$f":"CoverSheet!D8","v":"NCDC"},null,null,"TO BE COMPLETED ONLY ONCE A YEAR EXCEPT AT MONTH 18 FOR PURPOSES OF PHASE 2 REVIEW"]
["Currency",null,{"$f":"CoverSheet!D11","v":"EUR"}]
["Disease(Component)",null,{"$f":"CoverSheet!D6","v":"Tuberculosis"},null,null,null,"dd-mm-yyyy",null,null,null,"dd-mm-yyyy"]
[null,null,null,null,"Current Reporting Period","Start Date:",null,null,"Cumulative Reporting Period","Start Date:"]
[null,null,null,null,null,"End Date:",null,null,null,"End Date:"]
[null,null,null,null,null,null,null,"The end date for the current reporting period and cumulative reporting period must be the same"]
[null,null,{"$f":"CONCATENATE(\"EFR\",SUBSTITUTE(SUBSTITUTE(C8,\"/\",\"\"),\" \",\"\"))","v":"EFRTuberculosis"}]
[null,null,{"$f":"CONCATENATE(\"SDA\",SUBSTITUTE(SUBSTITUTE(C8,\"/\",\"\"),\" \",\"\"))","v":"SDATuberculosis"},null,"The \"TOTAL\" rows in Table A, B and C will have a RED background if the amounts in each table do not agree. If the Totals for each Table agrees, these rows will have a YELLOW background. "]
[]
[]
["A- BREAKDOWN* BY  EXPENDITURE CATEGORY",null,null,null,"Current Reporting Period",null,null,null,"Cumulative Reporting Period",null,null,null,null,null,null,{"$f":"IF('[3]PR_Programmatic Progress_1A'!R15=\"Select\",\"Please select currency on Page\n 'PR_Programmatic Achievement (1)'\", \"All amounts are in: \"&'[3]PR_Programmatic Progress_1A'!R15)","v":"All amounts are in: "},null,"Budget for Reporting Period","Actual Cash Outflow for Reporting Period","Variance","Reason for Variance",null,"Cumulative Budget through period of Progress Update","Cumulative Actual Cash Outflow through period of Progress Update","Variance","Reason for Variance"]
["#","Category",null,null," \nBudget","\nExpenditures","Variance","Reason for Variance","Cumulative Budget","Cumulative Expenditure","Variance","Reason for Variance",null,null,null,"1. Total PR cash outflow vs. budget",null,{"$f":"R18+R19","v":0},{"$f":"S18+S19","v":0},{"$f":"IF(R17=\"\",IF(S17=\"\",\"\",R17-S17),R17-S17)","v":0},null,null,{"$f":"W18+W19","v":0},{"$f":"X18+X19","v":0},{"$f":"IF(W17=\"\",IF(X17=\"\",\"\",W17-X17),W17-X17)","v":0}]
[1,"Human Resources",null,null,0,0,{"$f":"E18-F18","v":0},null,0,0,{"$f":"I18-J18","v":0},null,null,null,null,"    1a. PR's total expenditures",null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!C13","v":0},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!D13","v":0},{"$f":"IF(R18=\"\",IF(S18=\"\",0,R18-S18),R18-S18)","v":0},null,null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!H13","v":0},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!I13","v":0},{"$f":"IF(W18=\"\",IF(X18=\"\",0,W18-X18),W18-X18)","v":0}]
[2,"Technical Assistance",null,null,0,0,{"$f":"E19-F19","v":0},null,0,0,{"$f":"I19-J19","v":0},null,null,null,null,"    1b. Disbursements to sub-recipients",null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!C14","v":0},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!D14","v":0},{"$f":"IF(R19=\"\",IF(S19=\"\",0,R19-S19),R19-S19)","v":0},null,null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!H14","v":0},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!I14","v":0},{"$f":"IF(W19=\"\",IF(X19=\"\",0,W19-X19),W19-X19)","v":0}]
[3,"Training",null,null,0,0,0,null,0,0,0]
[4,"Health Products and Health Equipment",null,null,0,0,0,null,0,0,0,null,null,null,null,null,null,"Budget for Reporting Period*","Actual Cash Outflow for Reporting Period","Variance","Reason for Variance",null,"Cumulative Budget through period of Progress Update","Cumulative Actual Cash Outflow through period of Progress Update","Variance","Reason for Variance"]
[5,"Medicines and Pharmaceutical Products",null,null,0,0,0,null,0,0,0,null,null,null,null,"2. Total pharmaceutical & health product expenditures vs. budget",null,{"$f":"R23+R24","v":0},{"$f":"S23+S24","v":0},{"$f":"IF(R22=\"\",IF(S22=\"\",\"\",R22-S22),R22-S22)","v":0},null,null,{"$f":"W23+W24","v":0},{"$f":"X23+X24","v":0},{"$f":"IF(W22=\"\",IF(X22=\"\",\"\",W22-X22),W22-X22)","v":0}]
[6,"Procurement and Supply Management Costs",null,null,0,0,0,null,0,0,0,null,null,null,null,"    2a.  Medicines and pharmaceutical products",null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!C18","v":0},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!D18","v":0},{"$f":"IF(R23=\"\",IF(S23=\"\",0,R23-S23),R23-S23)","v":0},null,null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!H18","v":0},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!I18","v":0},{"$f":"IF(W23=\"\",IF(X23=\"\",0,W23-X23),W23-X23)","v":0}]
[7,"Infrastructure and Other Equipment",null,null,0,0,0,null,0,0,0,null,null,null,null,"    2b.  Health products and health equipment",null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!C19","v":0},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!D19","v":0},{"$f":"IF(R24=\"\",IF(S24=\"\",0,R24-S24),R24-S24)","v":0},null,null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!H19","v":0},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!I19","v":0},{"$f":"IF(W24=\"\",IF(X24=\"\",0,W24-X24),W24-X24)","v":0}]
[8,"Communication Materials",null,null,0,0,0,null,0,0,0]
[9,"Monitoring & Evaluation",null,null,0,0,0,null,0,0,0]
[10,"Living Support to Clients/Target Populations",null,null,0,0,0,null,0,0,0]
[11,"Planning and Administration",null,null,0,0,0,null,0,0,0]
[12,"Overheads",null,null,0,0,0,null,0,0,0]
[13,"Other",null,null,0,0,0,null,0,0,0]
[null,null,null,"TOTAL",{"$f":"SUM(E18:E30)","v":0},{"$f":"SUM(F18:F30)","v":0},{"$f":"SUM(G18:G30)","v":0},null,{"$f":"SUM(I18:I30)","v":0},{"$f":"SUM(J18:J30)","v":0},0]
[]
[]
["B- BREAKDOWN* BY PROGRAM ACTIVITY",null,null,null,"Current Reporting Period",null,null,null,"Cumulative Reporting Period"]
["#","Macro-category","Objectives","Service Delivery Area"," \nBudget","\nExpenditures","Variance","Reason for Variance","Cumulative Budget","Cumulative Expenditure","Variance","Reason for Variance"]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E36-F36","v":0},null,0,0,{"$f":"I36-J36","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E37-F37","v":0},null,0,0,{"$f":"I37-J37","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E51-F51","v":0},null,0,0,{"$f":"I51-J51","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E63-F63","v":0},null,0,0,{"$f":"I63-J63","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E77-F77","v":0},null,0,0,{"$f":"I77-J77","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E84-F84","v":0},null,0,0,{"$f":"I84-J84","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E87-F87","v":0},null,0,0,{"$f":"I87-J87","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
["TOTAL",null,null,null,{"$f":"SUM(E36:E90)","v":0},{"$f":"SUM(F36:F90)","v":0},0,null,{"$f":"SUM(I36:I90)","v":0},{"$f":"SUM(J36:J90)","v":0},{"$f":"SUM(K36:K90)","v":0}]
[]
[]
[]
[]
["C- BREAKDOWN* BY IMPLEMENTING ENTITY",null,null,null,"Current Reporting Period",null,null,null,"Cumulative Reporting Period"]
["#","PR/SR","Name","Type of\nImplementing Entity"," \nBudget","\nExpenditures","Variance","Reason for Variance","Cumulative Budget","Cumulative Expenditure","Variance","Reason for Variance"]
[null,"Please Select …",null,"Please Select…",0,0,{"$f":"E98-F98","v":0},null,0,0,{"$f":"I98-J98","v":0}]
[null,"Please Select …",null,"Please Select…",0,0,{"$f":"E99-F99","v":0},null,0,0,{"$f":"I99-J99","v":0}]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,{"$f":"E102-F102","v":0},null,0,0,{"$f":"I102-J102","v":0}]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,{"$f":"E107-F107","v":0},null,0,0,{"$f":"I107-J107","v":0}]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,{"$f":"E111-F111","v":0},null,0,0,{"$f":"I111-J111","v":0}]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,null,null,"TOTAL",{"$f":"SUM(E98:E120)","v":0},{"$f":"SUM(F98:F120)","v":0},0,null,{"$f":"SUM(I98:I120)","v":0},{"$f":"SUM(J98:J120)","v":0},0]
[]
[]
[]
[]
["* The sum of all three breakdowns should be equal (A- Budget Line-item, B- Program Activity, C- Implementing Entity)."]
["** For the purposes of this report, the SDA Program management and administration should be included in the Supportive Environment Macro Category."]
[]
["D- ADDITIONAL INFORMATION"]
["Please disclose any relevant information concerning the information in the above tables. Refer to the Guidelines for Completing the Template if required."]
[]
[]
[]
[]
[]
[]
["E- DISBURSEMENTS BREAKDOWN BY IMPLEMENTING ENTITY",null,null,null,"Cumulative Reporting Period"]
["#","Name","Type of\nImplementing Entity","Cumulative Disbursements","Comments"]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"TOTAL",{"$f":"SUM(D139:D155)","v":0}]

{"sheet":"Annual Cash Forecast_8A","index":20,"n_rows":36,"n_cols":16,"rows_kept":36,"cut":false,"hidden":false,"merged":[[9,1,9,2],[10,1,10,2],[0,0,0,7],[3,1,3,2],[4,1,4,2],[5,1,5,2],[6,1,6,2],[7,1,7,2],[8,1,8,2]]}
["Ongoing Progress Update and Disbursement Request"]
[]
["Section 8A: The Global Fund Annual Forecast Template"]
[{"$f":"#REF!","v":{"$error":"#REF!"}},{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[{"$f":"#REF!","v":{"$error":"#REF!"}},{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[{"$f":"#REF!","v":{"$error":"#REF!"}},{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[{"$f":"#REF!","v":{"$error":"#REF!"}},{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[{"$f":"#REF!","v":{"$error":"#REF!"}},{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[{"$f":"#REF!","v":{"$error":"#REF!"}},{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[{"$f":"#REF!","v":{"$error":"#REF!"}},{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[{"$f":"#REF!","v":{"$error":"#REF!"}},{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[]
["Reporting Cycle","From","To"]
["Current reporting period","2015-01-01","2015-12-31"]
["Cumulative Reporting period","2015-01-01","2015-12-31"]
[]
[]
[]
[]
["Summary Breakdown by Cost Grouping"]
[]
["Costing Dimension (Cost Grouping)","Budget for Forecast Period","Unspent from previous periods","Budget for the Buffer Period","Total Budget available (including the buffer)","Adjustment for the  Forecast Period (based on implementable activities)","Adjustment for the Buffer Period","Total Principal Recipient Forecast (including Buffer)","Comments",null,"Local Fund Agent Adjustment on PR Budget","Local Fund Agent Adjustment on Budget for the Buffer Period","Local Fund Agent Adjustment on the Forecast","Local Fund Agent Adjustment on the Buffer Forecast","Local Fund Agent - Adjusted Forecast (including the buffer)","Comments"]
["Human Resources (HR)",135454.14007096039,{"$f":"'PR EFR_7A'!K18","v":86572.969892208173},0,{"$f":"B23+C23+D23","v":222027.10996316856},39048.220251582796,0,{"$f":"E23+F23+G23","v":261075.33021475136},"Project Management costs attributed to HIV Grant will be covered from TB Budget during the HIV Grant Extension period",null,null,null,null,null,{"$f":"K23+L23+H23+M23+N23","v":261075.33021475136}]
["Technical Assistance",13420,{"$f":"'PR EFR_7A'!K19","v":104218.67203338235},0,{"$f":"B24+C24+D24","v":117638.67203338235},181447.74050183845,0,{"$f":"E24+F24+G24","v":299086.41253522079},"Project Management costs attributed to HIV Grant will be covered from TB Budget during the HIV Grant Extension period; New activities added (transition plan)",null,null,null,null,null,{"$f":"K24+L24+H24+M24+N24","v":299086.41253522079}]
["Training",3000,{"$f":"'PR EFR_7A'!K20","v":10893.257124592797},0,13893.257124592797,50036.881589152472,0,63930.138713745269,"Project Management costs attributed to HIV Grant will be covered from TB Budget during the HIV Grant Extension period; New activities added (TB support; TB education)",null,null,null,null,null,63930.138713745269]
["Health Products and Health Equipment",447048.89307732024,{"$f":"'PR EFR_7A'!K21","v":581549.72546247987},0,1028598.6185398002,-210055.85818694544,0,818542.76035285473,null,null,null,null,null,null,818542.76035285473]
["Medicines and Pharmaceutical Products",1151470.3529311728,{"$f":"'PR EFR_7A'!K22","v":2099149.5268651345},0,3250619.8797963075,-2606700.7563321707,0,643919.12346413685,"Savings coming from the procurement of SLDs will be spent during the next 6 months for the interventions approved by TGF through the respective Notes for the Records and Funds Reallocation Requests. ",null,null,null,null,null,643919.12346413685]
["Procurement and Supply Management Costs",126085.14813311728,{"$f":"'PR EFR_7A'!K23","v":225713.6635870077},0,351798.81172012497,-343810.94057487679,0,7987.8711452481803,null,null,null,null,null,null,7987.8711452481803]
["Infrastructure and Other Equipment",7864.1829071233315,{"$f":"'PR EFR_7A'!K24","v":39025.343099561025},0,46889.526006684355,-31526.493039481018,0,15363.032967203337,null,null,null,null,null,null,15363.032967203337]
["Communication Materials",0,{"$f":"'PR EFR_7A'!K25","v":0},0,0,0,0,0,null,null,null,null,null,null,0]
["Monitoring & Evaluation",43629.711687670308,{"$f":"'PR EFR_7A'!K26","v":70462.270759745239},0,114091.98244741555,-66519.662612568514,0,47572.319834847032,null,null,null,null,null,null,47572.319834847032]
["Living Support to Clients/Target Populations",338856.12,{"$f":"'PR EFR_7A'!K27","v":878234.60085372545},0,1217090.7208537254,-966404.38860946253,0,250686.33224426291,null,null,null,null,null,null,250686.33224426291]
["Planning and Administration",53317.403837406266,{"$f":"'PR EFR_7A'!K28","v":26635.134347136292},0,79952.538184542558,30234.030908035667,0,110186.56909257823,"Project Management costs attributed to HIV Grant will be covered from TB Budget during the HIV Grant Extension period",null,null,null,null,null,110186.56909257823]
["Overheads",4239.0842080638377,{"$f":"'PR EFR_7A'!K29","v":9659.5564887672845},0,13898.640696831122,-6587.2821085912647,0,7311.3585882398575,null,null,null,null,null,null,7311.3585882398575]
["Other",0,{"$f":"'PR EFR_7A'!K30","v":-3.1011070577733335E-3},0,-3.1011070577733335E-3,-23681.552316682701,0,-23681.555417789757,null,null,null,null,null,null,-23681.555417789757]
["Grand Total",{"$f":"SUM(B23:B35)","v":2324385.0368528343},{"$f":"SUM(C23:C35)","v":4132114.7174126329},{"$f":"SUM(D23:D35)","v":0},{"$f":"SUM(E23:E35)","v":6456499.7542654695},{"$f":"SUM(F23:F35)","v":-3954520.0605301699},0,2501979.6937352992,null,null,{"$f":"SUM(K23:K35)","v":0},{"$f":"SUM(L23:L35)","v":0},0,0,2501979.6937352992]

{"sheet":" Request and Recommendation_8B","index":21,"n_rows":56,"n_cols":18,"rows_kept":56,"cut":false,"hidden":false,"merged":[[6,0,6,4],[6,5,6,9],[0,0,0,14],[2,0,2,4],[2,5,2,9],[5,5,5,9],[40,11,40,12],[40,13,40,17],[42,0,42,8],[9,0,9,17],[38,1,38,8],[30,0,31,6],[27,0,27,16],[28,0,28,16],[20,1,20,3],[30,7,31,17],[36,11,36,12],[36,13,36,17],[37,13,37,17],[38,11,38,12],[37,11,37,12],[38,13,38,17],[58,9,62,14],[36,1,37,8],[32,7,33,17],[55,9,55,14],[32,0,33,6],[36,0,39,0],[39,1,39,8],[48,9,48,12],[50,9,50,12],[52,9,52,12],[41,0,41,8],[52,1,52,4],[39,13,39,17],[41,13,41,17],[41,11,41,12],[39,11,39,12]]}
["Ongoing Progress Review and Disbursement Request"]
["DISBURSEMENT REQUEST PERIOD"]
["Grant Name:",null,null,null,null,{"$f":"#REF!","v":{"$error":"#REF!"}}]
["Disbursement Request  - Disbursement Period:",null,null,null,null,"Cycle:",null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Disbursement Request  - Period Covered:",null,null,null,null,"Beginning Date:",null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Disbursement Request  - Number:",null,null,null,null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Currency:",null,null,null,null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
[]
["Section 8B.  Disbursement Request and Recommendation"]
[]
["Total forecasted net cash expenditures by the Principal Recipient for the period immediately following the period covered by the Progress Update:"]
[" "]
["1.  Period beginning date:",null,null,null,null,{"$f":"IF(CoverSheet!J11=\"\",\"\",CoverSheet!J11)","v":"2016-01-01"},null,"end date:",{"$f":"IF(CoverSheet!L11=\"\",\"\",CoverSheet!L11)","v":"2016-06-30"},null,"Approved budget amount (PR):",null,{"$f":"'Annual Cash Forecast_8A'!B36","v":2324385.0368528343},null,"Forecasted amount  (PR)",{"$f":"'Annual Cash Forecast_8A'!B36+'Annual Cash Forecast_8A'!C36+'Annual Cash Forecast_8A'!F36","v":2501979.6937352968}]
[]
[null,null,null,null,null,null,null,null,null,null,"LFA-verified approved budget amount:",null,{"$f":"'Annual Cash Forecast_8A'!B36+'Annual Cash Forecast_8A'!K36","v":2324385.0368528343},null,"LFA-adjusted forecasted amount:",{"$f":"P13+'Annual Cash Forecast_8A'!M36","v":2501979.6937352968}]
["2a. Cash buffer period (by default)"]
["  (cash \"buffer\") beginning date:",null,null,null,null,{"$f":"IF(I13=\"\",\"\",I13+1)","v":"2016-07-01"},null,"end date:",{"$f":"IF(F17=\"\",\"\",DATE(YEAR(F17),MONTH(F17)+3,DAY(F17)-1))","v":"2016-09-30"},null,"Approved budget amount (PR):",null,{"$f":"'Annual Cash Forecast_8A'!D36","v":0},null,"Forecasted amount  (PR):",{"$f":"'Annual Cash Forecast_8A'!D36+'Annual Cash Forecast_8A'!G36","v":0}]
[]
[null,null,null,null,null,null,null,null,null,null,"LFA-verified approved budget amount:",null,{"$f":"'Annual Cash Forecast_8A'!D36+'Annual Cash Forecast_8A'!L36","v":0},null,"LFA-adjusted forecasted amount:",{"$f":"P17+'Annual Cash Forecast_8A'!N36","v":0},null,"PR Total Forecast"]
["2b.  Additional \"buffer\" (discretionary, select only if there is a prior agreement with the FPM) (1)",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"P13+P17+P24","v":2501979.6937352968}]
[null,"Cash \"buffer\" agreed with FPM (2)",null,null,null,"Select ",null,null,null,null,null,null,null,null,null,null,null,"LFA Total Forecast"]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"P15+P19+P26","v":2501979.6937352968}]
[]
["(cash \"buffer\") beginning date",null,null,null,null,{"$f":"IF(I17=\"\",\"\",I17+1)","v":"2016-10-01"},null,"end date:",{"$f":"IF(F21=\"\",\"\",IF(F21=\"1M\",DATE(YEAR(I17),MONTH(I17)+1,DAY(I17)-1),IF(F21=\"2M\",DATE(YEAR(I17),MONTH(I17)+2,DAY(I17)-1),IF(F21=\"3M\",DATE(YEAR(I17),MONTH(I17)+3,DAY(I17)-1),\"\"))))","v":""},null,"Approved budget amount:",null,0,null,"Forecasted amount:",0]
[]
[null,null,null,null,null,null,null,null,null,null,"LFA-verified approved budget amount:",null,null,null,"LFA-adjusted forecasted amount:"]
[]
["(1) Upon agreement with the FPM, additional Cash buffer can be requested if the PU/DR report contains a completed AFR or EFR report or if there is a request from the Secretariat for the PR to complete the report on SR Cash Reconciliation contained in the “SR Cash Reconciliation 2D”, or if there are any additional Global Fund-specific requirements that cannot be delivered within 60 days.  However such requests may or may not be satisfied based on the review of the current PU/DR."]
["(2) When the additional (cash \"buffer\" ) period is 1 or 2 months, the approved budget and forecasted amounts should be calculated as prorated values for the period following the regular buffer period."]
[]
["PR's explanation of any significant variance between forecasted amounts and amounts as originally budgeted.  Please explain any significant variance (based on your judgment) between the forecasted amounts and the amounts as per approved budgets.  Please specify the main factors and related amounts that are the major drivers of the variance. \nNB. Consider the following items when providing the analysis. \n  - Expected timing of payments for any significant budgetary items,\n  - Impact of existing cash balance at SR levels\n  - Current confirmed commitments to be paid during disbursement request period \n  - Current/expected unit prices compared to those in the budget \n  - Change in quantities compared to budget\n  - Exchange rates and inflation\n  - Linkage between budget absorption and programmatic performance to-date.\n\n! The forecast should include any existing commitments (eligible under this grant) as of the end of the reporting period and which are likely to be paid during the disbursement period",null,null,null,null,null,null,"It has to be emphasized that although the budget absorption was less than planned 53,6 % (due to reasons justified below), the entire programme activities were performed accordingly.\nThe major reasons for developing variance are as follows:\nlocal procurement with competitive bidding, with preceding market assessment in 2014-2015 period, derived cheaper unit costs compared to the budgeted. The latter resulted in the saving totaled at: 242,000 GEL \nPR supported re-calculation of the available stock of medicines and lab. supplies at SR level, considering the fact of close-out of Expand TB project. Besides final shipments from the said donor were received during 2014 – 2015. The exercise resulted in the development of the updated request coming from the SR (Annex 5 of the contract with SR). Based on the updated request, PR revised the procurement budget for laboratory supplies.\nIn order to keep the procurements needs-based, PR supported SR in re-calculating average consumption rates for medicines and supplies. \nMDR scheme budget calculation was based on the 2012, 2013, 2014 TB cohort (75% of patients) data with 100% compliance to treatment. Budget amount for Sensitive patients was calculated for 1 year period covering 70% of all sensitive patients with 100% adherence (both installments). Actually patients enrolled in January - May, 2014 did not fit for being beneficiary of the scheme, as approved scheme was enrolling patients starting June 1.  Actual average number of patients for both schemes per month was less than projected. Based on the above, and also the fact that 150 MDRs were covered through the state funding (225 MDRs from the year 2016), PR re-calculated 2015 -2016 budget for the scheme and latter resulted in saving of funds.\nSince year 2014, the significant devaluation of the Georgian national currency GEL took place (GEL's depreciation is 30 percent). This derived savings in the Grant currency.\nSavings from the current grant were aligned in the following directions: EUR 2,580,926 was added to the NFM budget, EUR 584,000 was moved to HIV NFM budget (Split); EUR 805,000 is anticipated for TB Extension Budget; \n"]
[]
["LFA comments on PR's explanation of any significant variance between forecasted amounts and amounts as originally budgeted."]
[]
[]
[]
["Less:","3. Cash Balance: End of period covered by Progress Update (Item 5.1 in PRLFA Cash Reconciliation):",null,null,null,null,null,null,null,"PR-reported amounts","PR Comments","LFA-verified amounts",null,"LFA Comments"]
[null,null,null,null,null,null,null,null,null,{"$f":"'PR Cash Reconciliation_2A,B,C'!D52","v":484367.28632317152},null,{"$f":"'PR Cash Reconciliation_2A,B,C'!H52","v":484367.28632317152}]
[null,"4. Cash in Transit for the reporting period (Disbursements to PR & third party disbursements):",null,null,null,null,null,null,null,{"$f":"'PR Cash Reconciliation_2A,B,C'!D63","v":0},null,{"$f":"'PR Cash Reconciliation_2A,B,C'!H63","v":0}]
[null,"5.Cash in Transit after the current reporting period (Disbursements to PR & third party disbursements) :",null,null,null,null,null,null,null,{"$f":"'PR Cash Reconciliation_2A,B,C'!D64","v":2017612.9},null,{"$f":"'PR Cash Reconciliation_2A,B,C'!H64","v":2017612.9}]
[null,null,null,null,null,null,null,null,null,"PR-requested amount","PR Comments","LFA-verified amounts",null,"LFA Comments"]
["6. Disbursement Request to the Global Fund for the period immediately following the period covered by the Progress Update, plus additional period (cash buffer):",null,null,null,null,null,null,null,null,{"$f":"IF(R20=0,0,IF(R20-J38-J39-J40<0,0,R20-J38-J39-J40))","v":0},null,{"$f":"IF(R22=0,0,IF(R22-L38-L39-L40<0,0,R22-L38-L39-L40))","v":0},{"$f":"IF(T22=0,0,IF(T22-M38-M39-M40<0,0,T22-M38-M39-M40))","v":0}]
[]
["7.  Does the PR's Disbursement Request include funds for health product procurement?",null,null,null,null,null,null,null,null,"Yes"]
["8.  Exchange Rate (used to translate local currency into grant currency)",null,null,null,null,null,null,null,null,"Yes"]
[]
[null,null,null,null,null,"Rates used by the PR",null,"LFA-verified rates",null,"Name of local currency, date and source of the exchange rate, and other comments (if appropriate) "]
[]
[null,"- used to convert Opening Cash Balance",null,null,null,2.4992000000000001,null,0,null,"Exchange rate at the closing date of the previous reporting period (source: www.nbg.gov.ge)"]
[]
[null,"- used to convert Closing Cash Balance",null,null,null,2.6168999999999998,null,0,null,"Exchange rate at the closing date of the current reporting period (source: www.nbg.gov.ge)"]
[]
[null,"- used to convert Total PR Cash Outflow for the Progress Update Period",null,null,null,"-",null,0,null,"Exchange rate at the date of transaction  (source: www.nbg.gov.ge)"]
[]
[]
[null,null,null,null,null,null,null,null,null,"LFA comments on the exchange rates used by the PR"]

{"sheet":"PR Authorization_9A","index":22,"n_rows":14,"n_cols":10,"rows_kept":14,"cut":false,"hidden":false,"merged":[[8,0,8,14],[16,0,16,14],[10,0,10,4],[0,0,0,14],[2,0,2,4],[2,5,2,9],[5,5,5,9],[6,0,6,4],[6,5,6,9],[10,5,10,9],[11,5,11,9],[12,5,12,9],[13,5,13,9]]}
["Ongoing Progress Review and Disbursement Request"]
["DISBURSEMENT REQUEST PERIOD"]
["Grant Name:",null,null,null,null,{"$f":"#REF!","v":{"$error":"#REF!"}}]
["Disbursement Request  - Disbursement Period:",null,null,null,null,"Cycle:",null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Disbursement Request  - Period Covered:",null,null,null,null,"Beginning Date:",null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Disbursement Request  - Number:",null,null,null,null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Currency:",null,null,null,null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Section 9A.  PR Authorization"]
["The undersigned acknowledges that: (i) all the information (programmatic, financial, or otherwise) provided in this Progress Update and Disbursement Request is complete and accurate; (ii) funds disbursed in accordance with this request shall be deposited in the bank account specified in the Facesheet; and (iii) funds disbursed under the Grant Agreement shall be used in accordance with the Grant Agreement."]
[]
["Signed on behalf of the Principal Recipient:\n(signature of Authorized Designated Representative)"]
["Name:",null,null,null,null,"Irma Khonelidze"]
["Title:",null,null,null,null,"Program Director"]
["Date and Place:",null,null,null,null,"16 March 2016      Tbilisi, Georgia"]

{"sheet":"LFA Authorization_9B","index":23,"n_rows":19,"n_cols":10,"rows_kept":19,"cut":false,"hidden":false,"merged":[[13,0,13,14],[21,0,21,14],[0,0,0,14],[2,0,2,4],[2,5,2,9],[5,5,5,9],[6,0,6,4],[6,5,6,9],[10,0,10,14],[12,0,12,14],[11,0,11,14],[15,3,15,5],[16,3,16,5],[17,3,17,5],[18,3,18,5]]}
["Ongoing Progress Review and Disbursement Request"]
["DISBURSEMENT REQUEST PERIOD"]
["Grant Name:",null,null,null,null,{"$f":"#REF!","v":{"$error":"#REF!"}}]
["Disbursement Request  - Disbursement Period:",null,null,null,null,"Cycle:",null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Disbursement Request  - Period Covered:",null,null,null,null,"Beginning Date:",null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Disbursement Request  - Number:",null,null,null,null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Currency:",null,null,null,null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["For LFA Use Only"]
["Section 9B.  LFA Authorization"]
["Summary of the LFA's approach used for verification of financial, programmatic and procurement data and Quality Assurance undertaken by the LFA"]
["In this section the LFA should indicate, as applicable, what percentage of expenditures was verified at PR level, if any expenditures were verified at SR level, how many site visits were made, what tender documentation was verified, and any other material parts of verification procedures in line with the verification approach agreed upfront between the LFA and the Global Fund's Secretariat based on country/grant risks.  As a good practice, the verification approach needs to be reviewed jointly by the LFA and the Secretariat annually."]
[]
[]
["The LFA should sign a printed version of the verified PU/DR and send it to the Secretariat as a pdf file by email, or include an electronic signature in the Excel file to be submitted to the Global Fund."]
[]
["Signed on behalf of the LFA:"]
["Name:"]
["Title:"]
["Date and Place:"]

{"sheet":"PR_Disbursement Request_7","index":24,"n_rows":45,"n_cols":19,"rows_kept":45,"cut":false,"hidden":true,"merged":[[30,0,32,0],[0,0,0,9],[2,0,2,4],[2,5,2,8],[5,5,5,8],[6,3,6,8],[10,0,10,18],[11,0,11,18],[23,0,23,19],[24,0,24,19],[26,0,27,7],[26,8,27,18],[33,7,33,12],[40,8,40,11],[42,8,42,11],[44,1,44,4],[44,8,44,11]]}
["On-going Progress Update and Disbursement Request"]
["DISBURSEMENT REQUEST PERIOD"]
["Grant number:",null,null,null,null,{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Reporting Period:",null,null,null,null,"Cycle:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Period Covered:",null,null,null,null,"Beginning Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Number:",null,null,null,null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Currency:",null,null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
[]
["Section 5: Cash Reconciliation and Disbursement Request"]
[]
["B: DISBURSEMENT REQUEST"]
[]
[]
["Total forecasted net cash expenditures by the Principal Recipient for the period immediately following the period covered"]
[" by the Progress Update:"]
["1.  Period beginning date:",null,null,null,{"$f":"IF(CoverSheet!J11=\"\",\"\",CoverSheet!J11)","v":"2016-01-01"},null,"end date:",{"$f":"IF(CoverSheet!L11=\"\",\"\",CoverSheet!L11)","v":"2016-06-30"},null,"approved budget amount:",null,"forecasted amount:"]
["2a. Cash buffer period (by default)"]
["  (cash \"buffer\") beginning date:",null,null,null,{"$f":"IF(H16=\"\",\"\",H16+1)","v":"2016-07-01"},null,"end date:",{"$f":"IF(E18=\"\",\"\",DATE(YEAR(E18),MONTH(E18)+3,DAY(E18)-1))","v":"2016-09-30"},null,"approved budget amount:",null,"forecasted amount:"]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"PR Total Forecast"]
["2b.  Additional \"buffer\" (discretionary, select only if there is a prior agreement with the FPM) (1)",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"N16+N18+N22","v":0}]
["cash \"buffer\" agreed with FPM (2)",null,"Select "]
["(cash \"buffer\") beginning date",null,null,null,{"$f":"IF(H18=\"\",\"\",H18+1)","v":"2016-10-01"},null,"end date:",{"$f":"IF(C21=\"\",\"\",IF(C21=\"1M\",DATE(YEAR(E22),MONTH(E22)+1,DAY(E22)-1),IF(C21=\"2M\",DATE(YEAR(E22),MONTH(E22)+2,DAY(E22)-1),IF(C21=\"3M\",DATE(YEAR(E22),MONTH(E22)+3,DAY(E22)-1),\"\"))))","v":""},null,"approved budget amount:",null,"forecasted amount:"]
[]
["(1) Additional Cash buffer can be requested if the next PU/DR report will contain a completed EFR report or a completed Annex on SR financials, requested by the Secretariat, or if there are any additional GF-specific requirements that cannot be delivered within 45 days. An agreement in principal from the FPM should be obtained prior to requesting an additional cash buffer."]
["(2) When the additional (cash \"buffer\" ) period is 1 or 2 months, the approved budget and forecasted amounts should be calculated as prorated values for the period following the regular buffer period."]
[]
["Please explain any significant variance (based on your judgment) between the forecasted amounts and the amounts as per approved budgets.  Please specify the main factors and related amounts that are the major drivers of the variance. \nNB. Consider the following items when providing the analysis. \n  - Expected timing of payments for any significant budgetary items,\n  - Impact of existing cash balance at SR levels\n  - Current confirmed commitments to be paid during disbursement request period \n  - Current/expected unit prices compared to those in the budget \n  - Change in quantities compared to budget\n  - Exchange rates and inflation\n  - Linkage between budget absorption and programmatic performance to-date.\n\n! The forecast should include any existing commitments (eligible under this grant) as of the end of the reporting period and which are likely to be paid during the disbursement period"]
[]
[]
[]
["Less:","3. Cash Balance: End of period covered by Progress Update (number 10 from PR Cash Reconciliation sheet):",null,null,null,null,null,null,null,null,null,null,null,{"$f":"+'PR Cash Reconciliation_2A,B,C'!#REF!","v":{"$error":"#REF!"}}]
[]
[null,"4.  Cash \"in transit\" disbursed to the PR:"]
[null,"5. Cash \"in transit\" disbursed to third parties by the Global Fund on behalf of the PR",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"+N31+N33+N34","v":{"$error":"#REF!"}}]
[]
["6.  PR's Disbursement Request to the Global Fund for the period immediately following the period covered by the Progress Update, plus additional period (cash buffer):",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"IF(S20=0,0,IF(S20-S34<0,0,S20-S34))","v":0}]
[]
["7.  Does the PR's Disbursement Request include funds for health product procurement?",null,null,null,null,null,null,null,"Select"]
[]
["8. Exchange Rate (used to translate local currency into grant currency)",null,null,null,null,null,null,null,"Name of local currency, date and source of the exchange rate, and other comments (if appropriate) "]
[null,"- used to convert Opening Cash Balance"]
[]
[null,"- used to convert Closing Cash Balance"]
[]
[null,"- used to convert Total Cash Outflow for the Progress Update Period"]

{"sheet":"Modules","index":25,"n_rows":24,"n_cols":6,"rows_kept":24,"cut":false,"hidden":true,"merged":[]}
[]
[null,"HIVAIDS_Module","HIVTB","Tuberculosis","Malaria","Health Systems Strengthening"]
[null,"Prevention programs for general population","Prevention programs for general population","TB care and prevention","Vector control","HSS - Procurement supply chain management (PSCM)"]
[null,"Prevention programs for MSM and TGs","Prevention programs for MSM and TGs","TB/HIV","Case management","HSS - Health information systems and M&E"]
[null,"Prevention programs for sex workers and their clients","Prevention programs for sex workers and their clients","MDR-TB","Specific prevention interventions (SPI)","HSS - Health and community workforce"]
[null,"Prevention programs for people who inject drugs (PWID) and their partners","Prevention programs for people who inject drugs (PWID) and their partners","HSS - Procurement supply chain management (PSCM)","HSS - Procurement supply chain management (PSCM)","HSS - Service delivery"]
[null,"Prevention programs for other vulnerable populations (please specify)","Prevention programs for other vulnerable populations (please specify)","HSS - Health information systems and M&E","HSS - Health information systems and M&E","HSS - Financial management"]
[null,"Prevention programs for adolescents and youth, in and out of school","Prevention programs for adolescents and youth, in and out of school","HSS - Health and community workforce","HSS - Health and community workforce","HSS - Policy and governance"]
[null,"PMTCT","PMTCT","HSS - Service delivery","HSS - Service delivery","HSS - Healthcare financing"]
[null,"Treatment, care and support","Treatment, care and support","HSS - Financial management","HSS - Financial management","Removing legal barriers to access"]
[null,"TB/HIV","TB care and prevention","HSS - Policy and governance","HSS - Policy and governance","Program management"]
[null,"HSS - Procurement supply chain management (PSCM)","TB/HIV","HSS - Healthcare financing","HSS - Healthcare financing"]
[null,"HSS - Health information systems and M&E","MDR-TB","Removing legal barriers to access","Removing legal barriers to access"]
[null,"HSS - Health and community workforce","HSS - Procurement supply chain management (PSCM)","Community systems strengthening","Community systems strengthening"]
[null,"HSS - Service delivery","HSS - Health information systems and M&E","Program management","Program management"]
[null,"HSS - Financial management","HSS - Health and community workforce","Results-based Financing","Results based Financing"]
[null,"HSS - Policy and governance","HSS - Service delivery"]
[null,"HSS - Healthcare financing","HSS - Financial management"]
[null,"Removing legal barriers to access","HSS - Policy and governance"]
[null,"Community systems strengthening","HSS - Healthcare financing"]
[null,"Program management","Removing legal barriers to access"]
[null,"Results-based Financing","Community systems strengthening"]
[null,null,"Program management"]
[null,null,"Results-based Financing"]

{"sheet":"EFR Data","index":26,"n_rows":48,"n_cols":12,"rows_kept":48,"cut":false,"hidden":true,"merged":[]}
["EFRHIVAIDS",null,null,null,null,"SDAMalaria",null,"SDATuberculosis",null,"SDAHIVAIDS",null,"SDAHealthSystemsStrengthening"]
["Please Select…",null,null,null,null,"please select…",null,"please select…",null,"Please select…",null,"Please select…"]
["Prevention",null,null,null,null,"Prevention:  Behavioral Change Communication - Mass media",null,"Improving diagnosis",null,"Prevention: Behavioral Change Communication - Mass media",null,"HSS: Service delivery"]
["Treatment",null,null,null,null,"Prevention:  Behavioral Change Communication - community outreach",null,"Standardized treatment, patient support and patient charter",null,"Prevention: Behavioral Change Communication - community outreach",null,"HSS: Human resources"]
["Care and Support",null,null,null,null,"Prevention: Insecticide-treated nets (ITNs)",null,"Procurement and supply management",null,"Prevention: Condom distribution",null,"HSS: Community Systems Strengthening"]
["TB/HIV Collaborative Activities",null,null,null,null,"Prevention: Malaria prevention during pregnancy",null,"M&E",null,"Prevention: Counseling and Testing ",null,"HSS: Information system & Operational research"]
["Supportive Environment",null,null,null,null,"Prevention: Vector control (other than ITNs)",null,"TB/HIV",null,"Prevention: PMTCT",null,"HSS: Infrastructure"]
["Health System Strengthening (HSS)",null,null,null,null,"Prevention: other - specify",null,"MDR-TB",null,"Prevention: Post-exposure prophylaxis (PEP)",null,"HSS: Procurement and Supply management"]
[null,null,null,null,null,"Treatment: Prompt, effective anti-malarial treatment",null,"High-risk groups ",null,"Prevention: STI diagnosis and treatment",null,"HSS: other - specify"]
[null,null,null,null,null,"Treatment: Home based management of malaria",null,"HSS (beyond TB)",null,"Prevention: Blood safety and universal precaution",null,"Supportive environment: Program management and administration"]
["EFRMalaria",null,null,null,null,"Treatment: Diagnosis",null,"PAL (Practical Approach to Lung Health)",null,"Treatment: Antiretroviral treatment (ARV) and monitoring"]
["Please Select…",null,null,null,null,"Treatment: other - specify",null,"PPM / ISTC (Public-Public, Public-Private Mix (PPM) approaches and International standards for TB care)",null,"Treatment: Prophylaxis and treatment for opportunistic infections"]
["Prevention",null,null,null,null,"Supportive environment: Monitoring drug resistance",null,"ACSM (Advocacy, communication and social mobilization) ",null,"Care and support: Care and support for the chronically ill"]
["Treatment",null,null,null,null,"Supportive environment: Monitoring insecticide resistance",null,"Community TB care",null,"Care and support: Support for orphans and vulnerable children"]
["Supportive Environment",null,null,null,null,"Supportive environment: Coordination and partnership development (national, community, public-private)",null,"Programme-based operational research",null,"TB/HIV collaborative activities: HIV care and support for HIV-positive TB patients "]
["Health System Strengthening (HSS)",null,null,null,null,"Supportive environment: other - specify",null,"Other:Specify",null,"Supportive environment: Policy development including workplace policy"]
[null,null,null,null,null,"Supportive environment: Program management and administration",null,"Supportive environment: Program management and administration",null,"Supportive environment: Strengthening of civil society and institutional capacity building "]
[null,null,null,null,null,"HSS: Service delivery",null,null,null,"Supportive environment: Stigma reduction in all settings"]
["EFRHealthSystemsStrengthening",null,null,null,null,"HSS: Human resources",null,null,null,"Supportive environment: Program management and administration"]
["Please Select…",null,null,null,null,"HSS: Community Systems Strengthening",null,null,null,"HSS: Service delivery"]
["Health System Strengthening (HSS)",null,null,null,null,"HSS: Information system & Operational research",null,null,null,"HSS: Human resources"]
["Supportive Environment",null,null,null,null,"HSS: Infrastructure",null,null,null,"HSS: Community Systems Strengthening"]
[null,null,null,null,null,"HSS: Procurement and Supply management",null,null,null,"HSS: Information system & Operational research"]
[null,null,null,null,null,"HSS: other - specify",null,null,null,"HSS: Infrastructure"]
[null,null,null,null,null,null,null,null,null,"HSS: Procurement and Supply management"]
[null,null,null,null,null,null,null,null,null,"HSS: Other, specify"]
[]
[]
["EFRTuberculosis"]
["Please Select…"]
["TB Detection"]
["TB Treatment"]
["TB/HIV Collaborative Activities"]
["Supportive Environment"]
["Health System Strengthening"]
[]
[]
[]
[]
["IE"]
["Please Select…"]
["FBO"]
["NGO/CBO/Academic"]
["Private Sector"]
["Ministry Health (MoH)"]
["Other Government"]
["UNDP"]
["Other Multilateral Organization"]

{"sheet":"Checklist","index":27,"n_rows":30,"n_cols":4,"rows_kept":30,"cut":false,"hidden":false,"merged":[[5,0,5,3],[12,0,12,3],[18,0,18,3],[27,0,27,3]]}
["List of supporting documents for PU/DR review"]
[]
["This checklist is included for information and not for completion."]
[]
["List of Latest Approved Documents by functional area","To be made available to the LFA by the PR  ","To be submitted by the LFA to the Secretariat","Comments"]
["M&E"]
["Performance Framework","x"]
["M&E Plan","x"]
["Survey results","x",null,"For Impact/Outcome indicators"]
["M&E Systems Strengthening Assessment","x",null,"If newly available during the reporting period."]
["Other M&E assessments done by partners to assess data quality and M&E system issues.","x",null,"If newly available during the reporting period."]
[]
["Procurement"]
["Consumption reports for pharmaceuticals and health products","x"]
["Supplier invoices","x"]
["Procurement Plan","x"]
["Stock level reports","x"]
[]
["Finance"]
["Approved budgets","x",null,"For the periods covered by Progress Update and Disbursement Request, including the buffer period."]
["Cash books","x"]
["General Ledger ","x"]
["Cash forecasts ","x"]
["Bank statements","x"]
["Bank Reconciliations","x"]
["Annual PR Audit Report, Financial Statements, Management Letters and Responses (if Due)","x"]
["Annual SR Audit Report, Financial Statements, Management Letters and Responses (if Due)","x"]
["General Management"]
["Grant Agreement (including implementation letters)","x"]
["Workplan","x"]

{"sheet":"Memo HIV","index":28,"n_rows":26,"n_cols":10,"rows_kept":26,"cut":false,"hidden":true,"merged":[]}
["Service Delivery Areas","Impact Indicators","IndicatorTypes","Outcome Indicators","DataSources"]
["Please select…","Please select…","Please select…","Please select…","Please select…",null,null,null,null,"Please select…"]
["Prevention: Behavioral Change Communication - Mass media","% of young women and men aged 15-24 who are HIV infected ","impact","% of young people aged 15-24 who had sex with more than one partner in the last year ","National Health Accounts","Please enter a corresponding indicator here…",null,null,null,"Please select disease and Impact/Outcome first"]
["Prevention: Behavioral Change Communication - community outreach","% of adults aged 15-49 who are HIV infected ","outcome","% of young people aged 15-19 who have never had sex ","DHS/DHS+ (Demographic and Health Survey)","Please enter a data source here…"]
["Prevention: Condom distribution","% of adults and children with HIV still alive 12 months after initiation of antiretroviral therapy (extend to 2, 3, 5 years as program matures) ",null,"% of young people aged 15-24 who never had sex in the last year of those who ever had sex","MICS (Multiple Indicator Cluster Survey)","Please enter a SDA here…"]
["Prevention: Counseling and Testing ","% of infants born to HIV infected mothers who are infected ",null,"% of young people aged 15-24 reporting the consistent use of a condom with non-regular sexual partners in the last year ","AIS (AIDS Indicator Survey)"]
["Prevention: PMTCT","% of most-at-risk population(s) (sex workers, clients of sex workers, men who have sex with men, injecting drug users) who are HIV infected ",null,"% of young women and men who had sex before the age of 15 ","SAMS (Service Availibility Mapping Survey)"]
["Prevention: Post-exposure prophylaxis (PEP)","% of HIV seroprevalence among all newly registered TB patients",null,"% of adults and children who are still on treatment after 6 months, 1, 2, 3, 5 years from the initiation of treatment ","BSS (Behavioral and Surveillance Survey)"]
["Prevention: STI diagnosis and treatment",null,null,"% of injecting drug users who have adopted behaviors that reduce transmission of HIV. ","Sentinel surveillance"]
["Prevention: Blood safety and universal precaution",null,null,"% of orphaned children compared to non-orphaned children aged 10-14 who are currently attending school ","Serological surveys"]
["Treatment: Antiretroviral treatment (ARV) and monitoring",null,null,"% of young people aged 15-24 reporting the use of a condom the last time they had sex with a non-regular sexual partner ","Prevalence surveys"]
["Treatment: Prophylaxis and treatment for opportunistic infections",null,null,"% of people expressing accepting attitudes towards PLWHA, of all people surveyed aged 15-49 ","Facility-based survey "]
["Care and support: Care and support for the chronically ill",null,null,"% of female sex workers reporting the use of a condom with every client in the last month ","Key informant survey"]
["Care and support: Support for orphans and vulnerable children",null,null,"% of men who have had sex with a female sex worker in the last year ","Specific surveys (to be defined)"]
["TB/HIV collaborative activities: HIV care and support for HIV-positive TB patients ","TB/HIV collaborative activities: Intensified case-finding among PLWHA",null,"% of men reporting the use of condom the last time they had anal sex with a male partner in the last 6 months ","Civil registration systems (vital/disease specific registration) "]
["Supportive environment: Policy development including workplace policy","TB/HIV collaborative activities: Prevention of TB disease in PLWHA",null,null,"Census"]
["Supportive environment: Strengthening of civil society and institutional capacity building ","TB/HIV collaborative activities: Prevention of HIV in TB patients",null,null,"Health service statistics"]
["Supportive environment: Stigma reduction in all settings","TB/HIV collaborative activities: Prevention of opportunistic infections in PLWHA with TB",null,null,"Patient register"]
["Supportive environment: Program management and administration",null,null,null,"Clinical cohort follow-up studies "]
["HSS: Service delivery","TB/HIV collaborative activities: Provision of antiretroviral treatment for TB patients during TB treatment",null,null,"Community services assessment"]
["HSS: Human resources","HSS: PAL (Practical Approach to Lung Health)",null,null,"Records: laboratory, patient (e.g. treatment cards), training, certification, other (to be specified)"]
["HSS: Community Systems Strengthening",null,null,null,"Operational research"]
["HSS: Information system & Operational research"]
["HSS: Infrastructure"]
["HSS: Procurement and Supply management"]
["HSS: Other, specify"]

{"sheet":"Memo TB","index":29,"n_rows":27,"n_cols":5,"rows_kept":27,"cut":false,"hidden":true,"merged":[]}
["Service Delivery Areas","Impact Indicators","IndicatorTypes","Outcome Indicators","DataSources"]
["please select…","please select…","please select…","please select…","please select…"]
["Improving diagnosis","TB prevalence rate","impact","Case detection","National Health Accounts"]
["Standardized treatment, patient support and patient charter","TB incidence rate","outcome","Treatment success rate","DHS/DHS+ (Demographic and Health Survey)"]
["Procurement and supply management","TB mortality rate",null,"Smear conversion rate","MICS (Multiple Indicator Cluster Survey)"]
["M&E",null,null,null,"AIS (AIDS Indicator Survey)"]
["TB/HIV",null,null,null,"SAMS (Service Availibility Mapping Survey)"]
["MDR-TB",null,null,null,"BSS (Behavioral and Surveillance Survey)"]
["High-risk groups ",null,null,null,"Sentinel surveillance"]
["HSS (beyond TB)",null,null,null,"Serological surveys"]
["PAL (Practical Approach to Lung Health)",null,null,null,"Prevalence surveys"]
["PPM / ISTC (Public-Public, Public-Private Mix (PPM) approaches and International standards for TB care)",null,null,null,"Facility-based survey "]
["ACSM (Advocacy, communication and social mobilization) ",null,null,null,"Key informant survey"]
["Community TB care",null,null,null,"Specific surveys (to be defined)"]
["Programme-based operational research"]
["Other:Specify"]
["Supportive environment: Program management and administration",null,null,null,"Civil registration systems (vital/disease specific registration) "]
[null,null,null,null,"Census"]
[null,null,null,null,"Health service statistics"]
[null,null,null,null,"Patient register"]
[null,null,null,null,"Clinical cohort follow-up studies "]
[null,null,null,null,"Community services assessment"]
[null,null,null,null,"Records: laboratory, patient (e.g. treatment cards), training, certification, other (to be specified)"]
[null,null,null,null,"Operational research"]
[null,null,null,null,"R&R TB system, quarterly report"]
[null,null,null,null,"R&R TB system, yearly management report "]
[null,null,null,null,"Other Surveillance reports, specify"]

{"sheet":"Memo Malaria","index":30,"n_rows":25,"n_cols":5,"rows_kept":25,"cut":false,"hidden":true,"merged":[]}
["Service Delivery Areas","Impact Indicators","IndicatorTypes","Outcome Indicators","DataSources"]
["please select…","please select…","please select…","please select…","please select…"]
["Prevention:  Behavioral Change Communication - Mass media","Death rates associated with Malaria: all-cause under-5 mortality rate in highly endemic areas ","impact","% of U5 children (and other target groups) with malaria/fever receiving appropriate treatment within 24 hours (community/health facility)","National Health Accounts"]
["Prevention:  Behavioral Change Communication - community outreach","Incidence of clinical malaria cases (estimated and/or reported) ","outcome","% of U5 children (and other target group) with uncomplicated malaria correctly managed at health facilities","DHS/DHS+ (Demographic and Health Survey)"]
["Prevention: Insecticide-treated nets (ITNs)","Anaemia prevalence in children under 5 years of age",null,"% of U5 children (and other target groups) admitted with severe malaria and correctly managed at health facilities","MICS (Multiple Indicator Cluster Survey)"]
["Prevention: Malaria prevention during pregnancy","Prevalence of malaria parasite infection ",null,"% of children U5 sleeping under an ITN the previous night","MIS (Malaria Indicator Survey)"]
["Prevention: Vector control (other than ITNs)","Laboratory-confirmed malaria cases seen in heath facilities",null,"% of households with at least one ITN","SAMS (Service Availibility Mapping Survey)"]
["Prevention: other - specify","Laboratory-confirmed malaria deaths seen in health facilities",null,"% of pregnant women (and other target groups) sleeping under an ITN the previous night","BSS (Behavioral and Surveillance Survey)"]
["Treatment: Prompt, effective anti-malarial treatment","Malaria-attributed deaths in sentinel demographic surveillance sites",null,"% of pregnant women on Intermittent preventive treatment (IPT) according to national policy (specific to Sub-Saharian Africa)","Sentinel surveillance"]
["Treatment: Home based management of malaria","API (Annual Parasite Index) (specific to Latin America and Asia)",null,"% of households in malaria areas protected by IRS","MOH (routine HIS or HMIS)"]
["Treatment: Diagnosis",null,null,null,"RBM (Roll Back Malaria)"]
["Treatment: other - specify",null,null,null,"Serological surveys"]
["Supportive environment: Monitoring drug resistance",null,null,null,"Prevalence surveys"]
["Supportive environment: Monitoring insecticide resistance",null,null,null,"Facility-based survey "]
["Supportive environment: Coordination and partnership development (national, community, public-private)",null,null,null,"Key informant survey"]
["Supportive environment: other - specify",null,null,null,"Specific surveys (to be defined)"]
["Supportive environment: Program management and administration",null,null,null,"Civil registration systems (vital/disease specific registration) "]
["HSS: Service delivery",null,null,null,"Census"]
["HSS: Human resources",null,null,null,"Health service statistics"]
["HSS: Community Systems Strengthening",null,null,null,"Patient register"]
["HSS: Information system & Operational research",null,null,null,"Clinical cohort follow-up studies "]
["HSS: Infrastructure",null,null,null,"Community services assessment"]
["HSS: Procurement and Supply management",null,null,null,"Records: laboratory, patient (e.g. treatment cards), training, certification, other (to be specified)"]
["HSS: other - specify",null,null,null,"Operational research"]
[null,null,null,null,"Questionnaire"]